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ABSTRACT 
 
ZIRCONIUM-89: RADIOCHEMISTRY AND LIGAND DEVELOPMENT TOWARD 
IMPROVED PET APPLICATIONS 
by 
Melissa Ann Deri 
 
 
Advisors: Professor Lynn C. Francesconi & Professor Jason S. Lewis 
 
Antibodies are attractive targeting vectors for positron emission tomography (PET) based 
imaging agents due to their high affinity and selectivity to a variety of biological targets. 
Creating such imaging agents requires a radionuclide with suitable decay characteristics. This 
role has been filled by zirconium-89 which has a 78.41 h half-life that ideally matches the multi-
day biological half-life of IgG antibodies. 
However, the use of a radiometal necessitates the use of a bifunctional chelator to bind 
the metal and conjugate to the antibody. For 
89
Zr this has been the purview of various derivatives 
of desferrioxamine B (DFO); however, the observed uptake of radioactivity in the bones of mice 
is evidence of in vivo release of 
89
Zr
4+
. A more robust chelator designed specifically around the 
chemistry of Zr
4+
 could eliminate the release of the bone-seeking 
89
Zr
4+
 cation in vivo and thus 
make for a safer, more effective PET tracer with reduced dose to non-target tissues. 
The investigation of alternative ligands will be described with an emphasis on the lead 
compound: a hydroxypyridinone based chelator — 3,4,3-(LI-1,2-HOPO) or HOPO. The 
v 
 
evaluation of the chelator itself will be detailed leading to the development of a bifunctional 
derivative — p-SCN-Bn-HOPO — that can be applied within the world of PET imaging. 
vi 
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CHAPTER 1: INTRODUCTION 
This chapter is an adaptation of published work, and is reproduced in part, from Deri, M. A.; 
Zeglis, B. M.; Francesconi, L. C.; Lewis, J. S. PET Imaging with 
89
Zr: From Radiochemistry to 
the Clinic. Nucl. Med. Biol. 2013, 40, 3-14, Copyright 2012 Elsevier Inc. 
 
1.1:  Introduction 
 The exquisite specificity and affinity of antibodies have made them extremely attractive 
candidates for cancer therapeutics and drug delivery agents.
1
 Consequently, over the past two 
decades, considerable effort has been invested into the construction and development of 
antibody-based imaging agents as companion diagnostics for the characterization, treatment 
planning, and treatment monitoring of cancer.
2
 Positron emission tomography (PET) is a 
quantitative, non-invasive, whole-body imaging technique which provides excellent sensitivity 
and high resolution images for medical applications.
3, 4
 It is an extremely valuable clinical tool in 
the practice of personalized medicine and for monitoring tumor response following therapy. The 
combination of antibody-based targeting and PET-based imaging is known as immunoPET and 
is a powerful formula for highly selective, highly sensitive imaging agents. 
Importantly, one of the most fundamental principles in the construction of effective 
antibody-based nuclear imaging agents is matching the physical half-life of the radioisotope to 
the pharmacokinetic half-life of the immunoglobulin.
5
 Generally, intact antibodies have 
relatively slow pharmacokinetics, often requiring multiple days to reach their optimal 
biodistribution within the body. As a result, up until just a few years ago, the exigency of 
matching physical and biological half-lives has led 
111
In, 
99m
Tc, 
67
Ga, 
86
Y, 
64
Cu, and 
124
I  with 
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half-lives of 2.80 d, 6.0 h, 3.26 d, 14.74 h, 12.70 h, and 4.18 d, respectively  to be the most 
often employed radioisotopes for antibody-based nuclear imaging agents.
6
  
Each of these isotopes, however, possesses characteristics that ultimately limit their 
suitability for clinical antibody-based imaging. 
64
Cu, for example, has been employed 
successfully as a radiolabel for antibodies in numerous pre-clinical studies in rodents, but its 12.7 
h half-life is ultimately too short to prove effective under the slower pharmacokinetic conditions 
of imaging in humans.
7-10
 Y-86 likewise possesses a half-life that is too short for human imaging 
and also adds the limitations of sub-optimal decay characteristics and difficult radionuclide 
production and purification protocols. I-124, in contrast, has a near ideal half-life for antibody-
based imaging and has thus long been the radionuclide of choice for immunoPET.
11, 12
 However, 
the expense of the isotope, its relatively low resolution due to the high energy of its positrons, 
and the significant dehalogenation of 
124
I-labeled antibodies in vivo combine to limit its ultimate 
clinical potential. Finally, while 
111
In and 
67
Ga also boast favorable physical half-lives and 
behavior for antibody-based applications, they emit gamma rays rather than positrons, which 
place them in the world of SPECT imaging. The inherent limitations of SPECT relative to its 
higher resolution and quantitative cousin, PET, have resulted in a far greater interest in the 
clinical translation of immunoPET agents. Tc-99m, of course, combines the aforementioned 
limitations of SPECT imaging with a half-life that is regarded as too short for antibody imaging.    
The desire to find a more suitable radioisotope for antibody-based imaging has been the 
driving force behind the tremendous surge in research into 
89
Zr-based imaging in recent years, 
largely pioneered by the laboratories of Elisabeth de Vries and Guus van Dongen in the 
Netherlands, among others.
13-16
 Indeed, 
89
Zr has almost ideal physical characteristics for 
antibody-based imaging, with a half-life of 78.4 h and a relatively low positron energy of 
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395.5 keV, and its advantages over the alternatives are manifold: its physical half-life is better 
suited to antibody-based imaging than that of 
64
Cu or 
86
Y, particularly in the clinic; it is safer to 
handle, cheaper to produce, more stable in vivo, and residualizes in tumors far more effectively 
than 
124
I; additionally, its emission of positrons rather than single photons allows for higher 
resolution, quantitative imaging.
17, 18
 Taken together, these characteristics have spurred the rise 
of 
89
Zr from obscure positron-emitting radiometal less than ten years ago to what is fast 
becoming the isotope of choice for both pre-clinical and clinical immunoPET imaging. It is also 
important to note that while antibodies represent perhaps the most significant and promising 
application of 
89
Zr, the isotope may also prove extremely useful with other types of targeting 
vectors, particularly nanoparticles with slow pharmacokinetics and peptides for which longer 
imaging studies may prove informative.  
 In the following pages, we hope to provide a comprehensive review of the rapidly 
growing field of 
89
Zr-based PET imaging. It would be remiss not to mention that other excellent 
reviews on 
89
Zr currently exist in the literature written by Vugts and van Dongen at Vrije 
University in the Netherlands and Severin and Nickles at the University of Wisconsin.
19, 20
 Our 
more comprehensive review stands apart from these, however, as the former focuses primarily 
on 
89
Zr radiochemistry while the latter primarily addresses conjugation methodologies. In the 
following pages, we will strive to cover a wide range of topics, ranging from 
89
Zr production and 
purification to the design and bioconjugation of chelators for 
89
Zr to the most recent clinical 
imaging studies. Ultimately, it is our hope that this review will provide an in-depth portrait of the 
current state of the field, illustrate both the successes and limitations of 
89
Zr-based imaging, help 
identify specific areas that are in need of additional research, and, in so doing, prove useful to the 
scientist new to the field and veteran investigator alike. 
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1.2:  Decay Characteristics 
 Any discussion of PET imaging with 
89
Zr must necessarily begin with the fundamentals 
of the decay of the isotope
17, 21-24
. 
89
Zr decays with a half-life of 78.41 h via both positron 
emission and electron capture to an intermediate 
89m
Y state which in turn decays to stable 
89
Y via 
a gamma ray emission (909 keV) with a half-life of 15.7 s (Figure 1.1). The relatively low 
translational energy of the emitted positrons, 395.5 keV, results in high image resolution, and the 
energy disparity between the 511 keV photons and the 909 keV prevents the latter from 
interfering with the detection of the coincident photons. Importantly, the suitability of the 
89
Zr 
decay characteristics for imaging markedly contrasts with 
124
I, which emits much higher energy 
positrons (687 and 974 keV) and also emits a number of photons with energies within 100-150 
keV of the positron-created 511 keV 
18
. Both phenomena combine to grant 
89
Zr noticeably better 
resolution than its halogen competitor.   
1.3: Production and Purification 
89
Zr has been produced on a cyclotron via both the 
89
Y(p,n)
89
Zr and 
89
Y(d,2n)
89
Zr 
reactions.
17, 20, 22, 25-27
 In both cases, these routes provide the added advantage of employing a 
89
Y 
metal target that is commercially available, non-reactive, and in 100% natural abundance, which 
drives down costs and precludes the need for cumbersome recycling of the target. For the 
deuterium reaction, a minimum beam energy of 5.6 MeV is required.
27
 In practice, the proton 
reaction is the much more popular of the two and typically employs proton beams at or above 14 
MeV, though early reports employed beams of 13 MeV. In both cases, the avoidance of the 
isotopic impurity 
88
Zr by inadvertent (p, 2n) or (d, 3n) reactions, respectively, poses a particular 
concern, for both 
88
Zr (t1/2 = 83.4 d) and its daughter 
88
Y (t1/2 = 106 d) are potentially 
complicating impurities.
26, 27
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Figure 1.1. (A) A simplified decay scheme of 
89
Zr; (B) Some salient decay characteristics of 
89
Zr; (C) Photograph of the custom-made water-cooled solid-target assembly for the TR19/9 
cyclotron used at Memorial Sloan Kettering Cancer Center; (D) A static 10 minute PET image 
recorded by using a Derenzo phantom, with corresponding hole diameters in mm. (C) and (D) 
are modified and reprinted from Holland, et al. Nuclear Medicine and Biology 2009; 36:729-39. 
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  The isolation and purification of 
89
Zr have been subjects of considerable interest. 
Methods ranging from solvent extraction to anion exchange chromatography have been 
employed, though weak cation exchange chromatography using hydroxamate-modified resin has 
emerged as the method of choice 
22, 25, 27-29
.  Using this method, the 
89
Zr is loaded onto a column 
of hydroxamate resin in 2 M HCl, washed with additional 2 M HCl and metal-free water, and 
eluted in a 1.0 M oxalic acid solution that can then be employed for radiolabeling reactions. As a 
practical example of the techniques for production and purification described above, at our 
institution, Memorial Sloan Kettering Cancer Center in New York City, 
89
Zr is produced via the 
89
Y(p,n)
89
Zr reaction using a 
89
Y thin-foil target (99% purity, 0.1 mm width) using a 15 MeV 
proton beam and a 10 angle of incidence to the target. Using these conditions and the 
hydroxamate resin purification methodology described above, 
89
Zr oxalate is produced reliably 
and reproducibly in high specific activity (470–1195 mCi/mmol) and radionuclidic purity 
(>99.99%).
17
  
1.4:  Zirconium Chemistry 
As we progress, a fundamental understanding of the aqueous chemistry of zirconium is 
critical, both to better evaluate the coordinative relationship between the zirconium cation and its 
chelator and to provide insight into the possible behavior of the metal if it were released from its 
chelate in vivo. 
 1.4.1:  Basics 
Zirconium is a group IV metal, which exists primarily as a +4 ion in aqueous solution. 
This Zr
4+
 cation is a relatively large, highly-charged ion which typically forms coordination 
complexes with high coordination numbers, and, as a ‘hard’ cation, typically prefers anionic 
oxygen donors.
30
 The effective ionic radius of the Zr
4+
 cation with a coordination number of 
7 
 
eight is 0.84 angstroms.
31
 The complexity of aqueous zirconium chemistry has led to somewhat 
limited study of the area. Oxides and hydroxides of zirconium exhibit very poor solubility in 
water, less than 10
-8
 M, as well as pH-dependent changes in speciation. At very low pH, less than 
zero, zirconium forms polynuclear species upon hydrolysis, while under slightly less acidic 
conditions, between zero and two, mononuclear hydrolysis species predominate. However, 
around pH two, the solubility of the zirconium species decreases and precipitation can occur.
32
 
Even at very low pH, delicate equilibria exist between different polynuclear zirconium species 
and slight changes in pH can lead to aggregation.
33
 In contrast to the zirconium hydroxide 
species, Zr
4+
 salts of halides, perchlorate, and sulfate are soluble in acidic solution. 
30
 
Outside of its radioisotopic applications that form the focus of this review, zirconium is 
heavily used in ceramics, some of which are used in medical prosthetic applications, in the form 
of zirconia or  ZrO2.
34
 Additionally, due to the low neutron capture cross section of zirconium, 
its metal alloys are used for cladding in nuclear reactors. However, the predominant use of 
zirconium in chemistry is in the application of organometallic catalysis including olefin 
metathesis
35
, ring-opening polymerizations
36
, aminoalkene hydroamination
37
, and other 
reactions.
38-40
 For different catalytic and waste separation purposes, a number of different 
zirconium coordination complexes have been studied, however, in the context of the construction 
of 
89
Zr-labeled bioconjugates for PET, only a handful of stable, aqueous, bio-compatible 
complexes are appropriate. 
 1.4.2:  Chelation 
The foundation of any biomolecular PET tracer lies in the formation of a stable 
radiometal chelate. To date, a number of different aqueous chelators have been employed with 
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zirconium (Figure 1.2), of which desferrioxamine B (DFO) has become by far the most 
successful and oft-employed. 
 Prior to the development of any specialized ligands for Zr
4+
, the majority of research into 
the coordination chemistry of Zr employed some of the most commonly used bifunctional 
chelates: ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), 
and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Crystal structures have 
been obtained for Zr-EDTA 
41
 and Zr-DTPA 
6
, and a solution structure has been obtained in the 
case of Zr-DOTA using NMR methodologies 
42
. Despite the differences in chelators, each 
structure indicates a coordination number of eight. EDTA binds zirconium through two nitrogen 
atoms, four oxygen atoms, and two exogenous water molecules, whereas both DTPA and DOTA 
coordinate the metal using solely the constituent atoms of the ligand: three nitrogens and five 
oxygens for DTPA and four of each atom for DOTA. The log K values for thermodynamic 
stability constants are reported as 29.4 for Zr-EDTA at 25
o
C in water and an ionic strength of 0.1 
and 35.8 for Zr-DTPA at 20
o
C at water and an ionic strength of 0.23, but remain unreported for 
Zr-DOTA.
43
 The higher thermodynamic stability of Zr-DTPA is most likely due to the fact that 
DTPA coordinatively saturates the Zr
4+
, in contrast to EDTA which requires two exogenous 
water molecules to complete the coordination sphere. Despite this, an attempt to radiolabel an 
antibody using DTPA as the chelator resulted in less than 0.1% successful labeling.
44
 
A different tactic for finding chelators came from the study of siderophores or natural 
iron-chelating molecules produced by bacteria. The most prominent chelator of Zr
4+
 currently 
employed, desferrioxamine (DFO), is an example of a hexadentate, bifunctional siderophore with 
three hydroxamate groups for chelating metals and a primary amine tail which can be modified 
for conjugation to a biomolecule. Investigations in the 1960s involving the 
9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. The ligand structure, coordination scheme, and experimental structure of some 
commonly-employed chelators for Zr
4+ 
and their complexes with the metal.  
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reprocessing of nuclear fuel found that zirconium had an affinity for hydroxamic acid groups, 
displaying stability constants of β1=2.7×10
12
 and β2=1.2×10
24
 with respect to benzohydroxamic 
acid.
45
 It follows, then, that the presence of the hydroxamate groups in DFO would make it a 
suitable and effective chelator for Zr
4+
, and indeed, the success of the vast majority of 
89
Zr-based 
PET imaging is a testament to the value of DFO as a chelate. In one of the earliest investigations 
into the utility of 
89
Zr as a PET radionuclide, Meijs and co-workers reported that DFO exhibits 
rapid and efficient labeling with a 1:1 ratio of metal to chelate and demonstrates good stability 
with regard to demetallation, releasing less than 0.2% of the metal in serum after 24 hours.
46
 
Further evaluation of the complex by Holland and coworkers utilizing density functional theory 
(DFT) models Zr-DFO as an octadentate complex combining the six binding oxygens of DFO 
with two additional water molecules. Also, stability studies over longer periods of time indicated 
that still less than 2% demetallation occurs after seven days in serum.
47
 Unfortunately, thus far, 
neither physical structural studies nor thermodynamic stability constants have been reported for 
Zr-DFO. 
While DFO is by far the most widely used zirconium chelator and behaves reasonably 
well in vivo, there is a growing school of thought that an even better ligand could be designed 
and synthesized. The most basic argument here is that zirconium favors octadentate coordination 
and the DFO ligand itself only offers hexadentate chelation. As discussed above, DFT modeling 
of DFO and Zr
4+
 that suggests two water molecules are bound to the zirconium in addition to 
DFO reinforces this idea. A ligand that incorporates all eight binding sites for Zr
4+
 should benefit 
from the preorganization of the coordination environment and thus should demonstrate superior 
stability compared to DFO when complexed with 
89
Zr. However, initial experiments with ligands 
such as EDTA, DTPA, and DOTA illustrated that these ligands, despite achieving higher 
11 
 
coordination numbers, form complexes with lower stability compared to DFO.
43, 44
 While not 
proven, the reduction in stability in these cases is likely due to the additional chelation arising 
from nitrogen atoms, rather than the oxygen donors preferred by the oxophilic Zr
4+
cation. 
Ultimately, it is believed that the ideal solution for stable Zr
4+
 chelation would be a ligand that is 
both octadentate and oxygen-rich. More specifically, catechols, hydroxypyridinones, and 
hydroxamates are likely candidates for promising binding groups. The design, synthesis, and 
evaluation of novel, high-stability Zr
4+
 ligands is a topic ripe for investigation. 
1.5:  Conjugation Chemistry 
With the selection of a targeting vector and radiometal-chelate pair comes the necessity 
for a method to covalently link the units together. In the case of 
89
Zr, the overwhelming majority 
of bioconjugates have utilized DFO as the chelator, so that will be the focus of the following 
discussion. The conjugation of DFO to an antibody or other construct has been achieved in a 
variety of ways: exploiting thiol linkages, amide couplings, and even click chemistry (Figure 
1.3). Taken together, these conjugation techniques are based most frequently on the reaction of 
an activated bifunctional chelator with a lysine or cysteine residue of the protein.  
 1.5.1:  Early work 
Some of the earliest work of attaching DFO to an antibody comes not from the zirconium 
literature, but rather from past work on 
67
Ga-based radiopharmaceuticals. In these cases, 
conjugation was accomplished by modifying both the primary amine of a lysine residue on an 
antibody and the amine tail of DFO with hetero-bifunctional agents and then joining the units 
together.
48
 For example, the modification of each piece with N-succinimidyl-3-(2-pyridyldithio) 
propionate (SPDP) allows for the formation of a disulfide linkage and
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic of some common DFO conjugation strategies.  
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N-(6-maleimidocaproyloxy)succinimide (EMCS) can be used to attach a maleimide functionality 
to DFO which could then be connected to a thiolated antibody. Alternatively, a homo-
bifunctional agent such as glutaraldehyde can be used to connect the antibody and chelate in one 
step. This method, however, comes with the risk of the antibody linking to itself and forming 
polymers instead of creating one to one antibody-chelate complexes.
48
 With the advent of 
89
Zr as 
a radionuclide for PET imaging came an increased interest in DFO-antibody conjugation. At this 
time, the notion of attaching hetero-bifunctional agents to both the antibody and DFO was still 
prevalent, but now two different agents were used, namely N-succinimidyl-S-acetylthioacetate 
(SATA) to append the antibody and succinimidyl 4-(N-maleimidomethyl)cyclohexane- 1 -
carboxylate (SMCC) to modify DFO. These two structures could then be combined through the 
formation of a succinimide ring-thioether bond.
49
 However, it was later shown that such a 
linkage was unstable at physiological pH.
50
 
 1.5.2:  Lysine methods 
A major breakthrough was made by Verel and coworkers with the introduction of a new 
conjugation method utilizing an activated 2,3,5,6-tetrafluorophenol (TFP) ester of DFO that 
could be coupled to the unmodified, native lysine side-chains of an antibody. This involves a five 
step procedure which includes the extension of DFO with succinyl anhydride, the protection of 
the ligand’s hydroxamate groups with Fe(III), the formation of the activated TFP ester, 
conjugation to the unmodified antibody, and removal of the iron to free the chelate for 
radiolabeling.
29
 Conjugation in this manner with Fe-coordinated TFP-N-succinylDFO (N-suc-
DFO) offers a reliable procedure to form a stable linkage without the need to pre-modify the 
antibody with its own bifunctional moiety and has to date been the most prevalent conjugation 
method used in preclinical 
89
Zr PET imaging. More recently, Perk and Vosjan et al. introduced 
14 
 
an even simpler method using a p-isothiocyanatobenzyl-bearing DFO (DFO-Bz-NCS). This 
commercially available chelate can be attached to the lysine residues of an unmodified antibody 
in one step, forming a stable thiourea linkage between chelator and biomolecule.
51, 52
 In only the 
few years that the isothiocyanate derivative has been available, it has been gaining popularity 
due to its simplicity. However, it is not a perfect solution, primarily due to the water insolubility 
of the p-isothiocyanatobenzyl-DFO precursor, which requires more finesse than the 
straightforward N-suc-DFO chemistry. 
 1.5.3:  Thiol methods 
A significant concern with regard to the lysine-based conjugation methodologies is that 
nonspecific attachment of a chelator to an antibody has the potential to hinder immunoreactivity 
by attaching the chelate at an antigen-binding site. In response to this problem, increasing 
attention has been dedicated to the development of site-specific conjugation strategies using 
engineered cysteine residues. In the most prevalent example of this approach, the thiol-reactive 
DFO derivatives bromoacetyl-desferrioxamine (DFO-Bac), iodoacetyl-desferrioxamine (DFO-
Iac) and maleimidocyclohexyl-desferrioxamine (DFO-Chx-Mal) were constructed and then 
attached to cysteine residues designed into non-bioactive sites on an antibody. Both DFO-Bac 
and DFO-Iac attach to the cysteine through nucleophilic substitution reactions, whereas DFO-
Chx-Mal undergoes a Michael addition with the residue. The resulting radiolabeled antibodies 
were found to be stable and demonstrated imaging characteristics analogous to the lysine-linked 
complexes. In the models tested, however, no significant advantage in immunoreactivity was 
demonstrated for site-specific conjugation.
53
 
 
 
15 
 
 1.5.4:  Click methods 
Very recently, the use of click chemistry has emerged as a specialized conjugation 
method to expand the scope of 
89
Zr PET imaging possibilities. A click strategy using an inverse 
electron demand Diels-Alder reaction between the strained dienophile norbornene and 3-(4-
benzylamino)-1,2,4,5-tetrazine has been harnessed by coupling a norbornene functionality to 
lysine residues of an antibody and attaching a tetrazine to DFO. The benefit of this type of click 
chemistry is that it allows for modularity, allowing researchers to switch out different chelator-
radiometal pairs or different antibodies while still maintaining the same overall conjugation 
methodology.
54
 Another click-based strategy attempted to take advantage of the Staudinger 
ligation between azides and phosphines for use in pre-targeting experiments by reacting azide-
modified antibodies with phosphine-containing radiometal-chelate complexes such as 
89
Zr-DFO-
phosphine. Unfortunately however, the Staudinger ligation was found thus far to be incompatible 
in vivo.
55
 
 1.5.5:  Choosing a Conjugation Strategy 
With such a variety of methods, it becomes important to select a conjugation method that 
fits the task at hand. In most cases, the N-suc-DFO or DFO-Bz-NCS methods are more than 
adequate, and while the most commonly used conjugation method is currently the N-succinyl-
DFO TFP ester, one would expect that the already increasing use of the p-isothiocyanate method 
will only become more widespread due to the fact that it is a more rapid and facile method and it 
employs commercially available starting materials. More specialized situations, however, may 
call for other routes. For example, the site specific system is particularly appropriate in cases 
where the loss of immunoreactivity is a concern, and the click methodology may prove 
beneficial where modularity is desired. As the field continues to expand and 
89
Zr-based imaging 
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moves further into the mainstream, it is hoped that new methodologies will be developed that 
may combine the convenience of a commercially available starting materials with some of the 
benefits of the other systems. 
1.6:  Zirconium Biochemistry 
Moving from the test tube to the body, the behavior of free Zr
4+
 within biological systems 
has been studied in order to gauge the safety of using 
89
Zr as a PET tracer as well as to better 
understand the fate of the radionuclide in the case of metabolism of parts of the 
radiopharmaceutical. This is especially important in the case of zirconium because of the high 
affinity of Zr
4+
 for bone. 
 1.6.1:  Biodistribution 
The normal composition of the human body includes small amounts of zirconium found 
in fat, liver, and gall bladder tissue, as well as trace amounts in the brain. Excretion of zirconium 
from food and water intake is thought to involve the hepatobiliary system and results in 
hepatobiliary, rather than urinary, excretion.
34
 The fate of non-dietary zirconium, however, is 
less straightforward and depends upon the chemical speciation of the metal cation as well as 
perhaps the organism into which it is administered.  
An example of the clearance mechanism and rate varying between species can be seen 
when Zr
4+
 is complexed by citrate. In rats, 80-90% of Zr-citrate is rapidly excreted in the urine 
within 24 hours
56
, while in mice, only 30% of Zr-citrate was cleared within 24 hours.
57
 In an 
early study of 
89
Zr-citrate in man, activity was only found in the plasma of blood and zirconium 
was shown bound to serum proteins. This study, however, showed low urinary excretion of the 
activity.
58
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When a complex, such as Zr-chloride, is poorly defined or understood, its biological 
behavior is often unclear as well. For example, one study found that Zr-chloride accumulates in 
the liver, which suggests it is in a colloidal form
17
, while another study using a different 
preparation method of Zr-chloride showed no accumulation in soft tissue.
57
 More stable 
complexes lead to more straightforward biodistribution data. Zr-phosphate does not demonstrate 
significant clearance from the body, but instead collects in the liver and spleen most likely due to 
precipitation.
57
 Zr-DFO is cleared extremely quickly through the kidneys and can be excreted 
through the urine in a matter of minutes.
17, 49
 
Overall, the key to consistent biodistribution and fast, dependable clearance largely rests 
on the stability and control of the complexation. The stable, organized chelation of Zr-DFO 
exhibits clear, predictable biological behavior, while the complicated and uncertain speciation of 
lower denticity complexes leads to problematic or complex biological behavior. 
 1.6.2:  Bone uptake 
Zirconium is a bone seeker and so, when not tightly bound to a chelate, accumulates 
preferentially in bone in both rats
59, 60
 and mice
57, 61
. This is a particularly important 
consideration in the nuclear medicine community, as the accumulation of high levels of 
89
Zr in 
bone during clinical scans may act as a dose-limiting characteristic of 
89
Zr PET agents. A 
comparison of bone uptake from different zirconium species demonstrates that as the denticity 
and stability of the complexes increases, the bone uptake decreases since the osteophilic Zr
4+
 
cation is not released. In practice, this trend translates to the highest bone uptake observed upon 
the injection of Zr-chloride, followed by Zr-oxalate, then Zr-citrate, and lastly Zr-DFO with 
significantly less bone uptake (Figure 1.4). Notably, Zr-phosphate does not show considerable 
bone uptake comparatively. Additionally, the bone marrow is responsible for much less than one 
18 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. (A) Biodistribution of radioactivity at 6 days post-injection following i.v. 
administration of various chemical form of 
89Zr in female NIH Swiss mice (n ≥ 3; note the axis 
break). Reprinted with permission from Abou, et al. Nuclear Medicine and Biology 
2011;38:675-81. (B) PET images showing maximum intensity projection of 
89
Zr-oxalate at 24 h 
after intravenous administration and dynamic PET images of 
89
Zr-DFO at 1 and 4 min after 
injection. Adapted with permission from Holland, et al. Journal of Nuclear Medicine  2010; 51: 
1293-300. 
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percent (0.1%) of the activity of the bone, while the calcified tissue comprises the bulk of the 
zirconium uptake with 33% concentrated in the epiphyses.
57
 Since free Zr
4+
 is responsible for the 
observed bone uptake, a more stable chelate for zirconium should further limit the observed bone 
activity. It is worth noting that early clinical trials with 
89
Zr do not demonstrate the extent of 
bone uptake exhibited in preclinical images. 
1.7:  Preclinical Applications 
In the past decade, the use of 
89
Zr for small animal PET imaging has become increasingly 
widespread and a considerable amount of work has been undertaken at a variety of different 
institutions (Table 1.1). By far the most prevalent use of 
89
Zr lies in the radiolabeling of 
antibodies due to the favorable match up of the half-life of 
89
Zr and the circulation time of IgG 
antibodies.  
 1.7.1:  ImmunoPET 
The ability to image a radiolabeled antibody several days after its injection allows for 
vastly improved image contrast due to decreased background signal. As a residualizing isotope, 
89
Zr remains inside cells once the antibody-antigen complex is internalized, allowing activity to 
accumulate and concentrate in tumors while non-localized activity clears from the body, 
ultimately resulting in high contrast images. An analysis of each of the individual preclinical 
studies would, of course, be outside of the scope of this chapter; instead, we will provide a few 
interesting examples to demonstrate the utility of 
89
Zr in different areas of the preclinical arena. 
The potential use of 
89
Zr immunoPET to monitor and predict the effectiveness of therapy has 
been demonstrated by Nagengast and co-workers in ovarian cancer using 
89
Zr-bevacizumab and 
the HSP90 inhibitor NVP-AUY922.
62
 HSP90 inhibition has an antiangiogenic effect and leads to 
a downstream reduction in the secretion of VEGF which, as this work shows, can be effectively 
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 Targeting Moiety Target Type of cancer Conjugation 
Method 
References 
Antibodies Cetuximab EGFR Multiple N-suc-DFO 
63-66
 
Bevacizumab VEGF Squamous cell head and neck 
carcinoma, ovarian, breast 
N-suc-DFO 
64, 67-69
 
Trastuzumab HER2 Breast, ovarian N-suc-DFO 
23, 62, 69, 70
 
J591 PSMA Prostate N-suc-DFO 
47
 
71
 
cmAb U36 CD44v6 Head and neck squamous 
cell carcinoma 
N-suc-DFO 
72, 73
 
5A10 fPSA Prostate N-suc-DFO 
60
 
cG250 MN/CA IX Renal cell carcinoma N-suc-DFO 
74
 
R1507 IGF-1R Triple-Negative Breast N-suc-DFO 
75
 
Fresolimumab TGF-b Multiple N-suc-DFO 
76
 
DN30 Met Gastric, head and 
Neck 
N-suc-DFO 
77
 
7E11 PSMA Prostate N-suc-DFO 
78
 
hRS7 EGP-1 Prostate N-suc-DFO 
79
 
Panitumumab HER1 Colorectal DFO-Bz-NCS 
80
 
TRC105 CD105 Breast DFO-Bz-NCS 
66
 
Anti-B220 B cells Unspecified DFO-Bz-NCS 
81
 
E48 and 323/A3 Unspecified 
surface antigens 
Head and neck squamous 
cell carcinoma 
SATA/SMCC 
thioether 
61
 
Antibody 
fragments 
(aHGF)-Nanobodies HGF Glioma DFO-Bz-NCS 
82
 
Ranibizumab (Fab) VEGF-A 
isoforms 
Ovarian N-suc-DFO 
83
 
cG250-F(ab9)2 CAIX Head and neck carcinoma N-suc-DFO 
84
 
Peptides c(RGDfK) with and 
w/o PEG 
Integrin αvβ3 Breast DFO-Bz-NCS 85 
Nanomaterials Albumin n/a Prostate N-suc-DFO 
86
 
resin microspheres 
and SIR-Spheres 
n/a Liver n/a 
87
 
nanocolloidal 
albumin 
n/a Head and Neck DFO-Bz-NCS 
88
 
Dextran 
Nanoparticles 
macrophages Colon DFO-Bz-NCS 
89
 
Single wall carbon 
nanotube 
VE-cad based on 
attached antibody 
E4G10 
Colon adenocarcinoma N-suc-DFO 
90
 
Table 1.1. Summary of pre-clinical imaging studies using 
89
Zr-based imaging agents.   
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imaged with 
89
Zr-bevacizumab. The decrease in 
89
Zr-bevacizumab uptake in A2780 xenografts 
after treatment with NVP-AUY922 corresponds to the decrease in VEGF levels due to HSP90 
inhibition, as confirmed by in vitro experiments (Figure 1.5). Additionally, no such change in 
uptake was found with CP70 tumors which are known to not respond to AUY922 therapy. 
Hence, 
89
Zr-bevacizumab acts as an early biomarker for the effectiveness of HSP90 inhibition 
and allows for in vivo visualization and quantification of early antiangiogenic tumor response.
67
 
One recent study demonstrating immediate clinical relevance for castration-resistant prostate 
cancer was conducted by Ulmert, Evans, and colleagues, who developed a 
89
Zr-labeled 5A10 
antibody targeting free prostate specific antigen (fPSA) that was shown to be able to track 
intratumoral androgen receptor (AR) signaling due to testosterone levels or pharmacological 
triggers such as antiandrogen MDV3100 (Figure 1.6).
91
 The clinical importance of PSA levels 
and the changes thereof has been thoroughly investigated and the ability to non-invasively 
monitor these changes in the tumor environment could prove greatly beneficial. 
89
Zr-5A10 is not 
only able to provide diagnostic imaging of a tumor, but can be used to trace disease progression 
and evaluate treatment response. Additionally, and importantly, in contrast to clinically used 
radiotracers such as 
99m
Tc-MDP or 
18
F-NaF, 
89
Zr-5A10 was able to differentiate cancerous bone 
metastases from normal bone repair. The ability of this radiotracer to evaluate therapeutic effects 
and AR-driven tumor activity on the level of individual lesions could be of great value 
clinically.
60
 
 1.7.2:  Non-Antibody Applications 
While immunoPET applications make up the majority of the literature regarding 
89
Zr-
based PET imaging, there is also a growing amount of research into the development of 
89
Zr-
labeled nanomaterials. One such study consists of nanoparticles made up of cross-linked, short 
22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Representative transversal and coronal small animal PET images of 
89
Zr-
bevacizumab obtained before treatment of A2780 (A) and CP70 (B) xenografts (left) and after 
NVP-AUY922 treatment (right). Images were obtained at 144 h after injection of 
89
Zr-
bevacizumab. Tumor is indicated by arrow. Reprinted with permission from Nagengast, et al. 
Journal of Nuclear Medicine 2010; 51: 761-767.  
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Figure 1.6. 
89
Zr-5A10 detects pharmacologic inhibition of AR in vivo Left: representative 
transverse and coronal PET slices of intact male mice bearing LNCaP-AR xenografts on the right 
flank and imaged with 
89
Zr-5A10 24 hours post-injection after manipulation with a subcutaneous 
testosterone  pellet or a daily oral gavage of vehicle  or MDV3100 for 7 days. Arrows indicate 
the position of the tumor (T) and the murine liver (L). Right: region-of-interest analysis of the 
tumors from the PET study shows statistically significant changes in tumor-associated 
89
Zr-
5A10. *P , 0.01 compared with vehicle. **P , 0.05 compared with vehicle. Error bars represent 
the standard deviation from mean. Reprinted with permission from Ulmert, et al. Cancer 
Discovery 2012; 2(4): OF1–OF8.  
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chain dextran that were conjugated to p-isothiocyanate DFO for radiolabeling with 
89
Zr. These 
dextran nanoparticles (DNPs) are used as imaging probes for macrophages as they are engulfed 
by mononuclear phagocytic cells. The optimal DNPs tested had an average diameter of 13 
nanometers and were surface modified through succinylation to achieve a blood half-life of 3.9 
hours. The 
89
Zr-labeled DNPs were used to image and quantitate tumor-associated macrophages 
(TAMs) in mice with colon carcinoma xenografts. The resulting PET images showed significant 
tumor uptake and histology confirmed the co-localization of TAMs and the 
89
Zr-labeled DNPs at 
the microscopic level. This methodology represents a step forward in the imaging and 
understanding of macrophage and inflammation levels associated with cancer and is expected to 
be helpful in several applications including the evaluation of cancer therapies using 
antimacrophage strategies.
89
 
1.7.3:  Challenges  
As a longer-lived medical radionuclide, one of the principal concerns regarding the use of 
89
Zr in the clinic is the substantial radiation dose received by patients compared to shorter-lived 
nuclides. However, as long as the radiotracer clears the healthy tissue as expected, the prevailing 
viewpoint is that the increased diagnostic value is worth the additional dose. Along these lines, a 
notable issue with 
89
Zr PET imaging preclinical mouse models is the uptake in bones. The 
release of osteophilic Zr
4+
 in vivo leads to accumulation of the cation in the bone, which can 
often be seen in the resulting images. Biodistribution results commonly show up to 10% injected 
dose per gram activity in the bone. Localization of radioactivity in the bone is disadvantageous 
due to the resulting increased dose to the bone marrow. As discussed earlier, the development of 
a more favorable zirconium chelate may be the key to reducing this issue. 
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1.8:  
89
Zr-Based Imaging in the Clinic 
 Despite the youth of the field, the tremendous success of 
89
Zr-based radiopharmaceuticals 
in pre-clinical imaging studies with rodent models has led to the rapid clinical translation of a 
number of 
89
Zr-labeled antibodies. In 2013, all of the published clinical investigations with 
89
Zr-
labeled antibodies had been performed in the Netherlands; however, since then the rapid advent 
of 
89
Zr-based immunoPET has led to a surge of new clinical trials throughout Europe, the United 
States, and most recently, Australia.
92
 Due to the abundance of recent investigations, we have 
summarized them in Table 1.2 while a more detailed discussion is included for four specific 
89
Zr-labeled antibody conjugates: 
89
Zr-cmAb-U36, 
89
Zr-trastuzumab, 
89
Zr-ibritumomab, and 
89
Zr-J591.
44, 93-97
 The selected studies include three of the oldest and most established clinical 
investigations of 
89
Zr and the first 
89
Zr clinical trial here at Memorial Sloan Kettering Cancer 
Center.  
 The first report of a clinical study employing a 
89
Zr-labeled antibody was published in 
2006 by Börjesson, et al., investigating the safety and diagnostic value of 
89
Zr-cmAb U36 for the 
imaging of CD44v6-positive head and neck tumors.
94
 In the study, twenty patients with head and 
neck squamous cell carcinoma (HSNCC) underwent 
89
Zr-cmAb U36 immunoPET along with CT 
and/or MRI. The patients received 75 MBq of the 
89
Zr-labeled conjugate, corresponding to 10 
mg of the antibody, and were imaged up to 144 h after injection of the radiopharmaceutical. The 
authors report that the conjugate was safe (only two of twenty patients developed an antichimeric 
antibody response), and all primary tumors were detected as well as lymph node metastases in 18 
of 25 positive levels (Figure 1.7). Significantly, the lymph nodes that were missed were 
determined to be small, contain relatively little tumor tissue, and were often also missed by CT 
or MRI, resulting in the sensitivity of the immunoPET for lymph node metastases (72%) being 
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 Compound Type of Disease Number of Trials 
& Status 
Antibodies 
9
Zr-bevacizumab Breast Cancer, Neuroendocrine 
Cancer, Renal Cell Carcinoma, 
Von Hippel-Lindau Disease,  
Hemangioblastoma, 
Pheochromocytoma, & Multiple 
Myeloma 
6 Completed.  
1 Recruiting, 
1 Unknown 
89
Zr-cetuximab Stage IV Cancer, & Colorectal 
Cancer 
1 Completed, 
2 Recruiting 
89
Zr-DS-8895a EphA2 Positive Cancer 1 Recruiting 
89
Zr-GC1008 Glioma 1 Completed 
89
Zr-girentuximab Renal Cell Carcinoma 1 Recruiting 
89
Zr-GSK2849330 HER3-Positive Solid Tumors 1 Recruiting 
89
Zr-J591 Prostate Cancer, 
& Glioblastoma 
1 Active, not 
recruiting, 
1 Recruiting 
 
89
Zr-MMOT0530A Ovarian & Pancreatic 1 Completed 
 
89
Zr-MPDL3280A Bladder, Non Small Cell Lung, & 
Breast Cancer 
2 Not yet 
recruiting 
89
Zr-MSTP2109A Prostate Cancer 1 Recruiting 
89
Zr-panitumumab Neoplasms 1 Recruiting 
89
Zr-RO5323441 Glioblastoma 1 Withdrawn 
 
89
Zr-RO5429083 Neoplasms 1 Completed 
 
89
Zr-trastuzumab Breast Cancer, & Esophagogastric 
Cancer 
1 Completed,  
7 Recruiting 
Minibodies 
89
Zr-IAB2M Prostate, & EphA2 Positive Cancer 1 Withdrawn,  
3 Recruiting 
 
Table 1.2. Summary of 
89
Zr-based imaging agents involved in clinical trials currently registered 
with the U. S. National Institutes of Health.
92
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Figure 1.7. ImmunoPET images with 
89
Zr-cmAb U36 of head and neck cancer patient with a 
tumor in the left tonsil (large arrow) and lymph node metastases (small arrows) at the left (level 
II and III) and right (level II) side of the neck. Images were obtained 72 hours post-injection. A: 
sagittal image; B: axial image; and C: coronal image. Reprinted with permission from Borjesson, 
et al. Clinical Cancer Research  2006; 12: 2133-40.  
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comparable if not better to that of CT/MRI (60%). Further, the authors found that in a subset of 
the patients (n = 6), imaging with 
89
Zr-cmAb U36 gave comparable results to imaging with 
18
F-
FDG.  
In a later report from the same group, both the radiation dosimetry and potential for 
89
Zr-
cmAb-U36 quantification were studied.
93
 Here, the authors report that the PET-based 
quantification of activity in the left ventricle of the heart agreed quite well with values obtained 
from blood samples; likewise, good correlation between PET- and biopsy-derived values was 
also observed for tumor uptake. Taken together, these data suggest that 
89
Zr-cmAb-U36 may be 
used to quantitatively assess antibody biodistribution, thereby helping to differentiate patients 
with high and low tumor uptake and in turn aiding in treatment planning. In the same study, the 
authors determined that the mean effective dose of the immunoPET was 0.53 ± 0.03 mSv/MBq 
in men and 0.66 ± 0.03 mSv/MBq in women, resulting in an average dose of approximately 40 
mSv for the patients in the study receiving 74 mBq. This, of course, is high and could certainly 
limit the repeated application of 
89
Zr-immunoPET, though the authors reasonably argue that 
subsequent studies employing different doses and more modern PET scanners can reduce the 
dose. 
Soon after the first-in-man reports of 
89
Zr-cmAb-U36, an overlapping group of 
researchers from the VU Medical Center published a pilot study investigating the use 
89
Zr-
ibritumomab tiuxetan for monitoring and predicting the biodistribution of 
90
Y-ibritumomab 
tiuxetan (Zevalin
®
) in patients with relapsed or refractory low-grade B-cell non-Hodgkin’s 
lymphoma.
44
 The authors report that co-injected 
89
Zr- and 
88
Y-ibritumomab tiuxetan have very 
comparable biodistributions, despite a few small differences, particularly liver and bone uptake. 
As a result, they conclude that 
89
Zr-ibritumomab tiuxetan is well-suited to predict 
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90
Y-ibritumomab tiuxetan dosimetry. More recently, a complementary study has been published 
illustrating that immunoPET scout scans with 
89
Zr-ibritumomab tiuxetan prior to 
radioimmunotherapy with 
90
Y-ibritumomab tiuxetan can be used to effectively and accurately 
predict the biodistribution of the 
90
Y-labeled antibody and the dose-limiting organ during 
therapy, a development which could aid significantly in patient selection and dose 
optimization.
95
   
 
In 2010, researchers at the University of Groningen published an investigation into the 
use of 
89
Zr-trastuzumab for imaging Her2-positive lesions in patients with metastatic breast 
cancer.
96, 98
 In the study, the patients (n = 14 total) were divided into three groups that received 
10 or 50 mg of trastuzumab for antibody-naïve patients or 10 mg for patients on trastuzumab 
treatment. It was found that for the trastuzumab-naïve patients, a 50 mg dose of 
89
Zr-trastuzumab 
was required for effective imaging, while a 10 mg dose was sufficient for patients on 
trastuzumab treatment. The 
89
Zr-trastuzumab produced excellent images, with high spatial 
resolution and good signal-to-noise ratio as well as high tumor uptake. It also allowed for the 
observation of metastatic lesions in the liver, lung, bone, and brain (Figure 1.8). The uptake in 
brain lesions was particularly interesting, especially because of the common belief in the poor 
penetration of trasuzumab through the blood brain barrier. The authors report that most favorable 
imaging times were 4-5 d after injection of the radiopharmaceutical, and while a full study 
between imaging modalities was not conducted, the immunoPET results generally correlated 
well with complementary imaging with CT, MRI, and bone scans. Finally, and importantly, the 
radiation dose to patients was significantly attenuated in this study compare to the 
89
Zr-cmAb-
U36 investigations: patients received 37 MBq 
89
Zr-trastuzumab for an average dose of 20 mSv. 
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Figure 1.8. Examples of fusion images from 
89
Zr-Trasutuzmab PET and MRI scans. (a) In a 
vertebral metastasis seen on MRI but unapproachable for biopsy, HER2 status was revealed by 
89
Zr-trastuzumab uptake on PET imaging. (b) Example of HER2-positive brain lesion undetected 
by conventional scans, revealed by 
89
Zr-trastuzumab PET imaging, and subsequently confirmed 
by MRI. Arrows indicate lesions. Reprinted with permission from Dijkers, et al. Journal of 
Nuclear Medicine  2009; 50: 974-81. 
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More recently, Memorial Sloan Kettering Cancer Center has started its own clinical 
investigation of 
89
Zr-based probes. The first of these focuses on the use of 
89
Zr-DFO-huJ591 
(
89
Zr-J591) for the detection of prostate-specific membrane antigen-positive lesions in castrate-
resistant prostate cancer patients.
97
 The pilot study results were very promising: the 
89
Zr-J591 
displays high spatial resolution in addition to uptake both in primary tumors and distant 
metastases (Figure 1.9) and led to a full Phase I/II study. In a study of fifty patients, injected 
with 5 mCi of the radioimmunoconjugate and imaged with whole body PET/CT, 
89
Zr-J591 was 
found to be comparable to current modalities for detecting soft tissue lesions, but highly 
advantageous for bone metastases. Overall, 
89
Zr-J591 had an accuracy of 95.2% (20/21) for 
osseous lesions and 60% (15/25) for soft tissue lesions. With this superior detection of bone 
metastases, 
89
Zr-J591 is not only a promising clinical compound, but will also serve as a 
benchmark for comparison with other PSMA targeting imaging agents for application in prostate 
cancer.    
1.9:  Conclusions 
 In the preceding pages, we have hoped to illustrate to the reader both the depth and 
breadth of the research in the rapidly expanding field of 
89
Zr-based PET imaging, with 
investigations ranging from basic metal coordination chemistry to on-going clinical trials. 
Indeed, the field is proceeding at such an exciting pace that important contributions to our 
knowledge of 
89
Zr-PET will no doubt be made between the writing of this manuscript and its 
ultimate publication. Yet despite the manifold successes, much work is yet to be done as this 
field grows and matures. In particular, we believe that particular emphasis should be placed on 
five areas: (A) the synthesis and evaluation of novel chelators with fast coordination kinetics and 
high kinetic and thermodynamic stability in order to address the observed in vivo release of 
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Figure 1.9. 
18
F-FDG (13.2 mCi), 
18
F-NaF (10.2 mCi), and 
89
Zr-DFO-J591 (4.8 mCi) sagittal 
PET images of a 56 year-old male with castrate-resistant prostate cancer. Images courtesy of Drs. 
N. Pandit-Taskar, J. Carrasquillo, M. Morris, and S.M. Larson, MSKCC. 
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89
Zr
4+ 
and its subsequent mineralization in the bone; (B) the development of mild, modular, and 
site-specific bioconjugation strategies with which to attach DFO to antibodies; (C) the expansion 
of 
89
Zr-based PET imaging from antibodies to other targeting vectors with suitable 
pharmacokinetics; (D) the advancement of our understanding of the metabolism of 
89
Zr
4+
-labeled 
compounds and the fate of free 
89
Zr
4+ 
in vivo; and finally, but perhaps most important, (E) the 
performance of direct comparison studies between 
89
Zr-labeled antibodies and antibodies labeled 
with other relevant isotopes in both pre-clinical models and a clinical environment to allow for 
the quantitative and comprehensive comparison between 
89
Zr-immunoPET and its competitor 
modalities.  
As these issues are addressed, new 
89
Zr-labeled radiopharmaceuticals are developed, and 
new pre-clinical and clinical studies are performed, we believe that 
89
Zr-based PET imaging will 
continue to progress, expand to involve new disciplines and address different pathologies, and 
ultimately take an extremely important place at the forefront of medical imaging.   
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CHAPTER 2: PHYSICAL, CHEMICAL, AND BIOLOGICAL INSIGHTS INTO 
89
ZR-DFO AND THE STUDY OF SMALL MOLECULE 
89
ZR COMPLEXES 
This chapter is an adaptation of unpublished work from Deri, M. A.; Abou, D. S.; Ramos, N. E.; 
Carlin, S. S.; Francesconi, L. C.; Lewis, J. S. 2013. 
 
2.1:  Introduction 
 While considerable work has utilized DFO to radiolabel larger targeting moieties,
1,2,3,4
 
insufficient effort has focused on the understanding of 
89
Zr-labeled small molecules or 
89
Zr-DFO 
itself. Delineating this chemistry is becoming increasingly important to probe the chelation 
chemistry of Zr and in developing novel bifunctional chelators for use in 
89
Zr-mAb PET 
studies.
5,6
  This will necessitate not only the development of methodology to prepare and analyze 
small molecule 
89
Zr-ligand complexes, but a fuller understanding of the 
89
Zr-DFO complex 
itself, both chemically and biologically, as a basis for comparison for future applications. 
In order to address the first of these needs, we have herein developed a radiolabeling method 
using an oxalate-free, colloidal solution of 
89
Zr. This approach makes it possible to purify 
radiolabeled small molecules such as 
89
Zr-DFO utilizing classic chromatographic methods which 
are unable to provide sufficient separation when using the standard method of radiolabeling with 
89
Zr-oxalate. Furthermore, we have endeavored to more fully characterize the Zr-DFO complex 
with both traditional macroscopic chemical techniques and radioanalytical techniques. The 
methodology to efficiently monitor the radiolabeling of small molecule ligands is essential to the 
investigation of possible alternative chelators.  
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One of the limitations of PET is the inability to differentiate an intact radiotracer from its 
radiometabolites. The signal always comes from the radioactive atom, whether it is still part of 
the original molecule or not. This phenomenon is particularly relevant when the 
89
Zr-labeled 
mAb or immunocomplex is internalized in tumor cells
7
,
8
 leading to possible radiotracer 
metabolism. Among others, two conceivable metabolic products of 
89
Zr-DFO-mAbs are 1) free 
89
Zr, released from DFO, which binds serum proteins and is known to exhibit bone-seeking 
properties
9
 and 2) the intact 
89
Zr-DFO complex which is rapidly excreted within 20 min when 
injected in healthy mice.
1
 However, little is known about the behavior of 
89
Zr-DFO when 
administered in tumor-bearing mice, particularly the fate of the radiotracer within the tumor 
microenvironment. With this in mind, a particular focus on the pharmacokinetics of 
89
Zr-DFO in 
tumor-bearing mice is presented herein to interrogate the biological behavior of 
89
Zr-DFO. 
Additionally, more comprehensive characterization of 
89
Zr-DFO complex and the development 
of appropriate HPLC methods could prove beneficial for metabolic analysis of future 
89
Zr-DFO 
conjugates.  
2.2:  Results and discussion 
The ideal preparation of 
89
Zr-labeled small molecules would fulfill a few basic conditions 
(1) it should provide fast radiolabeling under mild conditions; (2) it should allow for quick and 
easy monitoring of the radiolabeling without wasting product; and (3) it should allow for the 
separation of desired product from any starting materials or side products. In order to achieve 
this balance, we have investigated novel radiolabeling techniques as well as improved 
characterization and analytical methods. Additionally, once the 
89
Zr-DFO complex was produced 
and characterized, we evaluated its interaction with tumor cells in vitro and behavior in healthy 
and tumor-bearing mice in vivo. 
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 2.2.1:  Radiolabeling 
Radiolabeling of monoclonal antibodies with 
89
Zr is generally achieved in high yields 
using a solution of 
89
Zr-oxalate which has been neutralized to pH 7.
10
 One challenge of this 
approach is the renal toxicity of calcium-oxalate crystals in patients,
11
 which necessitates the 
removal of any lingering oxalate contaminations post-radiolabeling. Traditionally, this approach 
relies on the great size discrepancy between 
89
Zr-oxalate and the radiolabeled immunoconstruct 
for purification and analysis. It is, however, difficult to apply the same methodology when 
radiolabeling small molecules with 
89
Zr because the final product is not sufficiently larger than 
the starting materials. To achieve this goal, we faced challenges in the choice of appropriate 
chromatographic techniques including: (1) compatibility with the high oxophilicity of 
89
Zr and 
(2) ability to separate free 
89
Zr from complexes and small molecules.  
RP-HPLC was excluded due to severe retention (up to 100%) of free or weakly chelated 
89
Zr by the stationary phase constituted of C18-coated silica. In comparison, the cross-linked 
dextran gel used in size exclusion chromatography (SEC) exhibited weaker 
89
Zr retention, and 
thus represented a compatible option for analysis of 
89
Zr-labeled molecular tracers. However, the 
separation of neutralized 
89
Zr-oxalate from 
89
Zr-DFO by SEC was poor with a significant 
overlapping of the two peaks (Figure 2.1a), thus limiting the ability to isolate and purify 
individual species produced using 
89
Zr-oxalate for radiolabeling.  
We overcame this limitation by utilizing an alternative starting species of 
89
Zr wherein 
free 
89
Zr was prepared from a strong acidic digestion of 
89
Zr-oxalate resulting, after saline 
dissolution, in a colloidal polymeric solution herein called “89Zr-colloid”.9 The colloidal nature 
of 
89
Zr-colloid was confirmed with dynamic light scattering (Figure 2.1b). 
89
Zr-colloid and 
89
Zr-
DFO were successfully separated based on size retention. 
89
Zr-colloid was eluted earlier (elution 
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Figure 2.1. (a) SEC (Sephadex G-25) of 
89
Zr -colloid separated from 
89
Zr -DFO, enabling the 
monitoring of the radiolabeling efficiency, whereas neutralized 
89
Zr-oxalate presented poor 
separation from 
89
Zr-DFO; (b) Dynamic light scattering report of 
89
Zr -colloid indicating the 
average diameter at various solvation times. Notice the non-assigned (N/A) values after 25 min 
due to a dramatic increase in particle size (> 5 µm); (c) Radiolabeling of DFO with 
89
Zr-colloid 
at pH 2 depicts a single peak characteristic of labeling completion; Radiolabeling of DFO at pH 
4 shows two peaks indicative of partial radiolabeling. 
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volume < 5 mL) than 
89
Zr-DFO (elution volume > 5 mL) further indicating the colloidal nature 
of 
89
Zr-colloid as compared to 
89
Zr-DFO, a single molecule moiety (Figure 2.1a).  
Starting from 
89
Zr-colloid allowed for the monitoring of the radiolabeling of DFO using 
SEC. Now the excess free 
89
Zr-colloid was substantially larger than the 
89
Zr-DFO product 
resulting in appreciable separation. Through SEC analysis, the radiolabeling of DFO was shown 
to be only partial when the pH of the solution was higher than 2, whereas complete chelation was 
observed when the labeling was conducted at ~pH 2 (Figure 2.1c). This observation suggests 
that the polymeric 
89
Zr-colloid is likely increasing in size concomitantly with pH increase.
12
 The 
same trend results from increasing solvation time as demonstrated by DLS. Combined, these two 
factors lead to the precipitation of the radiometal and thus reduce the potential radiolabeling 
yield. This indicates that this radiolabeling approach is most likely only compatible with ligands 
that are stable under acidic conditions. This pH requirement also eliminates the possibility of 
adapting this radiolabeling method to antibody applications which would not tolerate the low pH. 
Given the renal toxicity associated with calcium-oxalate crystals,
11
 the ability to eliminate 
oxalate contaminations makes SEC a great purification technique when combined with the 
colloidal based 
89
Zr radiolabeling of DFO. However, SEC is not ideal for in situ reaction 
monitoring since it requires a substantial amount of compound for ease of analysis and takes 
several steps which would be time consuming and inconvenient to repeat at multiple time points. 
In contrast, radio-ITLC can be carried out on sub-microliter samples and completed in just a few 
minutes which makes it well suited for reaction monitoring. Yet, there was no established 
method suitable for analyzing small molecule 
89
Zr complexes. 
  Traditionally, the radiolabeling of 
89
Zr-DFO-mAb complexes is monitored via radio-TLC 
using ITLC-SG strips and 50 mM EDTA at pH 5 as the mobile phase. The 
89
Zr-DFO-mAb 
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complexes remain at the origin, while free 
89
Zr is taken up by EDTA in the mobile phase and 
migrates along the ITLC strip. Unfortunately, when the 
89
Zr-DFO complex is analyzed in such a 
way, it does not result in a single clean peak. Instead it gives a broad, indistinct result. This led to 
the exploration of other stationary and mobile phases to find conditions compatible with small 
89
Zr-ligand complexes. We evaluated ITLC-SG, ITLC-SA, and cellulose stationary phases in 
combination with EDTA, citric acid, and water mobile phases. Of the conditions tested, ITLC-
SA strips run in 50 mM EDTA was found to give the cleanest separation of 
89
Zr-DFO remaining 
at the origin and free 
89
Zr being taken up by the EDTA and migrating with the solvent front 
(Figure 2.2). A close second was ITLC-SA strips run in 0.5 M citric acid
13
 which gave similar 
separation, but with a broader signal for the free 
89
Zr since it likely forms multiple species when 
chelated by the citric acid eluant. All radio-ITLC methods discussed were evaluated with 
89
Zr-
oxalate as the starting material because 
89
Zr-colloid unavoidably sticks at the origin and makes 
such analysis impractical. Just as SEC was poorly matched to 
89
Zr-oxalate, ITLC was unsuitable 
for 
89
Zr-colloid.  
 2.2.2:  Characterization  
 In order to verify the identity of the complex, 
89
Zr-DFO was analyzed via HPLC against 
Zr-DFO and DFO standards. Non-radioactive Zr-DFO (structure confirmed by NMR and MS, 
Figures A.2.1 & A.2.2) and DFO were respectively detected at 8.3 min and 9.5 min by UV 
absorbance at 210 nm (Figure 2.3a). Radioactive detection of 
89
Zr-DFO indicated a single peak 
at 8.5 min consistent with the UV detection of the non-radioactive analogue (taking into account 
the small time delay due to the sequential placement of the UV and radioactive detectors; Figure 
2.3b). Upon the injection of 
89
Zr-DFO, there is no appreciable UV peak for the complex; 
however this is as expected due to the tracer level (picomolar) concentration of the complex. 
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Figure 2.2. Radio-ITLC analysis of 
89
Zr-DFO complex and free 
89
Zr-oxalate using ITLC-SA 
strips and 50 mM EDTA at pH 5. The 
89
Zr-DFO complex remains at the origin while the free 
89
Zr is taken up by the EDTA in the mobile phase and carried to the solvent front. 
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Figure 2.3. RP-HPLC analysis of (a) the separation of non-radioactive Zr-DFO from DFO as 
seen by UV absorbance and (b) 
89
Zr-DFO radiolabeling mixture with UV and radioactive 
detection. The UV signal corresponds to excess, unlabeled DFO. Analysis was carried out on a 
C18 RP-HPLC column at a flow rate of 1 mL/min with an increasing gradient from 10 to 100%  
MeCN in water over a 20 min acquisition time (all solvents contained 0.1% TFA).
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Instead, an intense UV peak was read at 9.5 min indicating the presence of excess non-metallated 
DFO due to low specific activity of 
89
Zr-DFO (1.5 µCi/mg). Accordingly, the presented HPLC 
method may be utilized to evaluate a relative specific activity of the radiocomplex by examining 
the amount of free ligand observed. This HPLC methodology may also be suitable for further 
utilization to identify 
89
Zr-DFO-mAb metabolites in the context of in vivo studies. 
The hydrophilicity of 
89
Zr-DFO was then evaluated measuring the distribution coefficient 
(log D). The log D at pH 7.4 was found to be -2.33±0.02 using an extraction between 1-octanol 
and PBS. This value indicated the poor solubility of 
89
Zr-DFO at pH 7.4 in 1-octanol which is in 
agreement with the known 2+ positive charge of 
89
Zr-DFO. 
6, 9
 It predicts the extreme 
hydrophilicity of 
89
Zr-DFO, corresponding to the low protein affinity and rapid in vivo renal 
clearance observed in the rest of this study.
14
 
 2.2.3:  In vitro studies  
Incubation of 
89
Zr-DFO in serum protein for 1 h at room temperature was carried out in 
order to assess the stability of the radiocomplex. The samples were analyzed using SEC with UV 
detection at 280 nm as well as gamma counting of the collected fractions (Figure 2.4). Although 
the retention time of 
89
Zr-DFO overlaps with the elution of a small subsection of lower 
molecular weight serum proteins, the retention time observed by HPLC of 
89
Zr-DFO before and 
after protein incubation remained unchanged (Figure A.2.4). 
89
Zr-DFO is therefore inert to 
serum proteins showing no binding affinity in contrast to free 
89
Zr.
15
 Moreover, the incubation of 
89
Zr-DFO with SW1222 tumor cells shows no internalization and a negligible affinity for tumor 
cells and membranes as compared to 
89
Zr-radiolabeled A33 antibody (
89
Zr-DFO-A33),
16
 here 
used as a positive control (Figure A.2.5). 
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Figure 2.4 
89
Zr-DFO was incubated with mouse serum proteins for 1 h at room temperature and 
then analyzed using SEC with UV detection at 280 nm (solid line) and radioactive detection 
(dashed line). The radioactive peak corresponding to 
89
Zr-DFO was eluted in the 1 KDa 
molecular weight range, consistent with the molecular weight of 
89
Zr-DFO (647 Da). The three 
lines represent triplicate samples. 
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 2.2.4:  In vivo studies  
  With an understanding of the chemistry of Zr-DFO in hand, we endeavored to probe the 
behavior of the complex in vivo in both healthy and tumor-bearing mice.  
2.2.4.1:  Dynamic imaging 
89
Zr-DFO was retro-orbitally injected in healthy and tumor-bearing mice directly on the 
PET imaging bed. Dynamic PET images were obtained for each animal for the first 20 min post-
injection. The reconstructed PET images (Figure 2.5), as well as the time activity curve (Figure 
2.6), initially indicated an elevated level of radioactivity in the blood and heart which then 
decreased from 15 to 10 %ID/g between 2 to 4 min in both healthy and tumor-bearing mice. 
From 6 to 20 min, the radioactivity rapidly migrated to the kidneys and bladder. 
89
Zr-DFO was 
almost completely renally excreted within 20 min p.i. with a negligible bone uptake (<2% ID/g 
for both groups), indicating the stability of the radiocomplex within the 20 min residency time in 
the body.  
As illustrated by the PET images (Figure 2.5), it is possible to visualize the tumors 
throughout the study, however we achieved poor tumor-to-background ratios and low tumor-to- 
blood ratios (Figure 2.7). Nevertheless, while the accumulation of radioactivity in the heart 
decreased over the 20 min, the amount of radioactivity in the tumor increased, until the two 
levels stabilized at approximately the same activity (3 %ID/g) for the final 7 min of the study. 
A difference in the distribution of the radioactivity in the tumor was observed throughout the 
study and is particularly noticeable in the axial PET slices (Figure 2.5). Interestingly, a ring 
shaped structure was observed at early time points (2-10 min), illustrating blood delivery by 
surrounding vessels and consistent with the tumor-to-blood ratio of about 1. Subsequently, at 16 
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Figure 2.5. Selected coronal and axial slices of 
89
Zr-DFO (150 µCi/animal) dynamic PET scans, 
from 2 to 20 min p.i. of retro-orbitally injected mice (NCRNU-M female) bearing SW1222 
tumors. Initially, the radioactivity is heterogeneously distributed in the tumor (indicated by an 
arrow) showing a ring-shaped structure, characteristic of a necrotic core. After 14 min, the 
distribution in the tumor changed to a disc-shaped structure.  
 
 
15.0 
0.0 
%ID/g 
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Figure 2.6. Time activity curve of the accumulation of radioactivity in: the hearts of tumor-
bearing mice (square); the hearts of healthy mice (dashed line); and the tumors (triangle). 
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Figure 2.7. Organ-to-blood ratio of radioactivity distribution 22 min after intravenous injection 
of 
89
Zr-DFO in SW1222 inoculated mice and healthy mice indicative of blood delivery in each 
organ, except kidney and bladder due to renal clearance of the radiocomplex (Tu: tumor; Mu: 
muscle; He: heart; Lu: Lung; Bo: bone; Ki: kidney; Blad: bladder).
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to 20 min p.i., the distribution of the radioactivity in the tumor changes, with higher levels of 
radioactivity filling in the core of the tumor.  
2.2.4.2:  Biodistribution 
Healthy and tumor-bearing mice showed comparable organ distribution of radioactivity 
(Table A.3.1). There were no notable differences and the tumor did not act as a sufficient sink of 
activity to change the in vivo behavior of the complex. The tumor uptake of 
89
Zr-DFO was quite 
low, only achieving a tumor to blood ratio of about 1 (Figure 3.7). 
2.2.4.3:  Histology 
Histology and autoradiography of the excised SW1222 tumors (22 min p.i.) further 
confirmed that most of the radioactivity was localized in the tumor core (Figure 3.8). The 
microscopic analysis showed the distribution of the radioactivity to be opposite that of the 
Hoechst and CD31 stained tissues. In areas of high perfusion and vascularization indicated by 
Hoechst (blue) and CD31 (red) staining respectively,
17
 the radioactivity was absent. Hematoxylin 
and eosin staining (H&E), revealed the tumor composition to be heterogeneous, with the core 
mostly constituted of collagen and fibrotic wire (stained in pink by eosin), likely indicative of a 
necrotic core, surrounded by a well-perfused and densely vascularized cellular tissue. Since 
89
Zr-
DFO did not get internalized by SW1222 tumor cells, as here demonstrated in vitro, the 
radioactivity was likely non-specifically trapped in the tumor necrotic core, resulting in a slower 
kinetic clearance than the other organs and viable tissues. A similar phenomenon has been 
reported when using Gd-DTPA, a blood perfusion probe for magnetic resonance imaging, where 
a slower clearance of the tracer has been observed in necrotic tumor tissue.
18
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Figure 2.8: Autoradiography and histology of SW1222 tumor section harvested 22 min p.i.; a) 
blue staining corresponds to Hoechst highlighting the blood perfusion; the red staining matches 
with CD31 indicating the presence of blood vessels. b) hematoxilin and eosin staining 
differentiating viable from necrotic tissue; c) overlay of a+b; d) 
89
Zr autoradiography overlapped 
with c. 
89
Zr-DFO accumulated in the tumor necrotic core underlining a slower clearance from the 
necrotic tissue as compared to well-perfused, viable tissue. 
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2.3:  Conclusions 
Using a colloidal preparation of 
89
Zr, an oxalate-free radiolabeling methodology was 
developed and optimized to overcome the existing challenges of radiolabeling small molecules 
with 
89
Zr. This approach combined with optimized SEC and HPLC methods considerably 
facilitated the monitoring, separation, and purification of 
89
Zr-DFO. In vitro studies showed the 
inertness of the radiocomplex to serum proteins or cells. A detailed pharmacokinetic evaluation 
in a tumor-bearing murine model demonstrated the rapid excretion of 
89
Zr-DFO. No meaningful 
differences were found between the in vivo behavior in healthy or tumor bearing mice. 
Interestingly, a particularly slow clearance of the radiocomplex from the necrotic area of the 
tumor was observed as compared to viable tissues, which provided information on the tumor 
quality. This characteristic of 
89
Zr-DFO may be useful for non-invasively assessing the 
heterogeneity of a tumor through PET imaging. 
In brief, a novel, technical method is here presented for the preparation, characterization, 
and purification of small molecule 
89
Zr-radiolabeled complexes which has allowed for an in 
depth evaluation of 
89
Zr-DFO. This methodology demonstrates potential for future application 
toward the identification of metabolites in the context of preclinical and clinical development of 
89
Zr-labeled mAbs as well as in the development and evaluation of novel 
89
Zr chelators.  
Ultimately, the 
89
Zr-colloid species was not carried over and used for the evaluation of 
the novel ligands due to concerns over the inability to fully characterize the species. The colloid 
system could not be mimicked on the macroscale and its precise composition could not be 
determined. Furthermore, the practice of drying down the 
89
Zr-oxalate samples in an open vessel 
was deemed an unnecessary contamination hazard. Although 
89
Zr-colloid was an interesting and 
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effective alternative to the traditional 
89
Zr-oxalate labeling, its disadvantages proved more 
persuasive than its benefits.  
While the 
89
Zr-colloid method was able to eliminate the risk of lingering oxalate from 
89
Zr-DFO solutions, it would be limited to small molecules and could not be carried over to 
ligand-antibody work due to its low pH requirements. Additionally, the 
89
Zr-colloid 
radiolabeling reaction was incompatible with convenient radio-ITLC analysis for reaction 
monitoring. The use of one radiolabeling method to test preliminary ligands when a different 
radiolabeling method would ultimately have to be used for their intended application would open 
up a world of potential issues as the difference in techniques may affect the performance and 
selection of the ligands under evaluation. Therefore, the 
89
Zr-oxalate method of radiolabeling 
prevailed and was used in the remainder of this work. 
2.4:  Experimental section 
 2.4.1:  Materials and methods 
  All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis, 
MO) and used as received without further purification. Human serum was purchased frozen from 
Sigma Aldrich. All water used was ultra-pure (>18.2 MΩ cm– 1). All instruments were calibrated 
and maintained in accordance with standard quality-control procedures. High resolution mass 
spectrometry (HRMS) measurements were performed on a Waters SYNAPT High Definition 
MS System (ESI-QTOF) and low resolution mass spectra (LRMS) were recorded with a Waters 
Acquity UPLC with electrospray ionization (ESI) SQ detector.
 1
H NMR spectra were recorded at 
ambient temperature on a Bruker 500 MHz NMR with Topsin 2.1 software. The NMR spectra 
are expressed on the δ scale and were referenced to residual solvent peaks and/or internal 
tetramethylsilane. The HPLC system used for analysis and purification compounds consisted of a 
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Shimadzu prominence system equipped with a diode array and a radioactive detector (Bioscan 
inc, DC). IR spectroscopy was performed on a solid sample using an attenuated total reflectance 
attachment on a PerkinElmer Spectrum 2 FT-IR spectrometer with a UATR Two attachment. 
UV-Vis spectroscopy was carried out using a Thermo Scientific Evolution 220 UV-Visible 
spectrophotometer. 
89
Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron 
(Ebco Industries Inc.) via the 
89
Y(p,n)
89
Zr reaction and purified to yield 
89
Zr with a specific 
activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose 
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on 
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored 
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent 
Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan 
Radio-TLC software (Bioscan Inc., Washington, DC).  All in vivo experiments were performed 
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and 
Use Committee (protocol 08−07−013).  
 2.4.2:  Zr-DFO 
  Non-radioactive Zr-DFO was prepared, dissolving ZrCl4 powder in deionized water with 
50 mM DFO at room temperature (ratio Zr : DFO; 1:1). Both DFO ligand and Zr-DFO were 
characterized using 
1
H NMR (Bruker 500 MHz NMR with Topsin 2.1 software - Figure A.2.2) 
as well as LRMS (Low resolution mass spectra were recorded with a Waters Acquity UPLC with 
electrospray ionization SQ detector – ESI – Figure A.2.1). 
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 2.4.3:  
89
Zr-oxalate radiolabeling  
  
89
Zr-oxalate was prepared in-house as described by Holland et al.
19
 An irradiated yttrium-
89 target was dissolved in strong acids and 
89
Zr was separated using a hydroxamate column and 
eluted with oxalic acid. This results in the 
89
Zr received after target processing being 
89
Zr-oxalate 
in 1.0 M oxalic acid. This solution is then neutralized with 1.0 M sodium carbonate to reach pH 
6.8-7.2. DFO was labeled at various concentrations in water or saline with the neutralized 
89
Zr 
solution at room temperature for varying lengths of time, typically 10-60 min. Samples were 
labeled with 10 μCi to 1 mCi depending on the nature of the experiment (for reference, 1 μCi of 
89
Zr equals 25 femtomoles).  
 2.4.4:  
89
Zr-colloid radiolabeling 
  
89
Zr-oxalate was evaporated on a heat-block at 120°C for 10 min. The dried material was 
digested with 40 µL of strong acid mix (1:1 – v/v; HCl - 37% and HNO3 - 70%) and 20 µL of 
glacial acetic acid and evaporated until dry.
9
 The final residue was then suspended in saline in 
order to reach a concentration of 1 µCi/µL. The resulting solution, here called 
89
Zr-colloid, was 
the starting material for DFO radiolabeling. The colloidal nature of 
89
Zr-colloid was verified 
using Dynamic Light Scattering (DLS) at various time points post-dissolution (Figure 3.1a). 
  
89
Zr-colloid solution were checked to be at pH 2 and then thoroughly mixed at room 
temperature with 50 mM saline solution of desferrioxamine mesylate (Calbiochem, Millipore). 
After incubation for at least 10 min, the final preparation was then neutralized to pH 7.5 adding 
1 M Na2CO3. For all experiments 
89
Zr-DFO specific activity was 1.5 µCi/mg. 
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 2.4.5:  Chromatographic methods 
  2.4.5.1:  Size exclusion 
  
89
Zr-DFO was evaluated using size exclusion chromatography (SEC). Neutralized 
89
Zr-
oxalate, 
89
Zr-colloid, and 
89
Zr-DFO were comparatively eluted and separated with using size 
exclusion chromatography with Sephadex G-25 gel (PD-10 desalting column, GE Healthcare) 
and deionized water. Fractions of 1 mL were collected and each fraction was gamma counted. 
  2.4.5.2:  ITLC 
  Reactions were monitored via radio-TLC using Varian ITLC-SA strips (Agilent 
Technologies) and 50 mM EDTA at pH 5 as the mobile phase. 
89
Zr-ligand complexes remained 
at the origin, while free 
89
Zr was taken up by EDTA in the mobile phase and migrated along the 
ITLC strip. Additional conditions evaluated included ITLC-SG strips (Agilent Technologies) and 
cellulose strips cut from Whatman filter paper as well as 0.5 M citric acid and Millipore water 
(see appendix for method comparison, Figure A.2.3). 
  2.4.5.3:  HPLC 
  The Ultra Fast Liquid Chromatography (UFLC) Shimadzu system was equipped with a 
diode array and a radioactive detector (Bioscan inc, DC), as well as a reverse-phase (RP) HPLC 
column (Jupiter 5u C18 300 Å; 250 × 4.6 mm, 5 micron) provided by Phenomenex, CA. The 
radiation detection was delayed approximately 30 s as compared to UV due to detectors 
sequential set-up of the detectors and the flow rate utilized. 
89
Zr-DFO, non-radioactive Zr-DFO 
and metal-free DFO were analyzed by HPLC at a flow rate of 1 mL/min eluted with water and 
acetonitrile, both spiked with 0.1 % trifluoroacetic acid, with an increasing gradient from 10 to 
100% acetonitrile over a 20 min acquisition.  
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 2.4.6: Diffusion coefficient 
  
89
Zr-DFO diffusion coefficient log D was measured (n=6) using an extraction method 
separating phosphate buffered saline pH 7.4 (PBS) from 1-octanol. A PBS and 1-octanol mixture 
(1:1; v/v) was stirred overnight in order to saturate each layer. 
89
Zr-DFO was added to the bi-
layered preparation (6 mL) and the mixture was stirred for 1 h. Then 1 mL of each layer was 
extracted and gamma counted. The diffusion coefficient log D was calculated in Equation 3.1: 
Log D = log (counts per min in octanol layer ÷ counts per min in water layer) (3.1) 
 2.4.7:  Serum stability 
  
89
Zr-DFO was incubated with mouse serum protein (5µCi in 250 µL of mouse serum 
protein from Sigma Aldrich) at room temperature for 1 h (n=3). A gel filtration standard solution 
was first eluted on the column to correlate molecular weight to elution time. 
89
Zr-DFO in serum 
protein sample mixture was then analyzed using size exclusion chromatography (SEC, 
automated Biorad size exclusion system, Biologic LP) Superdex 200 prep grade gel (column 
diameter 18 mm; length 180 mm) eluted with PBS at a flow rate of 1 mL/min. The 
chromatogram was acquired for 45 min using UV detection at 280 nm. Each eluted 1 mL 
fraction was collected and gamma counted (Figure 2.3). The radioactive fraction (30 mL eluted 
fraction) was then injected in HPLC (Figure A.2.4), in order to verify the unchanged quality of 
89
Zr-DFO, post-serum incubation. The same HPLC conditions were used as previously 
described. In order to get a higher radioactive signal from the HPLC analysis, this experiment 
was repeated with higher specific activity 
89
Zr to counteract the extensive dilution resulting from 
the SEC. 
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 2.4.8:  Cell affinity 
  Cell experiments were conducted using SW1222 human colorectal cancer cell line 
(ATCC) which were grown in Dulbecco’s modified Eagle’s medium (DMEM, Life Technolgies, 
CA) and kept under 5% CO2 incubation. 1×10
6 
cells/well were placed in a 6 wells-plate 24 h 
prior to the experiment. The following day cells were incubated with 5 µCi 
89
Zr-DFO (n=6) or 5 
µCi of 
89
Zr-DFO-A33 (specific activity 2.71 mCi/mg; n=6) for 1 hour at 37°C. Cells were then 
washed with cold PBS twice and harvested using trypsin (0.25%) treatment. Cells and standards 
were gamma counted. The radioactivity differential was calculated using 
89
Zr-DFO and 
89
Zr-
DFO-A33 standards, allowing the determination of the initial dose percentage (ID %) associated 
with the cells (Figure A.2.5). 
  
89
Zr-DFO-A33 was prepared by conjugation of p-Bn-SCN-DFO with A33 (a monoclonal 
antibody) and radiolabeled with neutralized 
89
Zr-oxalate as described by Zeglis et al.
16
  
 2.4.9:  PET imaging 
  Animal experiments were conducted according to National Institute of Health (NIH) 
guidelines and the Institutional Animal Care and Use Committee of MSKCC.  
  NCRNU-M (homozygote) female mice were implanted with tumors by subcutaneous 
injection of 5×10
6
 SW 1222 cells on the right shoulder. The tumors were allowed to grow for 10 
days, reaching an approximate tumor diameter of 5-7 mm.  
  After 
89
Zr-DFO quality control, continuous PET dynamic scans (Micro-PET Focus 120 
scanner, Siemens, IL) were conducted over 20 min using healthy (n=4) and tumor-bearing mice 
(n=4). The mice were retro-orbitally injected (150 µCi [5.55 MBq] 
89
Zr-DFO per animal) under 
inhalation of 1% isoflurane (Baxter Health-care, Deerfield, IL, USA) / oxygen gas mixture (flow 
rate: 2 L/min) for anesthesia. To minimize the dead-time between the injection and the beginning 
57 
 
of the scan, the animal was injected on the PET scanner bed. PET scans were immediately 
acquired over 20 min. Dynamic scans were reconstructed using ASIPRO VM Concorde 
Microsystems software, iterative 2D OSEM reconstruction method, corrected for dead-time (15 
s) and separated into 10 frames of 120 s each. Selected coronal and axial slices of animals are 
depicted in Figure 2.4. Time activity curves (Figure 2.5) were created averaging the regions of 
interest (ROI), n=4, of the specific organs (hearts of healthy and tumor-bearing mice as well as 
tumors). 
 2.4.10:  Biodistribution 
  Approximately 1 min prior to sacrifice, the vascular perfusion marker Hoechst 33342 (15 
mg/kg in 0.2 mL of sterile saline) was administered intravenously via the tail vein. About 20 min 
post-injection, mice were sacrificed and the organs were collected, weighed, and gamma counted 
with 
89
Zr-DFO standards. From this, the 
89
Zr activity percentage of injected dose per gram 
(%ID/g) of each organ was calculated. 
 2.4.11:  Histology 
  The harvested tumors were immersed in Tissue-tek® O.C.T. cryogenic gel and frozen. 
Series of contiguous fresh-frozen tumor sections of 10 μm thickness were cut. Tumor sections 
were exposed for one radionuclide half-life to a phosphor-imaging plate (Fujifilm BAS-MS2325, 
Fuji Photo Film, Japan) at -20° C. The plates were placed in a BAS-1800 II Bio-Imaging 
Analyzer (Fujifilm Medical Systems, USA) to readout the image. All autoradiographic and 
immunostaining procedures were carried out on the same section. Dual immunofluorescence 
staining of the endothelial cell marker CD31 and Hoechst was accomplished as previously 
described.
17
 Stained sections were imaged using an Olympus BX-40 fluorescence microscope 
equipped with a computer-driven motorized stage, a CC-12 digital camera and Olympus 5 
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acquisition software (Olympus America, Center Valley, PA). Image sets were co-registered in 
Olympus 5 software.  
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CHAPTER 3: COMPARISON OF LIGAND BINDING GROUPS FOR 
ZIRCONIUM-89 
 
3.1:  Introduction 
From an inorganic chemistry perspective, DFO is not ideally suited to the coordination 
properties of Zr
4+
. The Zr
4+
 cation is a highly charged, hard Lewis acid with a predilection for 
forming complexes with high coordination numbers. For example, eight coordinate complexes 
 such as zirconium oxalate, [Zr(oxalate)4]
4-
  are particularly common with Zr4+.1 With this in 
mind, it seems incongruous that a hexadentate ligand such as DFO is used with a metal that 
prefers forming octa-coordinate complexes. In fact, previous molecular modeling of the most 
favorable structure of the Zr-DFO complex revealed that in the optimized structure, two water 
molecules join the metal’s coordination sphere to form an eight coordinate complex.2 
Preliminary work by Brechbiel et al. has focused on investigating the coordination chemistry of 
Zr
4+
 with different hydroxamate binding groups with the goal of gaining insights toward the 
design of new chelators.
3
 Most notably, this work, including experimental and theoretical 
treatment, further confirmed that Zr
4+
 preferentially forms eight coordinate complexes and thus 
strengthens the argument for the development of an octadentate chelator.  
With this in mind, we wanted to start the search for a better chelator based on chemical 
principles. A ligand designed specifically with the chemistry of Zr
4+
 in mind should demonstrate 
improved stability upon complexation with Zr
4+
. Furthermore, and perhaps even more 
importantly, a more stable complex should be less prone to demetallation in vivo, resulting in 
reduced bone uptake and thus a safer and more efficient 
89
Zr-based PET tracer. While it is clear 
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from the above data that an alternative chelator for Zr
4+
 should be octadentate, insufficient work 
has been done to explore the affinity of different binding groups with Zr
4+
. Herein, we endeavor 
to expand the chelation of Zr
4+ 
beyond the hydroxamate group.  
Our inspiration for selecting potential new binding groups for Zr
4+
 came from a library of 
ligands developed by Raymond et al. as actinide sequestration agents.
4
 The library contained a 
number of ligands designed for plutonium(IV) decorporation
5-7
, and the similarity in 
coordination chemistry between Zr
4+
 and Pu
4+
 marked these as excellent candidates. The use of 
Hf
4+
 — the third row congener of Zr4+ — as a model for Pu4+ highlights this connection.8-11 
These ligands are comprised of hard oxygen donor groups, specifically hydroxamates, 
catecholates and hydroxypyridinonates.
4
 Both binding groups offer hard, oxygen donors 
appropriate for binding Zr
4+
, however they vary in terms of pKa’s with values of -0.8 and 5.8 for 
the hydroxypridinones compared to 9.2 and 13.0 for the catechol (Figure 3.1).
4
 The lower pKa 
of the 1,2-HOPO group may offer an advantage for radiolabeling at lower pHs, but 
hydroxamates, such as those in DFO, have a pKa of 9.4 and are known to chelate 
89
Zr under mild 
conditions, so the catechol group may still be suitable.  
Beyond the binding groups themselves, one pair of ligands in particular  3,4,3-(LI-1,2-
HOPO) and 3,4,3-LICAM (Figure 3.2)
4
  stood out as promising candidates for Zr4+ chelation. 
Both are octadentate chelators composed of a spermine backbone coupled with either four 
hydroxypyridinone (HOPO ligand) or catechol (LICAM ligand) groups for metal binding. These 
ligands were selected to be synthesized and evaluated for use with Zr in order to directly 
compare the hydroxypyridinone and catechol binding groups in the quest for an improved ligand 
for 
89
Zr
4+
. 
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Figure 3.1. Comparison of potential binding groups with their respective pKas. 
Adapted from Gorden, A.E.V. et al. Chem. Rev. 2003, 103, 4207-4282.
4
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Figure 3.2. Proposed chelators for zirconium with binding oxygens highlighted in red. The 
current standard chelator, desferrioxamine B, is included on the left for comparison with the 
alternative chelators shown on the right. 
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3.2:  Results and discussion 
 3.2.1:  Synthesis and characterization  
  The HOPO ligand was synthesized as previously reported, with minor changes (Figure 
3.3).
4, 12-15
 Despite this being a published synthesis, however, we encountered a number of 
challenges in our production of the ligand. The simultaneous coupling of four HOPO groups 
onto the amine backbone and the characterization of the resulting product proved difficult. Once 
we were able to confirm that we had all four groups on, the full deprotection of all four groups 
became the next hurdle. Additionally, the adaptation of this ligand for radiochemical applications 
required additional purification stringency in order to eliminate the possibility of preferentially 
labeling trace impurities. Therefore, for the investigation at hand, the final product was purified 
via reverse-phase HPLC.  
The high degree of symmetry of HOPO, combined with its flexibility, resulted in a 
1
H-
NMR with many overlapping multiplets due to different amide rotamers of the ligand. As a 
result, the classification of HOPO as a mixture of rotamers of one compound rather than distinct 
isomers or impurities was based on the identification of the expected compound by mass 
spectrometry as well as the appearance of a single peak by HPLC analysis (Figure A.3.1-2).  
 Similar issues were encountered with the synthesis of the LICAM ligand (Figure 
3.4); however it was undertaken after we had overcome the hurdles of the HOPO ligand so 
improved strategies were in place. Once again, the LICAM compound was characterized 
primarily through mass spectrometry and HPLC due to the complicated nature of its NMR 
spectrum (Figures A.3.3-4).  
Due to the complicated synthesis of the complete ligands, efforts were made to 
investigate the different binding groups using simpler molecules containing only a single
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Figure 3.3. Synthesis of 3,4,3-(LI-1,2-HOPO) (HOPO). 
Reagents and conditions: a) CH3COOOH (1.2 equiv), AcOH, TFA, 1 h, 79%; b) BnCl (1.2 
equiv), K2CO3 (2.0 equiv), CH3OH, 16 h, 63 
o
C, 92%; c) (COCl)2 (2.2 equiv), CH2Cl2, 0-
25 
o
C, 6 h; d) spermine (0.17 equiv), TEA (2.0 equiv), CH2Cl2, 0-25 
o
C, 24 h, 81% over 
steps c & d; e) AcOH, HCl (12 N), 18 h, 45 
o
C, 42% 
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Figure 3.4. Synthesis of 3,4,3-LICAM (LICAM). 
Reagents and conditions: a) acetone, BnBr, K2CO3 then MeOH, LiOH, HCl; b) DCM 
(COCl)2; c) spermine, DCM, NEt3, 0-25 
o
C, 12 h, 64%; d) 10% Pd/C, H2, MeOH, r.t, 6 h, 
73% 
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catechol or hydroxypyridinone group (Figure 3.5). Initially, a proof of principle experiment was 
carried out with dopamine since it contained a catechol group, but then two different 'monomers' 
were synthesized from the building blocks of the HOPO and LICAM ligands in order to probe 
the binding of radioactive and non-radioactive Zr. The HOPO methyl monomer (HMM) and 
catechol methyl monomer (CMM) units were produced by coupling the acid chloride derivatives 
of the binding groups with methylamine to mimic the coupling to the spermine backbone in the 
full ligands.  
 3.2.2:  Monomer studies  
  The synthesis of the octadentate ligands proved more challenging than originally 
expected due to the challenges of multiple coupling reactions and the stringent purification 
requirements intrinsic to tracer work. Therefore, initial evaluation was attempted with simpler 
molecules to compare binding groups without requiring the complex synthesis of full ligands. 
These single unit 'monomers' containing only a single catechol or hydroxypyridinone group were 
created to probe the binding of Zr
4+
 (Figure 3.5). Experiments were done to complex these 
monomers with radioactive and non-radioactive Zr on both the tracer level and macroscopic 
scale respectively. 
  Dopamine, a readily available catechol-based molecule, was first used to evaluate the 
binding potential of catechols for Zr
4+
. Radioactive 
89
Zr was added to a solution of dopamine and 
a crude challenge experiment was used to determine if there was any complexation. The 
radiolabeled mixture was run through a reverse phase extraction cartridge and the collected 
fractions were monitored for both UV absorbance and radioactive counts. A partial correlation 
between the UV and radioactive signal in the eluted fractions suggested some complexation of 
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Figure 3.5. Chemical structures of the single binding unit monomers investigated. Each 
monomer is a bidentate ligand with two electron donating oxygens highlighted in red. 
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the 
89
Zr by the dopamine (Figure 3.6). This served as a proof of concept demonstrating that 
catechols did indeed have some affinity for Zr
4+
 and should be evaluated for possible ligands.  
  With this encouraging pilot study, we moved to evaluate the binding groups using the 
specific monomer units we had designed to mimic the layout of the ultimate HOPO and LICAM 
ligands. Both monomers were combined with non-radioactive ZrCl4 and the samples were 
analyzed with LCMS in an attempt to identify potential Zr-monomer complexes. Unfortunately, 
while both binding groups showed a number of peaks, none could be reasonably assigned to any 
conceivable Zr-monomer complexes. It is reasonable that complexation would be complicated as 
different number of units could bind to one or more Zr centers and these complexes may include 
dimers or trimeric units as well as other components from the starting materials filling out the Zr 
coordination sphere. 
  Next, both HMM and CMM were radiolabeled with neutralized 
89
Zr oxalate solution to 
evaluate binding on the tracer level. However, radioITLC analysis of the 
89
Zr-monomer 
complexes was inconclusive. No appreciable amount of labeled complex was found, which could 
have two possible explanations: 1) no complexation occurred or 2) transient complexation did 
occur but was not adequate for this kind of chromatography. For example, the EDTA in the 
mobile phase of radioITLC analysis likely made a more stable complex with the 
89
Zr
4+
 and 
outcompeted any monomers which had initially bound to the metal, so no meaningful 
information could be garnered from that analysis. RadioITLC without a chelating component in 
the mobile phase proved unreliable in the separation of the free and bound 
89
Zr.  
  The radiolabeled monomers were also run through reverse phase solid phase extraction 
cartridges and compared to the behavior of free 
89
Zr under the same conditions (Figure 3.7). The 
free, unchelated 
89
Zr was found to elute primarily in the first 5% methanol in water wash fraction 
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Figure 3.6. Elution profile of preliminary 
89
Zr-dopamine experiment. A mixture of 
89
Zr and 
dopamine was run through a C18 solid phase extraction cartridges and 1 mL fractions were 
collected. The fractions were measured for radioactive counts and UV absorbance. A rough 
correlation can be seen between the two which suggests that the 
89
Zr is in some way complexing 
with the dopamine. This suggests a potential affinity of catechols for binding Zr. 
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Figure 3.7. Elution profile of 
89
Zr-monomer mixtures with free 
89
Zr as a control through C18 
Sep-Pak cartridges. 500 μL fractions were collected. The first 5 fractions were a wash with 5% 
methanol in water. The second 5 fractions were eluted with methanol. The fractions and the 
cartridges were gamma counted to account for all loaded activity. The 
89
Zr-HMM mixture elutes 
similarly to the free 
89
Zr, suggesting a lack of chelation, however the 
89
Zr-CMM shows a 
different elution profile suggesting some level of complexation occurred.  
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(88%). The 
89
Zr-HMM mixture exhibited very similar behavior (79% in the first wash fraction) 
suggesting that no meaningful complexation occurred, however the 
89
Zr-CMM sample behaved 
differently. Only 16% of the 
89
Zr-CMM activity came out in the first wash fraction and nearly 
30% of was found in the first methanol elution fraction. This suggests some level of 
complexation from the catechol monomer, although the extent of complexation or the actual 
speciation could not be determined in this method.  
  In order to probe the nature of the complexation observed in the cartridge study of the 
89
Zr-CMM sample, we tried to evaluate the non-radioactive Zr-CMM mixture. To this end, a 
mixtures of CMM and ZrCl4 were prepared at different ratios (1:1, 4:1, and 10:1 of CMM:ZrCl4) 
and were analyzed by UV/Vis spectroscopy to probe the difference in absorbance as the catechol 
groups bound to the metal. Unfortunately, the spectra did not change in any meaningful way 
between the samples (Figure A.3.5). Either the catechol groups did not bind the Zr or the 
conditions used in this study were insufficient to measure the differences.  
  Ultimately, the monomers proved insufficient to obtain any useful information on the 
affinity of the binding groups for Zr. It was determined that the preorganization offered by the 
full octadentate ligands would be necessary to evaluate the binding potential of the two groups. 
Individual bidentate chelation was not shown to be strong enough to produce any consistent 
measurable results.  
 3.2.3:  Ligand studies  
Due to the disappointing conclusiveness of the monomer studies, the full HOPO and 
LICAM ligands were synthesized and evaluated to compare the hydroxypyridinone and catechol 
binding groups. Non-radioactive Zr-ligand complexes were formed on the macroscopic scale to 
facilitate characterization. The complex was formed by mixing the HOPO and LICAM ligands 
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with a slight excess (1.5 eq.) of ZrCl4 in water at room temperature. Both mixtures as well as the 
ligands alone were analyzed by HPLC. The Zr-HOPO product was eluted as a single peak with a 
retention time shifted about 30 seconds compared to the ligand alone (Figure A.3.6). The Zr-
LICAM mixture, on the other hand, did not consistently change retention times compared to the 
ligand alone (Figure A.3.7). The slight movement may be due to wear on the column and may 
not indicate a new, distinct species. The 1:1 binding of Zr
4+
 and HOPO was confirmed by 
electrospray ionization mass spectrometry (ESI MS), which shows the expected mass signals 
(837.2 [M+H]
+
 & 859.2 [M+Na]
+
) (Figure A.3.8). While mass spectroscopy also showed Zr-
LICAM to be a 1:1 ratio, the best matches from low resolution ESI MS suggested that the 
LICAM ligand was deprotonated for only 4 out of the 8 catechol oxygens Zr-LICAM (832 [M-
H]
-
 & 865 [M+Cl]
-
) (Figure A.3.9). The evidence of Zr-ligand complexation is much stronger 
for the HOPO ligand than the LICAM on the macroscopic scale. 
For our initial radiolabeling studies we used relatively high concentrations of ligand and 
at 1 mM the HOPO ligand would reach 100% labeling at room temperature within 10 minutes of 
the addition of 
89
Zr. At 10 uM the HOPO ligand attained 100% radiolabeling within 45 min. In 
contrast, even at 1 mM, the LICAM ligand only achieved less than 30% radiolabeling even with 
an increase in incubation time, the addition of heat, and varying the pH. This is most likely due 
to the higher pKa of the catechol binding groups compared to the hydroxypyridinones. At pH 7, 
the catechols are not fully deprotonated, but when you raise the pH of the reaction the Zr begins 
to precipitate out of solution because Zr has very poor solubility in aqueous solution at higher 
pH. Due to this incompatibility between the base strength of the binding groups and the workable 
pH range of Zr and antibodies, the LICAM ligand was determined to be unsuitable for Zr 
chelation and not studied any further. The consequence of these data is that the HOPO ligand 
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was selected for further evaluation, while the LICAM ligand, and in fact catechols in general, 
were eliminated from our pool of chelation possibilities. 
3.3:  Conclusions 
The catechol-based ligand, 3,4,3-LICAM (LICAM), was evaluated since catechols are 
known functionalities in siderophores, but was ultimately found to be unsuitable for 
89
Zr
4+
 due to 
the incompatibility between the pKa of the catechol group and the solubility of the Zr
4+
 cation.  
Despite being octadentate and oxygen-rich, the maximum radiolabeling yield reached for the 
LICAM ligand was <30%, despite varying temperature, pH, and reaction time.  We believe the 
issue to lie in the fact that the pKa for full deprotonation of the catechol group is 13.0, which 
requires a higher pH for proper labeling; however, the Zr
4+
 cation is only soluble at lower pH, 
and antibody radiolabeling is typically performed at ~ pH 7.  This leads to a precarious balance 
between keeping the 
89
Zr
4+
 in solution and trying to get the coordinating oxygen atoms of the 
catechol moiety deprotonated.  Unfortunately, an appropriate compromise could not be found 
that achieved >30% radiolabeling, so the ligand and catechol groups in general were dropped 
from further development. 
In contrast, the hydroxypyridinone ligand3,4,3-(LI-1,2HOPO) (HOPO),  performed very 
well in initial evaluations. The HOPO ligand achieved quantitative labeling at mild conditions 
with short reaction times. This demonstrates the affinity of the hydroxypyridinone binding 
groups for Zr
4+ 
as well as the efficacy of the HOPO ligand itself. Therefore, the HOPO ligand 
advanced for further investigation detailed in the next chapter. 
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3.4:  Experimental section 
 3.4.1:  Materials and methods 
  All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis, 
MO) and used as received without further purification. All instruments were calibrated and 
maintained in accordance with standard quality-control procedures. High resolution mass 
spectrometry (HRMS) measurements were performed on a Waters SYNAPT High Definition 
MS System (ESI-QTOF) and low resolution mass spectra (LRMS) were recorded with a Waters 
Acquity UPLC with electrospray ionization (ESI) SQ detector.
 1
H NMR spectra were recorded at 
ambient temperature on a Bruker 500 MHz NMR with Topsin 2.1 software. The NMR spectra 
are expressed on the δ scale and were referenced to residual solvent peaks and/or internal 
tetramethylsilane. The HPLC system used for analysis and purification compounds consisted of a 
Shimadzu prominence system equipped with a diode array and a radioactive detector (Bioscan 
inc, DC). UV-Vis spectroscopy was carried out using a Thermo Scientific Evolution 220 UV-
Visible spectrophotometer. 
89
Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron 
(Ebco Industries Inc.) via the 
89
Y(p,n)
89
Zr reaction and purified to yield 
89
Zr with a specific 
activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose 
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on 
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored 
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent 
Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan 
Radio-TLC software (Bioscan Inc., Washington, DC).  All in vivo experiments were performed 
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and 
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Use Committee (protocol 08−07−013). Purity of greater than 95% was confirmed using 
quantitative HPLC analysis for non-radioactive compounds (HOPO and Zr-HOPO) and radio-
TLC for radioactive compounds (
89
Zr-HOPO). 
 3.4.2:  Synthesis 
  3.4.2.1:  HOPO-methyl monomer (HMM) 
  Methylamine was added to 1-Benzyloxy-2(1H)-pyridinone-6-carbonyl chloride in DCM. 
The reaction mixture was washed with 1 N HCl and 10% NaHCO3. The DCM layer was dried 
over Na2SO4 and evaporated to dryness. The product was washed with diethyl ether and purified 
on a semi-preparative C4 column (Jupiter 250 × 10 mm, 5 µM, Phenomenox) using a gradient of 
0-10% MeCN in water (both containing 0.1% TFA) over 20 min at a flow rate of 5 mL/min. The 
product was collected from 4.1-5.0 min and lyophilized. 
  3.4.2.2:  Catechol-methyl monomer (CMM) 
  2,3-bis(benzyloxy)benzoyl chloride was combined with methylamine in  DCM. The 
reaction mixture was washed first with 1 N HCL followed by a 10% NaHCO3 wash. The DCM 
layer was dried over Na2SO4 and evaporated to dryness. The product was washed with diethyl 
ether and purified on a semi-preparative C4 column (Jupiter 250 × 10 mm, 5 µM, Phenomenox) 
using a gradient of 5-25% MeCN in water (both containing 0.1% TFA) over 20 min at a flow 
rate of 5 mL/min. The product was collected from 4.8-6.5 min and lyophilized. 
  3.4.2.3:  3,4,3-(LI-1,2-HOPO) 
  The synthetic protocol from Xu et al. was employed with slight modifications.
12
 
 6-Carboxy-1-hydroxy-2(1H)-pyridinone [1,2-HOPO carboxylic acid] (1). 6-
Hydroxypicolinic acid (10.0 g, 71.9 mmol) and peracetic acid (21.0 g, 88.4 mmol) were added to 
a stirring solution of glacial acetic acid (40.0 mL) and trifluoroacetic acid (60.0 mL). This 
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mixture was stirred under nitrogen for 1 h at room temperature before being heated to 80 
o
C for 
12 h. The reaction mixture started off a red-brown color and turned orange over time. A light 
color precipitate formed, was collected by filtration, and washed with cold methanol. After 
drying, the product was obtained as a beige solid (yield 79%). 
 1-Benzyloxy-6-carboxy-2(1H)-pyridinone [1,2-HOPOBn carboxylic acid] (2). Compound 
1 (3.70 g, 23.8 mmol) and potassium carbonate (6.60 g, 47.7 mmol) were added to a stirring 
solution of benzyl chloride (3.60 g, 28.6 mmol) in methanol (10.0 mL). The mixture was heated 
to 63 
o
C and left to reflux for 16 h. The reaction mixture was a dark green suspension and formed 
a precipitate over time. The blue-gray solid was filtered out of the reaction mixture and the 
filtrate was collected. The solvent was evaporated and its residue was redissolved in 12.0 mL 
water. The solution was acidified to pH 2 by dropwise addition of 12 N HCl. An off-white 
precipitate was formed and was isolated by filtration. The product was washed with cold water 
and dried to yield a light beige solid (yield 92%).  
 1-Benzyloxy-2(1H)-pyridinone-6-carbonyl chloride [1,2-HOPOBn acid chloride] (3). A 
suspension of 2 (1.03 g, 4.20 mmol) in anhydrous dichloromethane (25 mL) was cooled to 0 
o
C. 
Excess oxalyl chloride (0.715 mL, 9.40 mmol) was added while stirring followed by catalytic 
amount of DMF (0.1 mL). Gas bubbles evolved, and the suspension became clear. The mixture 
was then left at room temperature for 6 h, and the solvent was removed by rotary evaporation to 
leave pale brown oil. After the oil was co-evaporated twice with toluene (10 mL), the crude acid 
chloride (3) was used directly for the next reaction without any purification.  
 3,4,3-(LI-1,2-HOPO)Bn [benzyl-protected HOPO] (4). A solution of crude 3 (0.79 g, 
3.0 mmol) in dichloromethane (15 mL) was added drop wise to a stirred solution of triethylamine 
(0.84 mL, 6.0 mmol), spermine (0.10 g, 0.50 mmol) and DMAP (0.0060 g, 0.050 mmol) in dry 
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dichloromethane (10 mL) at 0 
o
C. The reaction mixture was warmed to room temperature and 
stirring was continued for 24 h. The reaction mixture was washed with 10% NaHCO3 solution, 
followed by water. The organic phase was dried over anhydrous Na2SO4, filtered, and 
concentrated to dryness. Purification by column chromatography (SiO2, 2-6% MeOH in CH2Cl2) 
afforded the benzyl-protected precursor 3,4,3-LI(1,2-HOPOBn) (4) as white foam (yield 81%). 
 3,4,3-(LI-1,2-HOPO) (HOPO). Compound 4 (0.20 g, 0.18 mmol) was dissolved in 1:1 
mixture of acetic acid and concentrated HCl (15 mL) at room temperature and the reaction 
mixture was stirred at 50 
o
C for 18 h. The reaction progress was monitored by TLC. The crude 
product was dried, redissolved in water, and purified by HPLC on a semi-preparative C4 column 
(Jupiter 250 × 10 mm, 5 µM, Phenomenox) using a gradient of 5-28% MeCN in water (both 
containing 0.1% TFA) over 20 min. The product peak was collected from 7-8.92 min and the 
eluted solution was lyophilized to recover the product as a white solid. The purified ligand was 
collected in multiple small batches with an approximate combined yield of 42%. 
  3.4.2.4:  3,4,3-LICAM 
  The synthetic protocol was based off that of Weitl et al.
16
 in combination with the 
preparation of 2,3-bis(benzyloxy)benzoyl chloride as described by Zhang et. al.
17
  
 N,N'-(butane-1,4-diyl)bis(2,3-bis(benzyloxy)-N-(3-(2,3-bis(benzyloxy)benzamido) 
propyl)benzamide) (3). A solution of  2,3-bis(benzyloxy)benzoyl chloride in DCM (1.54g, 4.4 
mmol ) in 10 mL of DCM was added dropwise to a solution of spermine (0.202g, 1 mmol) and 
NEt3 (0.505g, 5 mmol) in DCM (15 mL) at 0 
o
C under argon over 10 min while stirring. The 
stirring was continued for another 30 min at 0 
o
C before the reaction mixture was allowed to 
warm to room temperature and the stirring was continued overnight.  The reaction mixture was 
transferred into a separatory funnel and the DCM layer was washed with 1N HCl, then with 10% 
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NaHCO3, followed by water. DCM layer was dried over anhydrous sodium sulfate and 
evaporated to dryness. The crude compound was recrystallized with diethyl ether (yield 64%). 
 N,N'-(butane-1,4-diyl)bis(N-(3-(2,3-dihydroxybenzamido)propyl)-2,3-dihydroxy 
benzamide) (3,4,3-LICAM). To a solution of 3 (0.146g, 0.1 mmol) in MeOH (10 mL) was 
added 10% Pd/C. The reaction mixture was hydrogenated at balloon H2 pressure at room 
temperature for 6 h. The catalyst was filtered through a celite pad under inert atmosphere. The 
filtrate was evaporated under reduced pressure to obtain the final product. (yield= 73%)  
 3.4.3:  Monomer studies 
  3.4.3.1: Cold complexation 
  The catechol and hydroxypyridinone monomers (CMM and HMM) were combined with 
various amounts of ZrCl4 in water at room temperature in an attempt to form Zr-monomer 
complexes. These mixtures were analyzed by LCMS as well as UV/Vis spectroscopy.  
  3.4.3.2: Radiolabeling 
  Neutralized 
89
Zr oxalate solution was added to a solution of dopamine for a proof of 
concept experiment. The radiolabeled mixture was run through an Alltech Maxi-Clean Solid-
Phase Extraction Cartridges (C18 900mg sorbent, 1.35mL volume). The cartridges were 
prewashed with 5 mL of each methanol, water, acetonitrile, and water again. After the samples 
were loaded, the cartridges were then eluted with 2 mL each of water, acetonitrile, and water 
again. 1 mL fractions were collected, promptly measured for radioactivity on a gamma counter, 
and then left to decay before being measured for UV absorbance on a UV/Vis 
spectrophotometer. 
  100 μM solutions of HMM or CMM were radiolabeled with varying amounts of 
neutralized 
89
Zr oxalate solution at room temperature. Reaction mixtures were monitored for up 
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to 1 d using radioITLC with Varian ITLC-SA strips (Agilent Technologies) and various mobile 
phases including 50 mM EDTA, 0.5 M citric acid, and water. Further analysis was carried out 
using Waters Sep-Pak C18 Plus Light Cartridges (130mg sorbent, 55-105 µm particle size). The 
cartridges were prewashed with 5 mL of methanol and 5 mL of water. 100 μL samples of free 
89
Zr oxalate, 
89
Zr-HMM, and 
89
Zr-CMM were each loaded onto cartridges, washed with 2.5 mL 
of 5% methanol in water, and then eluted with 2.5 mL of methanol. 500 μL fractions were 
collected during the wash and elution. Each cartridge and the collected fractions were then 
measured with a gamma counter.  
 3.4.4:  Ligand studies 
  3.4.4.1: Cold complexation 
Zr-ligand complexes were formed by mixing either HOPO or LICAM with a slight excess (1.5 
eq.) of ZrCl4 in water or methanol at room temperature. The Zr-ligand mixtures were analyzed 
by HPLC and MS (Figures A.3.6-9). 
  3.4.4.2: Radiolabeling 
 89
Zr was received after target processing as 
89
Zr-oxalate in 1.0 M oxalic acid. This 
solution is then neutralized with 1.0 M sodium carbonate to reach the desired pH (usually 7). 
Solutions of both the HOPO and LICAM ligands were prepared at 1 mM concentrations in water 
and reacted with the neutralized 
89
Zr solution at room temperature. While this was adequate for 
the HOPO ligand, it proved insufficient for the LICAM ligand. Additional radiolabeling attempts 
were made for varying lengths of time (up to 24 h), pHs (6-8), and temperatures (25 or 37 
o
C). 
None of these efforts led to considerable improvements in the labeling yield with a maximum of 
30% radiolabeling achieved (individual trends can be seen in Figures A.3.10-11). The HOPO 
ligand was also labeled at lower concentrations, down to 10 μM. Reactions were monitored via 
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radio-TLC using Varian ITLC-SA strips (Agilent Technologies) and 50 mM EDTA at pH 5 as 
the mobile phase. 
89
Zr-ligand complexes remained at the origin, while free 
89
Zr was taken up by 
EDTA in the mobile phase and migrated along the ITLC strip. 
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CHAPTER 4: AN ALTERNATIVE CHELATOR FOR 
89
ZR 
RADIOPHARMACEUTICALS: RADIOLABELING AND EVALUATION OF 
3,4,3-(LI-1,2-HOPO) 
This chapter is an adaptation of published work, and is reproduced in part, from Deri, M. A.; 
Ponnala, S.; Zeglis, B. M.; Pohl, G.; Dannenberg, J. J.; Lewis, J. S.; Francesconi, L. C. An 
Alternative Chelator for 
89
Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-
1,2-HOPO). J. Med. Chem. 2014, 57(11), 4849-4860, Copyright 2014 American Chemical 
Society. 
 
4.1:  Introduction 
 The past few decades have played witness to a revolution in the understanding of the 
intersection between transition metals and medicine. Not only has the body’s management of 
metals emerged as an important therapeutic target, but metals have become critical components 
of diagnostic and therapeutic agents. Unsurprisingly, the biomedical importance of chelators — 
organic molecules capable of binding metals — has increased in parallel to this advent of metals 
in medicine. The clinical use of chelators is most often associated with treatment for heavy metal 
poisoning, for example the administration of ethylenediaminetetraacetic acid (EDTA) to treat 
lead poisoning.
1, 2
 However, chelators are also critical components of metal-containing 
diagnostics and therapeutics, in particular nuclear imaging agents bearing metallic radioisotopes. 
In these cases, the role of the chelator is to stably sequester the radiometal and prevent its release 
from the agent. While a number of excellent chelators for common radiometals are known, the 
recent emergence of a few non-traditional medically useful isotopes have increased demand for 
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novel chelators specifically tailored to the chemistry of these new radiometals.
3, 4
 The case of the 
positron-emitting radiometal zirconium-89 (
89
Zr) provides a prime example of this phenomenon. 
89
Zr is readily attracting attention as a radionuclide for positron emission tomography 
(PET) imaging.
5-12
 In the last several years, a wide variety of preclinical studies have been 
published.
13-19
 A number of 
89
Zr-based imaging agents have been translated into the clinic, 
including five current clinical trials in the US alone.
20-25
  While 
89
Zr possesses a relatively low 
energy positron (βavg = 395.5 keV) which affords images with high resolution, the principal 
driver of its success has been its 78.41 h half-life. A half-life of just over 3 days allows images to 
be collected multiple days after injection, making it particularly well-suited for the radiolabeling 
of IgG antibodies. Radioimmunoconjugates have a circulation time of several days, and longer 
imaging windows allow for both the accumulation of the tracer in the target tissue as well as the 
clearance of any unbound tracer from the blood pool. This in turn leads to improved image 
contrast and tumor-to-background activity ratios.  
Yet a radionuclide with suitable decay characteristics is not sufficient to make an 
effective imaging agent. It is also necessary to have a reliable method of chelating the radiometal 
and attaching the chelate complex to the targeting vector. In the case of 
89
Zr, the most commonly 
used chelator is desferrioxamine B (DFO, Figure 4.1). DFO, a natural bacterial siderophore, is a 
hexadentate ligand with three hydroxamate groups which provide six oxygen donors  three 
anionic and three neutral  for metal binding.26 In addition, DFO has a pendant amine which 
has been derivatized in a number of ways to create bifunctional variants of the chelator for facile 
conjugation to antibodies and other biomolecular vectors; for example, one such derivative is the 
commercially available benzyl isothiocyanate DFO.
27
 Regardless of which bifunctional DFO 
derivative is used for conjugation, DFO-mAb conjugates are typically radiolabeled with 
89
Zr 
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Figure 4.1. Structures of the currently used chelator for 
89
Zr, DFO, and the newly investigated 
alternative chelator, HOPO, with binding oxygens highlighted in red. 
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under mild conditions (pH 6.5-8.0, RT, 1 h).
12, 28, 29
 These radiolabeled bioconjugates can then be 
purified by either size exclusion chromatography or centrifugal filtration prior to use. 
While DFO is currently the gold standard for 
89
Zr
 
chelation, there is certainly room for 
improvement. The primary issue with DFO is that even purified 
89
Zr-DFO-mAb conjugates have 
been shown to produce significant uptake of radioactivity in the bones of mice, typically on the 
order of 10 %ID/g.
14, 19, 30-32
 This uptake is not the result of the radioimmunoconjugate as a 
whole. Rather, the free 
89
Zr
4+
 cation is known to be osteophilic, meaning the metal itself is 
readily mineralized into the skeleton.
28, 33
 Therefore, it becomes clear that 
89
Zr
4+ 
is being released 
from its chelator within the body. This uptake of 
89
Zr
4+
 is of particular concern in the clinic, for 
accumulation of 
89
Zr
4+
 in the bone can dramatically increase radiation dose to the bone marrow, 
an especially radiosensitive tissue. This concern over in vivo stability has led several groups to 
investigate the possibility of developing a better chelator for 
89
Zr.  
As expressed in the Chapter 3, a ligand designed specifically with the chemistry of Zr
4+
 
in mind may demonstrate improved stability upon complexation with Zr
4+
. A more stable 
complex should be less prone to demetallation in vivo, resulting in reduced bone uptake and thus 
a safer and more efficient 
89
Zr-based PET tracer. However, at the time of this work, no novel 
chelators for 
89
Zr
4+
 have appeared in the literature since the advent of 
89
Zr-immunoPET.  
Our approach to finding a chelator for Zr
4+
 was inspired by a library of ligands developed 
by Gordon et al. as actinide sequestration agents.
34
  One ligand in particular  3,4,3-(LI-1,2-
HOPO) (Figure 4.1)  was found to be very effective for plutonium(IV) decorporation.35-37 
Knowing that zirconium and plutonium are both +4 metals with similar chemistries, it follows a 
ligand that binds plutonium so well might be a promising candidate for Zr
4+
 chelation. This 
ligand, referred to herein as HOPO, is an octadentate chelator composed of a spermine backbone 
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coupled with four hydroxypyridinone groups for metal binding. The hydroxypyridinone groups 
offer hard, oxygen donors appropriate for binding Zr
4+
 and have pKa’s of -0.8 and 5.8 compared 
to the much higher pKa’s of the catecholate, hydroxamate, and alkylhydroxamate (pKa 9.5, 9.3, 
and 8.7, respectively).
34, 38, 39
 In fact, hydroxamate groups were shown to be superior to catechol 
groups in preliminary studies (see details in Chapter 3). Zr
4+
 has been shown to successfully 
compete with Pu
4+
 in extraction experiments using a resin bearing 1,2-hydroxypyridinone 
groups,
40
 which supports our hypothesis that the 1,2-hydroxypyridinone moiety would form a 
strong chelator for Zr
4+
. The linear arrangement of donor atoms should impart faster binding 
kinetics compared to their arrangement in a macrocycle. Furthermore, the increased denticity of 
the HOPO ligand compared to DFO will allow for full saturation of the coordination 
environment of Zr
4+
.
38
 Taken together, the eight coordinate binding and the hard oxygen donor 
groups of the HOPO ligand should be an ideal coordination environment for Zr
4+
 and offer good 
in vivo stability. While the HOPO ligand is admittedly not novel, its application to 
89
Zr
4+
 and 
PET is unique.  
In this study, we investigate the synthesis and characterization of the HOPO ligand and 
the Zr-HOPO complex as well as the radiolabeling, characterization, stability, and in vivo 
behavior of 
89
Zr-HOPO in comparison to 
89
Zr-DFO. The comparative stabilities are further 
investigated by density functional theory (DFT) calculations. Taken together, these studies 
demonstrate the great potential of 3,4,3-(LI-1,2-HOPO) and that family of ligands as chelators 
for 
89
Zr
4+
.   
4.2:  Results and discussion 
An ideal chelator for Zr
4+
 must meet a few core requirements: (1) it must be octadentate 
to fully saturate the coordination sphere of Zr
4+
; (2) it must have hard, oxygen donors to 
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compliment the hard, oxophilic Zr
4+
 cation; and (3), it must offer an appropriate sized cavity for 
the 0.84 Å effective ionic radius of Zr
4+
.
41
 Additionally, an acyclic chelator would be preferred in 
order to facilitate faster, more efficient radiolabeling conditions. It was with these factors in mind 
that the HOPO ligand was chosen for investigation as an alternative, more effective chelator for 
Zr
4+
. 
 4.2.1:  Synthesis and characterization.  
  The HOPO ligand was synthesized as previously reported (also see Chapter 3).
31, 34, 42-44
 
However, the adaptation of this ligand for radiochemical applications required additional 
purification stringency in order to eliminate the possibility of preferentially labeling trace 
impurities. Therefore, for the investigation at hand, the final product was purified via reverse-
phase HPLC.  
The non-radioactive Zr-HOPO complex was formed on the macroscopic scale to 
facilitate characterization. The complex was formed by mixing the HOPO ligand with a slight 
excess (1.5 eq.) of ZrCl4 in water at room temperature. The 1:1 binding of Zr
4+
 and HOPO was 
confirmed by high resolution mass spectrometry (HRMS), which shows the expected mass 
signals (859.12; [M+Na]
+
) (Figure A.4.1). While the 
1
H-NMR of the Zr-HOPO complex 
contained the same type of complicated overlapping multiplets as the ligand itself, there were 
significant changes in the signals most closely associated with binding of Zr
4+
 (Figure A.4.2). 
The participation of the hydroxypyridinone rings in the complexation of zirconium was 
confirmed through infrared (IR) spectroscopy which shows a red-shift in the signals 
corresponding to the hydroxypyridinone’s carbonyl groups (from 1630 to 1610, 1564 to 1537, 
and 1375 to 1360 cm
-1
) groups as a result of the oxygens binding Zr
4+
 (Figure A.4.3).
45, 46
 The 
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calculated IR spectra resulting from the DFT work assign these signals to highly coupled 
asymmetric carbonyl stretches (Figure A.4.4). 
Next, the radioactive 
89
Zr-HOPO complex was synthesized by radiolabeling the HOPO 
ligand with a neutralized 
89
Zr solution at a pH of ~7.0.  The identity of the radioactive 
89
Zr-HOPO species was confirmed through a co-elution study wherein both the radioactive and 
non-radioactive Zr-HOPO complexes were injected into the HPLC system together (Figure 4.2). 
Their co-elution demonstrates that the 
89
Zr-HOPO species possesses the same structure and 
chemistry as the non-radioactive, characterized Zr-HOPO species. HPLC also confirmed the 
purity of both the HOPO ligand and the Zr-HOPO complex to be higher than 95%. Further 
characterization of the Zr-HOPO complex was attempted using ultraviolet–visible (UV-Vis) 
spectroscopy, however the results were inconclusive as the spectral changes associated with the 
ligand-metal complexation were minimal (Figures A.4.5-6). 
 4.2.2:  DFT Calculations.  
The difficulties intrinsic to studying the aqueous chemistry of Zr, and these Zr-ligand 
complexes in particular, preclude the use of potentiometric titrations or extensive NMR studies 
due to solubility issues. Therefore, in order to further investigate the coordination chemistry of 
the Zr-ligand complexes, we performed density functional theory (DFT) calculations on both Zr-
HOPO and Zr-DFO. Additionally, the results of the Zr-HOPO calculations led us to investigate a 
slightly modified HOPO ligand adapted to overcome an observed weakness in the Zr-HOPO 
structure. DFT calculations were performed using the GAUSSIAN 09
47 
suite of computer 
programs. All calculations used the CEP-121G basis set and the B3LYP functional. We tested 
four basis sets contained in GAUSSIAN 09 that can treat Zr (CEP-121G, CEP-31G, LanL2DZ 
and QZVP), for their accuracy treating the gas phase acidity of two simple alcohols (ethanol and 
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Figure 4.2. HPLC chromatogram of the co-injection of radioactive 
89
Zr-HOPO and non-
radioactive Zr-HOPO. The ~30 s separation between the two peaks is due to the sequential setup 
of the UV and radioactive detectors. 
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 methanol) as a test of their abilities to accurately treat the organic ligands (which are 
polyalcohols). CEP-121G and QZVP performed the best (and about equally well). We chose 
CEP-121G as it used less computational resources. The detailed data can be found in the 
appendix, Table A.4.1. The geometries of all the species were completely optimized in all 
internal degrees of freedom, while considering several different conformations of the ligands and 
complexes. We base our reports on the lowest energy conformations. The vibrational frequencies 
on the CP-corrected potential energy surface confirmed all structures to be stationary points (as 
all frequencies are real) and enabled the calculation of enthalpies at 298 K, using the normal 
harmonic approximations employed in the GAUSSIAN 09 program.
47
 The counterpoise 
correction for basis set superposition error
48-51
 was incorporated using via optimization on the 
CP-corrected potential energy surfaces (CP-OPT)
2
 in which two fragments were considered (the 
Zr and all ligands as a single fragment) for the gas phase calculations. We used these frequencies 
to calculate the IR spectrum of Zr-HOPO (Figure A.4.4) using a scaling factor of 0.992 which 
we obtained for the B3LYP/CEP-121G by comparing the C=O stretch of N=methylacetamide 
with the experimental value
52
, as we have done previously for B3LYP/D95**
53
. We used the 
GaussView
54
 program to visualize the spectrum, choosing a resolution of 15 cm
-1
 for the best 
match to the experimental spectrum. 
We used the CPCM polarizable conductor-like solvent continuum model
48, 50 
with the 
Bondi
49
 (rather than the default UFF
55
) option for the atomic radii used for the cavity as the 
model for the aqueous bulk. We have recently reported that the radii used to define the cavities in 
CPCM have a significant effect upon the ΔGsolv’s of both N-methylacetamide, NMA, and 
water.
56
 The Bondi radii
49
 generally gave the best results when the electrostatic part was used 
alone, as in this work. We note that CPCM gives ΔGsolv’s, rather than ΔH’s. For simplicity, we 
90 
 
have labeled as ΔH’s the quantities obtained from a normal vibrational correction for enthalpy 
calculated using the CPCM Hamiltonian. We used single point a posteriori CP corrections for 
these calculations as GAUSSIAN 09 does not allow CP-OPT to be used with solvation models. 
We calculated the geometry optimized structures of four complexes: (I) the Zr-HOPO complex 
[Zr
4+
 + 3,4,3-(LI-1,2-HOPO)
4-
]; (II) a complex of an alternate HOPO-based ligand, where the 
central aliphatic chain on the backbone possesses 3 carbons instead of 4 [Zr
4+
 + 3,3,3-(LI-1,2-
HOPO)
4-
]; (III) a previously studied Zr-DFO complex [Zr
4+
 + DFO
2-
 + 2 H2O]
2+
, as well as 
another conformation of the same complex that we found to be more stable (IIIa); and (IV) a 
neutral, uncharged Zr-DFO complex [Zr
4+
 +DFO
2-
 + 2OH
-
] (Figure 4.3). We considered III and 
IIIa for comparison with a previous study on Zr-DFO
2+
, but also included IV for a better 
comparison with I and II, which are both neutral complexes. All structures were evaluated in the 
gas phase as well as with the CPCM to mimic an aqueous environment. 
The previously reported DFT study
14
 of III used two different basis sets: LANL2DZ for 
the Zr and 6-31+G(d) for the DFO and water molecules. Additionally, no correction was made 
for basis set superposition error (BSSE). We thought it prudent to repeat this calculation using 
the CEP-121G basis set to provide direct comparison to our calculations. We also further 
explored the potential energy surface (PES) of III, finding a more stable structure, IIIa, that 
contains H-bonds from each of the H’s on the protonated terminal amine to the oxygens of the 
DFO (Figure 4.3). One of the H-bonds is bifurcated (the H interacts with two different oxygens), 
a common behavior for ammonium salts.
57
 We found the ΔH of IIIa to be 10.6 kcal/mol lower 
(gas phase) and 0.9 kcal/mol higher (aqueous solution using CPCM) than III. The lower ΔH of 
III in solution is due to the extended terminal ammonium that can be more easily solvated than 
the internally H-bonded structure of IIIa. Table 4.1 presents the calculated Zr-O bond distances 
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Figure 4.3. General chemical structures and optimized DFT structures for (I) the Zr-HOPO 
complex; (II) a complex of an alternate HOPO-based ligand [3,3,3-(LI-1,2-HOPO)] with Zr; 
(III) a previously studied positively charged Zr-DFO complex; (IIIa) a new, more stable 
conformation of the same charged Zr-DFO complex; and (IV) a neutral, uncharged Zr-DFO 
complex
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Table 4.1. DFT Calculated Zr-O Bond Lengths 
All bond lengths reported in Ǻ. DFT calculations were performed using the GAUSSIAN 09 
program with CEP-121G as the basis set. 
  Terminal Ligands Central Ligands 
 I CO-Zr 2.215 2.158 2.205 2.283 
NO-Zr 2.269 2.326 2.270 2.223 
II CO-Zr 2.220 2.167 2.205 2.291 
NO-Zr 2.266 2.298 2.263 2.218 
III (ref13) CO-Zr 2.261 2.254 2.199 n/a 
NO-Zr 2.121 2.220 2.111 n/a 
III CO-Zr 2.277 2.284 2.211 n/a 
NO-Zr 2.142 2.249 2.144 n/a 
IIIa CO-Zr 2.262 2.281 2.237 n/a 
NO-Zr 2.197 2.142 2.188 n/a 
IV CO-Zr 2.347 2.362 2.442 n/a 
NO-Zr 2.367 2.229 2.417 n/a 
Zr(1,2-HOPO)4 CO-Zr 2.222 2.222 2.212 2.212 
NO-Zr 2.252 2.252 2.242 2.242 
Zr(hydroxamate)4 
crystal (ref38) 
CO-Zr 2.172 2.196 2.163 2.199 
NO-Zr 2.215 2.233 2.189 2.178 
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in the five structures detailed above as well as for Zr chelated by four free 1,2-hydoxypyridinone 
(1,2-HOPO) groups (Figure A.4.7). The bond lengths of an X-ray crystallographic study on a 
related compound — Zr(hydroxamate)4 — are also included for reference.
38
 The Zr-O distances 
for the DFO oxygens are all longer than those previously reported, but those between Zr and the 
water oxygens are somewhat shorter (~0.01-0.03 Å, Table 4.1). However, the orientations of the 
waters in the two structures are slightly different. The difference might be due to the BSSE 
correction and/or the loss of basis set balance, especially across the Zr-O bonds. One generally 
expects bond elongation when optimization is performed on a BSSE-corrected surface, as noted 
for the Zr-O bonds in Zr-DFO. We have also noted that optimization of certain systems (e.g., 
water dimer
58
) converge to incorrect structures when small basis sets are used on a surface not 
corrected for BSSE. Due to the steric problems within the ligand that modification of the Zr-
DFO bonds would provoke, changing the orientations of these oxygens would be more difficult 
than those of the waters. 
While Zr-HOPO (I) has two more Zr-O interactions than Zr-DFO (IV), we could not 
assume it to be more stable, as IV has two Zr-OH interactions to compensate for the missing 
interactions with the ligand. We used Reaction 4.1 to determine the relative stability of the two 
complexes. We note that the structure of DFOH2 has a protonated amine that hydrogen bonds to  
three oxygens, one of which is not protonated, which results in a neutral structure (Figure 
A.4.8). 
I + DFOH2 + 2H2O  IV + HOPOH4 (4.1) 
The calculated enthalpies of this reaction are 47.9 kcal/mol (gas) and 31.8 kcal/mol (CPCM). 
These data strongly suggest that Zr-HOPO is more stable than Zr-DFO. The difference between 
the gas phase and CPCM enthalpies reflects the large solvation free energy of the small OH
-
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anion. However, the difference seems quite large for two species that each have eight Zr-O 
interactions. One reason for this large difference appears to be that Zr-O distances found in IV 
are about 0.01 Å larger on average, suggesting these bonds in IV to be weaker than in I or II. 
These calculations suggest a remarkable improvement in energetic favorability for Zr-HOPO 
over Zr-DFO. 
When we optimized the geometry of I, we found several local minima. Structure I has the 
lowest energy, but we thought that we might find a more stable conformation if we eliminated 
the unfavorable gauche orientation of the -(CH2)4- linker between the middle two chelating 
groups of I. As we could not find a more stable structure for I, we decided to eliminate one of the 
CH2 groups from I to form II: Zr complexed with a new HOPO-based ligand  3,3,3-(LI-1,2-
HOPO)  with a shortened center spacer in the backbone (Figure 4.3). We expect that the 
modified ligand of II would bind more tightly to the Zr since it eliminates the unfavorable 
gauche interaction. To test this hypothesis, we calculated the enthalpy of the reaction that 
exchanges the ligands of I and II (Reaction 4.2), which we found to be -2.8 kcal/mol (gas) and -
3.2 kcal/mol (CPCM), suggesting that the equilibrium constant for Reaction 4.2 be ~200 at 
298 K. 
I + 3,3,3-(LI-1,2-HOPO)  II + 3,4,3-(LI-1,2-HOPO) (4.2) 
Thus, we expect that II would provide even further advantages over I as a ligand for Zr
4+
. 
Accordingly, we are now exploring this possibility by synthesizing the 3,3,3-(LI-1,2-HOPO) 
ligand. 
 4.2.3:  Radiolabeling Experiments.  
Preliminary radiolabeling experiments demonstrated quantitative radiolabeling of 10 mM 
HOPO with 
89
Zr within 10 min at room temperature at pH 7 in water. Further experimentation 
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revealed that the time necessary for complete labeling was dependent on ligand concentration, 
with lower concentrations requiring more time. For example, a HOPO concentration of 10 μM 
required 45 min to achieve 100% labeling. In general, radiolabeling reactions were left to 
incubate for 1 h to ensure quantitative labeling, and all radiolabeling reactions were monitored 
by radioactive thin layer chromatography (radio-TLC). 
Radio-TLC analysis of the labeling solutions revealed an interesting concentration-
dependent speciation phenomenon (Figure 4.4). At high concentrations of HOPO (e.g. 10 mM), 
radio-TLC analysis 10 min after labeling revealed one sharp peak at the origin with a small bump 
immediately following it. Initially, this seemed like an artifact, however when radio-TLC 
analysis is repeated at later time points, this small bump grows into a second, distinct peak. Over 
time, the first peak slowly converts to the second, and 24 h later, only the second peak remains. 
These two peaks must represent two different complexes of 
89
Zr and HOPO, one which is the 
initial kinetic product and one which is the ultimate thermodynamically stable product. It is 
significant to note that throughout this conversion — and at every point from 10 min onward —
no free 
89
Zr
4+
 is observed. This suggests that all of the 
89
Zr
4+
 is initially complexed by HOPO in 
some fashion, but then over time converts to a different isomer or complex without the 
89
Zr
4+
 
ever being released. Most likely, this means the complex undergoes an intramolecular 
rearrangement of some kind. Upon further investigation, this phenomenon was found to be 
concentration-dependent. As the concentration of HOPO decreased, two things changed: the 
secondary peak became increasingly prevalent at early time points, and the two peaks appeared 
closer together and became less distinguishable by radio-TLC.  
The observation that the first peak is less prominent at lower ligand concentrations 
suggests a possible explanation for the identity of the first peak: a dimer of two ligands 
96 
 
 
 
 
 
Figure 4.4. Radio-TLC profiles of the 
89
Zr-HOPO radiolabeling reaction over time at different 
concentrations of ligand. Two peaks are observed, with the first peak (the kinetic product) 
converting to the second peak (the thermodynamic product) over time. The initial area ratio and 
separation of the two peaks is dependent upon the concentration of the ligand. 
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simultaneously binding one 
89
Zr atom. As the concentration of the ligand was decreased, the 
likelihood of forming such a dimer would also decrease, and thus the first peak would be less 
abundant. With this explanation, the second peak is most likely the 1:1 
89
Zr-HOPO complex that 
was expected. This explanation also explains how the conversion of the first species to the 
second could take place without releasing the metal. Converting from a dimer to a 1:1 complex 
seems like a reasonable transformation, as the unused binding groups of one ligand simply 
replace the binding sites of the second ligand. This hypothesis is supported by the fact that the 
HPLC co-elution study (see above) was carried out 24 h after the initial radiolabeling so that the 
sample only consisted of the second radio-TLC peak. HPLC analysis showed the compound 
responsible for the second radio-TLC peak to elute with the characterized, 1:1 non-radioactive 
Zr-HOPO complex, thus confirming its identity.  
An explanation for the second observation — that the two peaks get closer together as the 
ligand concentration decreases — is somewhat more elusive; however it is a consistently 
observable trend. The major difficulty in elucidating the exact speciation is that these phenomena 
seem only to occur at the tracer level. In these experiments, the ligand concentrations are in the 
mM to μM range, while the concentration of 89Zr is in the nM to pM range. These conditions 
cannot be mimicked on the macroscale without inordinate amounts of the HOPO ligand (e.g, 
~3.4 kg of HOPO for every 10 mg of Zr), so analysis is limited to tests that can be carried out on 
the radioactive samples. Furthermore, as the concentration of the ligand is reduced and 
approaches that of the metal, the two peaks move closer together to the point where they become 
indistinguishable. This trend complicates matters because as the two peaks move ever closer 
together, they begin to appear to be one peak, yet it is impossible to know for certain which of 
the two original peaks this species represents.  
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Finally, an alternative explanation for the two peaks is that they simply represent two 
different coordination structures of the 1:1 Zr-HOPO complex. For example, the initial peak may 
be HOPO bound to Zr by only six donor groups which converts to the second peak of full 
octadentate chelation as the final HOPO group changes conformation to bind the metal. While 
this explanation is consistent with the fact that the conversion between the two species does not 
involve releasing the metal, it does not provide a justification for the concentration dependence. 
Further investigations into these speciation phenomena are on-going. 
Recently, a study investigating the luminescence of Eu
3+
 complexes with the same (3,4,3-
LI-1,2-HOPO) ligand has shown a similar phenomenon. Examination of measured luminescence 
lifetimes of isolated Eu-HOPO compared to in situ formed Eu-HOPO suggested a kinetic 
isomer wherein the HOPO ligand binds the Eu
3+
 in such a way that the Eu
3+
 may be bound to a 
water molecule. The conversion of the kinetic isomer to the longer lived thermodynamic isomer 
was determined by luminescence quantum yield, luminescence lifetime measurements and 
magnetic circular dichroism spectroscopy. The authors propose that the Eu-HOPO kinetic isomer 
may possess a bound water molecule as well as a lower degree of f-orbital overlap.
59
 
 4.2.4:  Stability Studies 
While this study did not endeavor to measure stability constants due to the difficulty of 
such measurements and the need for specialized equipment, Sturzbecher-Hoehne has recently 
reported the solution thermodynamic stability of   the Zr-HOPO complex. The log β110 was 
determined to be 43.1 ± 0.6, attesting to the extraordinary stability of the Zr
4+
 complex further 
supporting development of this ligand for 
89
Zr PET radiopharmaceutical applications.
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4.2.4.1:  Serum Stability  
In order to gain insight into the in vitro and in vivo kinetic inertness of the Zr-HOPO 
complex, serum stability tests were performed to simulate biological conditions. Both 
89
Zr-
HOPO and 
89
Zr-DFO complexes were found to be stable over a 7 d period at 37 
o
C in human 
serum (98.8% and 98.3% intact respectively). Further, no protein-bound 
89
Zr was observed in the 
serum samples containing the 
89
Zr-ligand complexes, which confirms that the complexes 
remained intact. 
4.2.4.2:  EDTA challenge 
Both HOPO and DFO were labeled with 
89
Zr and then incubated with a 100-fold excess of 
EDTA at a range of pH values at 37 
o
C for a period of 7 d in order to examine the stability of the 
Zr-ligand complexes and their susceptibility to transchelation (Table 4.2). Analysis of the 
samples by radio-TLC allowed for the differentiation of the complexes since 
89
Zr-EDTA 
migrates along the ITLC strip, while both 
89
Zr-DFO and 
89
Zr-HOPO remain at the origin. DFO 
was shown to be surprisingly vulnerable to transchelation, most notably at lower pHs but also at 
neutral and biological pHs. In contrast, HOPO demonstrated a remarkable resistance to 
transchelation, remaining >99% intact over the full 7 days for the entire range of pH values 
tested. The fact that a 100-fold excess of EDTA was unable to strip the 
89
Zr from HOPO is a 
testament to the stability of the complex. In contrast, the release of 
89
Zr from DFO suggests that 
the ligand is susceptible to transchelation and may experience similar release in vivo to any 
number of competing substances in the body. Additionally, as tumors are known to be more 
acidic than healthy tissues, the greatly improved stability of the Zr-HOPO complex over Zr-DFO 
at lower pH may prove beneficial for cancer imaging. 
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Table 4.2. EDTA Ligand Challenge 
Radiolabeled ligand complexes were incubated with 100-fold excess EDTA at set pH values at 
37 
o
C for 7 d. The experiment was done in triplicate. Green shading indicates >99% intact, 
yellow indicates 99-90% intact, orange indicates 90-80% intact, and red indicates <80% intact.
Starting 
Complex 
pH 
% Intact Starting Species by Incubation Time 
Initial 1 h 3 h 1 d 3 d 5 d 7 d 
89Zr-HOPO  8.0 99.7±0.6 99.8±0.4 100 100 100 100 100 
7.5 100 99.3±1.3 100 100 100 100 100 
7.0 100 99.0±1.8 100 100 100 100 100 
6.5 100 100 100 100 100 100 100 
6.0 100 100 100 100 100 100 99.6±0.7 
5.5 99.5±0.9 100 100 100 100 100 100 
5.0 99.7±0.6 100 100 100 100 100 99.2±1.5 
89Zr-DFO  8.0 100 100 100 99.0±0.9 93.0±4.1 87.9±6.7 76.1±11.9 
7.5 100 100 99.3±0.6 97.3±2.3 93.7±3.2 89.9±4.0 75.5±14.1 
7.0 100 100 98.8±0.9 96.7±1.7 95.0±1.8 92.8±3.3 90.4±4.5 
6.5 100 100 98.7±0.8 96.5±1.3 93.4±3.1 90.1±8.5 87.0±6.8 
6.0 100 99.9±0.2 96.2±0.6 93.4±1.8 88.6±5.9 90.0±3.5 80.1±11.6 
5.5 100 97.1±0.8 90.7±1.7 64.7±3.0 44.1±10.0 39.7±12.8 36.3±17.0 
5.0 100 86.6±1.5 55.7±3.8 3.0±0.8 2.4±0.9 1.8±0.4 1.5±0.2 
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4.2.4.3:  Metal Cation Competition 
As a counterbalance to the EDTA challenge that evaluated the potential for another 
ligand to outcompete HOPO for the metal cation, a metal competition study was performed to 
see if other metal cations could outcompete 
89
Zr for the HOPO binding pocket. Both HOPO and 
DFO were labeled with 
89
Zr and then incubated with a 10-fold excess of various metal salts at 
pH 7.4 at 37 
o
C (Table 4.3). The samples were monitored for 7 d by radio-TLC to determine the 
percentage of intact 
89
Zr-ligand complex. Both 
89
Zr-DFO and 
89
Zr-HOPO proved relatively 
stable (>95% intact) when challenged with the majority of competing metals with the notable 
exception of Fe
3+
. In this case, after 7 d of incubation with FeCl3, HOPO released ~17% of the 
89
Zr
4+
 compared with DFO which released >50% of the 
89
Zr
4+
. Since DFO is originally a 
siderophore, its affinity for iron over zirconium is unsurprising. DFO also exhibited a slight 
release of 
89
Zr
4+
 in the presence of Ga
3+
 (~9%). This competition further demonstrates the 
stability of the Zr-HOPO complex and shows an advantage over Zr-DFO. 
 4.2.5:  In Vivo Studies. 
  An advantage of working with a ligand that has already been evaluated for a different 
biological application is that studies into the toxicity of the compound have already been carried 
out.
31
 The toxicity of HOPO was studied in both mice
42
 and baboons
44
 and neither showed any 
evidence of harm with frequent, repeated injections of the HOPO ligand at concentrations of 10 
μmol/kg and 30 μmol/kg respectively. These data — combined with the fact that the extremely 
small amounts of compound needed for radiopharmaceutical studies are far below the threshold 
for pharmacological effects — allowed for the immediate evaluation of 89Zr-HOPO in mice 
without concerns about adverse reactions. 
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Table 4.3. Metal Competition 
Radiolabeled ligand complexes were incubated with a 10-fold excess of various biologically 
relevant metal salts in PBS at a pH of 7.4 at 37 
o
C for 7 d. The experiment was repeated twice.  
  
Competing  
Metal 
Cation 
% Intact Starting Species by Incubation Time 
1 h 1 d 5 d 7 d 
89Zr-HOPO 89Zr-DFO 89Zr-HOPO 89Zr-DFO 89Zr-HOPO 89Zr-DFO 89Zr-HOPO 89Zr-DFO 
Co
2+
 98.5 ± 2.2 92.5 ± 0.4 98.2 ± 2.6 93.4 ± 3.1 98.6 ± 2.0 96.2 ± 0.5 98.9 ± 1.6 95.8 ± 1.1 
Cu
2+
 98.2 ± 2.5 95.8 ± 4.0 98.1 ± 2.7 98.2 ± 2.6 98.3 ± 2.4 96.8 ± 1.5 98.4 ± 2.3 95.3 ± 0.2 
Fe
3+
 97.0 ± 4.2 90.6 ± 4.5 89.8 ± 5.4 48.2 ± 27.0 90.5 ± 3.8 51.9 ± 11.2 83.0 ± 4.2 39.1 ± 9.9 
Ga
3+
 98.4 ± 2.3 94.2 ± 5.6 97.9 ± 3.0 94.9 ± 4.3 97.3 ± 1.9 93.0 ± 4.4 96.4 ± 0.6 91.1 ± 2.2 
Gd
3+
 98.2 ± 2.6 94.3 ± 1.4 97.8 ± 3.1 95.0 ± 2.7 96.5 ± 2.9 98.4 ± 2.2 94.5 ± 4.1 97.0 ± 0.7 
K
+
 99.0 ± 1.5 97.2 ± 4.0 98.7 ± 1.9 94.8 ± 3.5 98.5 ± 2.2 97.6 ± 0.7 98.1 ± 0.7 97.0 ± 1.6 
Mg
2+
 98.3 ± 2.5 94.4 ± 0.02 98.3 ± 2.5 95.6 ± 2.5 98.6 ± 2.0 98.1 ± 0.8 98.7 ± 1.8 96.5 ± 0.1 
Ni
2+
 98.4 ± 2.3 97.2 ± 4.0 98.4 ± 2.2 94.9 ± 3.2 98.7 ± 1.9 97.0 ± 1.2 97.4 ± 0.1 97.8 ± 1.1 
Zn
2+
 98.6 ± 2.0 92.9 ± 2.2 98.7 ± 1.9 97.9 ± 3.0 97.7 ± 3.3 97.6 ± 3.4 98.3 ± 2.4 96.4 ± 1.3 
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4.2.5.1:  Imaging 
PET imaging studies were performed in order to investigate the in vivo pharmacokinetics of the 
89
Zr-HOPO complex. To this end, the 
89
Zr-HOPO complex (260 μCi, 9.6 MBq, in 200 μL 0.9% 
sterile saline) was injected into healthy mice and imaged at four time points using PET (Figure 
4.5). At 10 min, the vast majority of the radioactivity is observed in the bladder, which indicates 
rapid renal clearance. At the remaining time points (4, 12, and 24 h), much of the radioactivity is 
seen in the gut, signifying hepatobiliary as well as renal excretion. Interestingly, there was 
significant activity localized in the gall bladder: this is most likely a consequence of the 
hepatobiliary excretion of the complex through the gut of the mice but is not fully understood at 
present. This explanation is supported by the fact that the activity in the gall bladder decreases 
over time. Importantly, no significant bone uptake was observed in the imaging at any time 
point, indicating that there was no release of the 
89
Zr
4+
 cation from the ligand in vivo. For 
comparison, previous studies with the 
89
Zr-DFO complex show only rapid renal clearance of the 
radiotracer.
14, 33, 61
  
4.2.5.2:  Biodistribution 
An ex vivo biodistribution study was also performed in healthy mice to further probe the 
biological behavior of the 
89
Zr-HOPO complex. The results of this study match the trends 
observed in the PET images, including the involvement of both the renal and hepatobiliary 
clearance pathways. (Table 4.4). At 10 min post injection, the activity was found largely in the 
kidneys (9.46 ± 2.71 %ID/g), suggesting rapid renal excretion, as well as the small intestine 
(5.99 ± 1.18 %ID/g) and the gall bladder (6.61 ± 2.87 %ID/g), consistent with hepatobiliary 
excretion. By the 1 h time point, most of the activity had already cleared through the kidneys 
(1.05 ± 0.51 %ID/g) but was still seen in the gall bladder (6.94 ± 3.38 %ID/g). The large 
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Figure 4.5. Coronal PET images of 
89
Zr-HOPO. Healthy mice were administered 
89
Zr-HOPO 
(260 µCi [9.6 MBq] in 0.9 % sterile saline) via tail vein injection and imaged between 10 min 
and 24 h after injection. The gall bladder (a), gut (b), and bladder (c) can be visualized. The 
89
Zr-
HOPO complex undergoes rapid renal clearance followed by slower hepatobiliary clearance. No 
uptake of 
89
Zr in the bone is observed. 
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intestine contains the majority of the radioactivity at 4 h (7.17 ± 2.15 %ID/g) while the 12 and 
24 h time points demonstrate the further clearance of the remaining activity from all of the 
organs examined. Notably, the low amount of activity in the bone, which decreases over time 
(from 1.04 ± 0.44 to 0.17 ± 0.03 %ID/g), is consistent with the clearance of the intact complex 
rather than accumulation due to mineralization of the free radiometal.   
The 
89
Zr-HOPO clearance pathways are similar to the clearance of the 
238
Pu-HOPO 
complex that was injected intraveneously or intraperitoneally.
62
 Also, dose dependent removal of 
238
Pu  from mice by orally administred HOPO resulted in similar hepatobiliary clearance at 
24 h.
63
 
In order to make direct comparisons, the in vivo biodistribution of 
89
Zr-DFO was 
investigated in the same study (Figure 4.6). As expected, 
89
Zr-DFO cleared exclusively through 
the kidneys and thus was eliminated more quickly than 
89
Zr-HOPO. The fact that 
89
Zr-DFO does 
not show any gall bladder uptake further suggests that the uptake of 
89
Zr-HOPO in the gall 
bladder is a result of hepatobiliary excretion. Other than the difference in excretory pathways, the 
clearance of the two complexes through the blood and other organs appears similar, with neither 
complex accumulating appreciably anywhere in the body.  
There is a statistically significant difference in the amount of activity in the bone between 
89
Zr-DFO and 
89
Zr-HOPO, with higher levels observed for 
89
Zr-HOPO. This could be the result 
of the release of the 
89
Zr
4+
 cation from the HOPO ligand due to instability or metabolism; 
however, if this were the case, we would expect to see a more substantial amount of radioactivity 
in the bone and for the amount of activity to stay constant or grow over time. Instead, with such a 
small amount of activity and no evidence of long-term accumulation of the radiometal in the 
bone, this is most likely a question of the perfusion and clearance kinetics of 
89
Zr-HOPO rather 
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 10 min 1 h 4 h 12 h 24 h 
 Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO 
Blood  3.24 ± 0.66 5.11 ± 0.90 0.17 ± 0.10 0.10 ± 0.04 0.05 ± 0.04 0.03 ± 0.01 0.02 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.02 
Heart  1.57 ± 0.22 2.17 ± 0.62 0.12 ± 0.06 0.06 ± 0.02 0.06 ± 0.01 0.03 ± 0.01 0.06 ± 0.01 0.02 ± 0.00 0.07 ± 0.01 0.02 ± 0.01 
Gall 
Bladder  
6.61 ± 2.87 1.57 ± 0.25 6.94 ± 3.38 0.47 ± 0.14 1.00 ± 0.41 0.26 ± 0.15 2.45 ± 1.02 0.16 ± 0.14 1.15 ± 0.59 0.23 ± 0.21 
Liver  3.29 ± 0.75 0.88 ± 0.49 0.22 ± 0.09 0.24 ± 0.07 0.13 ± 0.01 0.12 ± 0.03 0.09 ± 0.02 0.06 ± 0.02 0.06 ± 0.03 0.11 ± 0.02 
Stomach  1.22 ± 0.39 0.62 ± 0.28 0.30 ± 0.15 1.10 ± 0.51 0.50 ± 0.74 0.06 ± 0.02 0.01 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.01 
Large 
Intestine  
0.26 ± 0.15 0.43 ± 0.13 0.09 ± 0.06 0.02 ± 0.01 7.17 ± 2.15 0.62 ± 0.55 0.10 ± 0.03 0.07 ± 0.05 0.03 ± 0.02 0.02 ± 0.01 
Small 
Intestine  
5.99 ± 1.18 0.94 ± 0.16 1.11 ± 0.35 0.35 ± 0.17 0.12 ± 0.13 0.04 ± 0.02 0.02 ± 0.01 0.01 ± 0.01 0.02 ± 0.00 0.02 ± 0.01 
Kidney  9.46 ± 2.71 14.44 ± 5.88 1.05 ± 0.51 1.39 ± 0.55 0.40 ± 0.14 1.10 ± 0.44 0.53 ± 0.23 0.36 ± 0.13 0.51 ± 0.29 1.12 ± 0.33 
Bladder  2.04 ± 1.06 2.50 ± 0.48 0.73 ± 0.36 2.47 ± 1.30 0.58 ± 0.27 1.22 ± 0.77 0.54 ± 0.26 0.69 ± 0.31 0.28 ± 0.14 0.56 ± 0.41 
Muscle  0.36 ± 0.06 0.73 ± 0.56 0.10 ± 0.03 0.02 ± 0.01 0.09 ± 0.06 0.01 ± 0.01 0.06 ± 0.01 0.01 ± 0.00 0.06 ± 0.01 0.01 ± 0.00 
Bone  1.04 ± 0.44 0.43 ± 0.10 0.29 ± 0.09 0.07 ± 0.04 0.23 ± 0.12 0.04 ± 0.02 0.25 ± 0.07 0.03 ± 0.01 0.17 ± 0.03 0.06 ± 0.01 
Table 4.4. Biodistribution Results 
All values reported as %ID/g. Healthy, athymic nude mice were injected with either 
89
Zr-HOPO 
or 
89
Zr-DFO (24-35 µCi [0.89-1.29 MBq] in 0.9 % sterile saline) via the tail vein, sacrificed at 
specified time points, and necropsied. Organs were collected, weighed, and measured for 
radioactivity using a gamma counter. N = 4 for each compound at each time point. 
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Figure 4.6. Biodistribution of 
89
Zr-HOPO and 
89
Zr-DFO in select organs. Healthy, athymic nude 
mice were injected with either 
89
Zr-HOPO or 
89
Zr-DFO (24-35 µCi [0.89-1.29 MBq] in 0.9 % 
sterile saline) via the tail vein, sacrificed at specified time points, and necropsied. The 
concentration of radioactivity in the chosen organs is expressed as %ID/g and presented as an 
average value from four animals ± standard deviation. Bl = Blood, GB = Gall Bladder, L = 
Liver, LI = Large Intestines, SI = Small Intestines, K = Kidney, Bo = Bone. *Indicates P values 
of <0.05. 
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than demetallation. Since 
89
Zr-DFO is only cleared renally, and not through the hepatobiliary 
system, it is excreted from the body faster than 
89
Zr-HOPO, as evidenced by the blood clearance 
curve (Figure 4.7). We postulate that just as 
89
Zr-HOPO takes a longer time to clear the blood, it 
also takes a longer time to clear the bone. The higher levels of 
89
Zr measured in the bone are 
likely a result of higher levels of 
89
Zr still present in the mouse. 
The difference in clearance pathways between 
89
Zr-HOPO and 
89
Zr-DFO should not be a 
concern in the long run. Upon conjugation to an antibody, the pharmacokinetics of the 
89
Zr-
HOPO complex will be completely superseded by those of the biomacromolecule. However, at 
this point in the development of the ligand  with only the bare 89Zr-ligand complex available 
 it is only possible to test its in vivo stability for the comparatively short circulation time 
associated with the small molecule complex as opposed to the several day circulation time of a 
radioimmunoconjugate. Therefore, while the in vivo stability of the 
89
Zr-HOPO complex 
demonstrated here is very promising, it alone is insufficient to prove its viability in 
89
Zr-HOPO-
based radioimmunoconjugates. With this in mind, the longer duration in vitro studies were 
intended to supplement the in vivo experiments by allowing us to probe the longer stability 
requirements of the antibody labeling applications. In sum, the combination of the in vitro and in 
vivo experiments gives a more complete picture of the stability of the 
89
Zr-HOPO complex and 
illustrates the great potential of the HOPO ligand. 
4.3:  Conclusions 
In terms of Zr
4+
 chelation and stability, 3,4,3-(LI-1,2-HOPO) has proven to be a superior 
ligand compared to DFO. We have synthesized the HOPO ligand, synthesized and characterized 
the Zr-HOPO complex, and evaluated the stability and behavior of the 
89
Zr-HOPO complex both 
in vitro and in vivo. HOPO has proven comparable — and often superior — to DFO in every test 
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Figure 4.7. Blood clearance of 
89
Zr-HOPO and 
89
Zr-DFO in healthy, athymic nude mice (n = 4) 
over time. Inset shows a zoomed graph for further detail. 
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we have conducted, both experimentally and computationally. Our DFT calculations have shown 
Zr
4+
 complexed with HOPO to be significantly more stable than with DFO and have suggested 
that the complex with 3,3,3-(LI-1,2-HOPO) — a modified hydroxypyridinone-based ligand — 
might be even more stable still. The improved stability of the 
89
Zr-HOPO complex is most 
dramatically shown in the EDTA challenge experiments in which the 
89
Zr-HOPO complex is 
able to resist transchelation far better than 
89
Zr-DFO. This increase in stability is especially 
significant because it is observed  not only at lower pHs like 5.0-6.5 at which the lower pKa of 
the hydroxypyridinone was an expected advantage, but also at biologically relevant pHs like 7.0-
7.5 at which DFO was still susceptible to partial transchelation. In addition, we have shown the 
89
Zr-HOPO complex to have good biological behavior — clearing the body cleanly without any 
signs of demetallation.  
The ultimate test of the efficacy of the HOPO ligand will come when the ligand can be 
conjugated to an antibody, radiolabeled, and tested in vivo in the context of its desired 
application. To this end, bifunctionalization of the HOPO ligand is currently underway, and 
evaluation of the ligand when conjugated to an antibody was undertaken, and evaluation of the 
ligand when conjugated to an antibody will be discussed in Chapter 5. Additionally, the 3,3,3-
(LI-1,2-HOPO) ligand may be synthesized in the future  to follow up on the intriguing results of 
the DFT calculations which suggest that a shortened backbone will impart even greater stability 
upon binding of Zr
4+
. For now, the HOPO ligand shows tremendous promise as a chelator for 
89
Zr and may eventually supplant DFO for immunoPET applications. 
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4.4:  Experimental section 
 4.4.1:  Materials and methods 
  All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis, 
MO) and used as received without further purification. Human serum was purchased frozen from 
Sigma Aldrich. All water used was ultra-pure (>18.2 MΩ cm– 1). All instruments were calibrated 
and maintained in accordance with standard quality-control procedures. High resolution mass 
spectrometry (HRMS) measurements were performed on a Waters SYNAPT High Definition 
MS System (ESI-QTOF) and low resolution mass spectra (LRMS) were recorded with a Waters 
Acquity UPLC with electrospray ionization (ESI) SQ detector.
 1
H NMR spectra were recorded at 
ambient temperature on a Bruker 500 MHz NMR with Topsin 2.1 software. The NMR spectra 
are expressed on the δ scale and were referenced to residual solvent peaks and/or internal 
tetramethylsilane. The HPLC system used for analysis and purification compounds consisted of a 
Shimadzu prominence system equipped with a diode array and a radioactive detector (Bioscan 
inc, DC). IR spectroscopy was performed on a solid sample using an attenuated total reflectance 
attachment on a PerkinElmer Spectrum 2 FT-IR spectrometer with a UATR Two attachment. 
UV-Vis spectroscopy was carried out using a Thermo Scientific Evolution 220 UV-Visible 
spectrophotometer. 
89
Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron 
(Ebco Industries Inc.) via the 
89
Y(p,n)
89
Zr reaction and purified to yield 
89
Zr with a specific 
activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose 
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on 
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored 
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent 
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Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan 
Radio-TLC software (Bioscan Inc., Washington, DC).  All in vivo experiments were performed 
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and 
Use Committee (protocol 08−07−013). Purity of greater than 95% was confirmed using 
quantitative HPLC analysis for non-radioactive compounds (HOPO and Zr-HOPO) and radio-
TLC for radioactive compounds (
89
Zr-HOPO). 
 4.4.2:  3,4,3-(LI-1,2-HOPO) (HOPO) 
  The ligand was synthesized as previously described with slight modification. The details 
are presented in the supporting information. 
 4.4.3:  Zr-HOPO 
  A solution of zirconium chloride (1.5 mg, 6.0 µmol) in water (0.5 mL) was added to a 
solution of HOPO (3.0 mg, 4.0 µmol) in water (0.5 mL). The mixture was vortexed and left for 
15 min. The resulting solution was cloudy with some white precipitate. The complex was not 
very soluble in water; however enough compound remained in soluble to allow for analysis of 
the complex via HRMS and HPLC. NMR analysis remained difficult due to low solubility as 
well as the indistinct, overlapping multiplets of the HOPO ligand itself (Figure A.4.2). A 
solution of non-radioactive Zr-HOPO was lyophilized and the resulting off-white powder was 
analyzed by IR spectroscopy. Characterization of the Zr-HOPO complex by UV-Vis 
spectroscopy was attempted, but not conclusive. The details are presented in the supporting 
information. 
 4.4.4:  Radiolabeling studies 
  
89
Zr was received after target processing as 
89
Zr-oxalate in 1.0 M oxalic acid. This 
solution is then neutralized with 1.0 M sodium carbonate to reach pH 6.8-7.2. Both the DFO and 
113 
 
HOPO ligands were labeled at various concentrations in water or saline with the neutralized 
89
Zr 
solution at room temperature for varying lengths of time, typically 10-60 min. Samples were 
labeled with 10 μCi to 1 mCi depending on the nature of the experiment (for reference, 1 μCi of 
89
Zr equals 25 femtomoles). Reactions were monitored via radio-TLC using Varian ITLC-SA 
strips (Agilent Technologies) and 50 mM EDTA at pH 5 as the mobile phase. 
89
Zr-ligand 
complexes remained at the origin, while free 
89
Zr was taken up by EDTA in the mobile phase 
and migrated along the ITLC strip. 
 4.4.5:  Serum stability study 
  
89
Zr-HOPO and 
89
Zr-DFO were prepared according to the radiolabeling protocol as 
described above. For each 
89
Zr complex, as well as for free, unchelated 
89
Zr, solutions were 
made consisting of 1 mL human serum and 100 μL of the 89Zr species and were placed in a heat 
block at 37 
o
C with agitation. Samples were monitored using radio-TLC immediately after 
mixing and then daily for 1 week. Intact 
89
Zr-ligand complexes remained at the origin of the 
ITLC strip, while free 
89
Zr was either bound by serum proteins or was picked up by EDTA in the 
mobile phase and migrated along the ITLC strip. The stability of the complexes was measured as 
the percentage of 
89
Zr that was retained at the origin of the ITLC strip and therefore still bound to 
the chelator. Free 
89
Zr incubated in serum appeared on radio-TLC as a series of messy, broad 
peaks ranging from the origin to the solvent front. This was likely a result of 
89
Zr being bound to 
a variety of serum components with different retention factors. In order to confirm that the sharp 
peaks at the origin seen in the 
89
Zr-ligand samples were in fact the 
89
Zr-ligand complexes and not 
protein-bound 
89
Zr, size exclusion chromatography (SEC) was performed on the serum samples 
after 7 days (Figure 4.8). SEC was carried out with a hand-packed column (18 x 180 mm) of 
Superdex 200 prep grade gel filtration media (GE Healthcare) on a BioLogic LP automated  
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Figure 4.8. SEC chromatograms of 
89
Zr-HOPO, 
89
Zr-DFO, and free 
89
Zr in serum after 7 days. 
Solid lines are the UV absorbance due to the serum components and to the HOPO ligand itself. 
Dotted lines are the radiotrace associated with the 
89
Zr. 
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liquid chromatography system (BioRad) with a flow rate of 1 ml/min for 45 min using PBS as 
the eluant. Serum protein components were observed in the UV chromatogram (280 nm) while 
89
Zr species were tracked by gamma counting collected 1 mL fractions. Both 
89
Zr-ligand serum 
samples eluted at ~28 min, which corresponds to the retention time of the pure 
89
Zr-ligand 
controls. The control sample of free 
89
Zr in serum, however, eluted at ~20 min, which 
corresponds to the molecular weight of a major serum protein component as seen in the UV 
chromatogram. 
 4.4.6:  EDTA challenge study 
  100 μL samples were prepared of 100 μM ligand to be tested (HOPO or DFO). 100 μL of 
89
Zr solution (~100 μCi) at pH 7 were added to each sample. Each sample was then spotted onto 
an ITLC strip, developed, and analyzed to obtain an initial measure of the percent labeling. The 
samples were left to incubate at room temperature for 1 h. Following incubation, 200 μL of 
5 mM EDTA at different pHs (5.0, 5.5, 6.0, 6.5, 7.0, 7.5, and 8.0) were added to the samples. 
Lastly, 100 μL of 500 mM acetate buffer were added to each sample to maintain the 
experimental pHs of the solutions. The final composition of the samples was 500 μL total 
volume, ~100 μCi 89Zr, 100 mM acetate buffer, and a 1:100 ratio of ligand:EDTA. The samples 
were then transferred to a heat block at 37 
o
C to incubate for 7 d with agitation. Samples were 
monitored by radio-TLC at 1 h, 3 h, 1 d, 3 d, 5 d, and 7 d post-incubation. Three samples were 
prepared at each pH to obtain triplicate data for statistics.  
 4.4.7:  Metal cation competition study 
  1 mL solutions of 200 μM HOPO and DFO were prepared and radiolabeled with 1 mL 
(30-50 μCi) of neutralized 89Zr each. Samples were left to incubate at room temperature for 1 h 
before being monitored by radio-TLC to confirm complete labeling. The 
89
Zr-ligand samples 
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were then split into 200 μL aliquots and added to 200 μL solutions of prepared 1 mM metal salts 
[cobalt(II) chloride, copper(II) chloride, iron(III) chloride, gallium(III) nitrate, gadolinium(III) 
chloride, potassium carbonate, magnesium chloride, nickel(II) acetate, and zinc acetate]. 
Samples of 
89
Zr-ligands complexes in competing metal solutions were put in a heat block at 
37 
o
C to incubate with agitation. Sample mixtures were checked by radio-TLC after 1 h, 1 d, 5 d, 
and 7 d. Experimental data represent the averages and standard deviations of two sets of 
experiments.  
 4.4.8:  PET imaging 
  PET imaging experiments were conducted on a microPET Focus 120. Healthy female, 
athymic nude mice were administered 
89
Zr-HOPO (9.6 MBq [260 μCi] in 200 μL 0.9% sterile 
saline) via intravenous tail vein injection (t = 0). Approximately 5 min prior to the acquisition of 
PET images, mice were anesthetized by inhalation of 2% isoflurane (Baxter Healthcare, 
Deerfield, IL)/oxygen gas mixture and placed on the scanner bed; anesthesia was maintained 
using 1% isoflurane/gas mixture. PET data for each mouse were recorded via static scans at 
various time points between 10 min and 24 h. An energy window of 350-700 keV and a 
coincidence timing window of 6 ns were used. Data were sorted into 2D histograms by Fourier 
rebinning, and transverse images were reconstructed by filtered back-projection (FBP) into a 128 
× 128 × 63 (0.72 × 0.72 × 1.3 mm
3
) matrix. The image data were normalized to correct for non-
uniformity of response of the PET, dead-time count losses, positron branching ratio, and physical 
decay to the time of injection, but no attenuation, scatter, or partial-volume averaging correction 
was applied. The counting rates in the reconstructed images were converted to activity 
concentrations (percentage injected dose per gram of tissue, %ID/g) by use of a system 
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calibration factor derived from the imaging of a mouse-sized water-equivalent phantom 
containing 
89
Zr. Images were analyzed using ASIPro VM software (Concorde Microsystems). 
 4.4.9:  Biodistribution 
 Acute in vivo biodistribution studies were performed in order to evaluate the uptake of 
the 
89
Zr-HOPO and 
89
Zr-DFO in healthy female, athymic nude mice. Mice were warmed gently 
with a heat lamp for 5 min before administration of 
89
Zr-HOPO (0.89-1.11 MBq [24-30 μCi] in 
200 μL 0.9% sterile saline) or 89Zr-DFO (1.11-1.29 MBq [30-35 μCi] in 200 μL 0.9% sterile 
saline) via intravenous tail vein injection (t = 0). Animals (n = 4 per group) were euthanized by 
CO2(g) asphyxiation at 10 min, 1 h, 4 h, 12 h, and 24 h. After asphyxiation, 14 organs were 
removed, rinsed in water, dried in air for 5 min, weighed, and counted in a gamma counter 
calibrated for 
89
Zr. Counts were converted into activity using a calibration curve generated from 
known standards. Count data were background- and decay-corrected to the time of injection, and 
the percent injected dose per gram (%ID/g) for each tissue sample was calculated by 
normalization to the total activity injected. The full data set of organs is included in the appendix 
(Table A.4.2) along with values represented in %ID without normalization (Table A.4.3). 
Biodistribution data were assessed by unpaired t tests using GraphPad Prism (version 6.02 for 
Windows GraphPad Software, San Diego, CA, U.S.) in order to determine any significant 
differences (p <0.05) (Table A.4.4). 
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CHAPTER 5: P-SCN-BN-HOPO: A NOVEL BIFUNCTIONAL 
CHELATOR FOR 
89
ZR IMMUNOPET 
 
5.1:  Introduction  
 5.1.1: Literature review 
Recently there has been a surge of interest in the development of an alternative chelator 
for 
89
Zr
4+
 to replace DFO, with several novel ligand systems being reported within the past year 
or so (Figure 5.1).
1-7
 While multiple studies demonstrate the issue of bone uptake seen with 
89
Zr-
DFO complexes and stressed the need for improved chelators
8-11
, the first investigation towards 
designing a better chelator of Zr
4+
 came from Guérard et. al.
12
  While not testing a preorganized 
ligand system, this paper examined the coordination chemistry of the Zr
4+
cation using multiple, 
individual bidentate hydroxamate ligands.  Through a combination of density functional theory 
(DFT) calculations, potentiometry experiments, and X-ray crystal structure analysis, the 
advantage of an octa-coordinate zirconium complex was confirmed.  Zr
4+
 was shown to 
preferentially form complexes with eight oxygen donors contained within four hydroxamate 
groups.  Additionally, N-methyl acetohydroxamic acid was found to be superior to 
acetohydroxamic acid.  This study opened the door for the investigation of octadentate ligands to 
replace the hexadentate DFO chelator with the goal of improving in vivo stability.  
Not long after that report, Price et. al
1
 published work on H6phospa (Figure 5.1), an 
octadentate, picolinate-based chelator that they evaluated not only with 
89
Zr, but with 
111
In and 
177
Lu as well.  This N4O4 ligand combined 2 carboxylic acids, 4 nitrogen atoms in an acyclic 
backbone, and 2 methylene phosphonate groups to form a proposed eight coordinate 
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Figure 5.1. Chemical structures of newly developed ligands evaluated with 
89
Zr
4+
. The binding 
donor groups are highlighted in red and the conjugation points of the bifunctional ligands are 
shown in blue. The molecules are divided by their progress in development as: monofunctional 
ligand which cannot be attached to a targeting vector, bifunctional ligands that have yet to be 
attached to anything, and bifunctional chelators which have been shown to bind a metal and be 
conjugated to a targeting molecule. The ligands are further divided between those that were 
found to effectively bind Zr and those that were found to be unsuitable.  
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environment for Zr
4+
. However, when the bifunctional derivative of H6phospa — p-SCN-Bn-
H6phospa — was conjugated to an antibody and tested with 
89
Zr, it only achieved a maximum 
radiolabeling yield of 12% under optimized conditions.  This paper also reports previously 
unpublished results of a related ligand, H4octapa (Figure 5.1), containing more carboxylic acid 
groups instead of the methylene phosphonate groups in H6phospa, which was evaluated with 
89
Zr 
and achieved no appreciable radiolabeling.  So while the picolinate-based ligands were overall 
found to be inadequate for chelating 
89
Zr
4+
, it was shown that methylene phosphonate groups 
were superior binding groups than carboxylic acids.  Stability studies were not performed on the 
89
Zr-H6phospa-trastuzumab due to its low radiolabeling yield.  If the previous paper 
demonstrated that an octadentate ligand was needed to securely bind Zr
4+
, then this paper 
demonstrates the inadequacy of nitrogen-containing ligand systems for the oxophilic Zr
4+ 
cation. 
Another bifunctional chelator that was developed for a different radiometal, in this case 
68
Ga, but 
tested with 
89
Zr is YM103 from Ma et. al.
2
 YM103 is a bifunctional isothiocyanate derivative of 
the hexadentate ligand CP256 which is made up of three 3-hydroxy-4-pyridinone (HPO) groups. 
YM103 was shown to bind 
89
Zr
4+
 and performed well in in vitro studies showing >95% stability 
in serum; however, the 
89
Zr-YM103-trastuzumab complex was demonstrated to be unstable in 
vivo with nearly 30 %ID/g of the 
89
Zr localized in the bone. The release of the 
89
Zr
4+
 cation 
suggested by the high bone uptake is likely due to the lability of a six coordinate Zr complex. As 
confirmed by Guérard et. al.,
3
 Zr
4+
 ideally forms an eight coordinate complex and would thus 
benefit from an octadentate ligand. 
Following through on their exploratory hydroxamate work, Guérard et. al.
3
 developed a 
series of cyclic (C5-C7) and acyclic (L5-7) tetrahydroxamate ligands (Figure 5.1) for evaluation 
with Zr
4+
.  Of the synthesized ligands, the pair with the largest spacer, a 7 carbon alkyl chain 
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between hydroxamates, was found to be the best chelator both experimentally and 
computationally.  The 
89
Zr complexes of both the cyclic and acyclic versions of this ligand were 
stable after 7 d in sodium phosphate buffer at pH 7.4 at 20 °C as well as in human serum at 37 
°C, which is also true for 
89
Zr-DFO.  When the 
89
Zr-ligand complexes were incubated in a 1750 
fold excess of EDTA at 37 °C and pH 7 for 7 d, both tetrahydroxamate ligands showed greater 
stability than DFO, with the new cyclic ligand showing the greatest stability of 87% intact 
complex after 7 d.  Both ligands achieved over 99% radiolabeling yield at 7.5 nmol 
concentrations within 2 h at 20 °C at pH 7, and within 30 min if heated to 50 °C.  These 
octadentate, hydroxamate-based chelators look quite promising, and synthesis of the bifunctional 
versions of the two leading candidates are underway to enable further studies in vivo. 
Within our own group, we investigated the potential of a non-hydroxamate-based ligand 
— 3,4,3-(LI-1,2-HOPO)  or HOPO (Figure 5.1) 4  — which has four hydroxypyridinone groups 
for metal binding and comes from the actinide sequestration literature.
13
 We posit that the lower 
pKa of the 1,2-hydroxypyridinone as compared to that of the hydroxamic acid (5.8 vs. 9.4) will 
lead to easier deprotonation at physiological pH and thus greater stability of the Zr-ligand 
complex. DFT calculations suggest a significantly lower energy for the Zr-HOPO complex as 
compared to Zr-DFO. HOPO achieved 100% radiolabeling at 10 µM within 45 min at room 
temperature at pH 7. The 
89
Zr-HOPO complex showed equal stability to 
89
Zr-DFO in serum at 37 
°C over 7 d and slightly better stability in a metal competition experiment where Fe
3+
 was able to 
out compete 
89
Zr
4+
 for DFO about twice as much as HOPO. Most significantly, when incubated 
in a 100-fold excess of EDTA at 37 °C at various pH values from 5-8 for 7 days, 
89
Zr-HOPO 
was >99% stable over the full range of pH while 
89
Zr-DFO was susceptible to transchelation at 
every pH tested. 
89
Zr-HOPO was 10-98% more stable than 
89
Zr-DFO in the EDTA challenge, 
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with the most extreme difference in stability being at the lower pH values. Preliminary in vivo 
experiments were conducted on the 
89
Zr-HOPO to probe its biological behavior and stability. 
The 
89
Zr-HOPO complex was found to clear both renally and intestinally with no observable 
accumulation in the bone, which suggests the complex was stable over the 24 h experiment. 
Work towards the bifunctionalization of the HOPO ligand is currently being carried out in order 
to allow conjugation to an antibody for longer in vivo evaluation. 
Subsequently, Patra et. al
5
 published what is perhaps the most straightforward new ligand 
for Zr
4+
: an octadentate derivative of DFO called DFO* (Figure 5.1). Using desferrioxamine 
mesylate as a starting material, a simple extension containing an additional hydroxamate group 
was added to the amine tail of DFO.  This extended ligand continues the same spacer lengths as 
DFO, but with two additional oxygen donors available for binding.  The complex of Zr
4+
 with 
this octadentate DFO* was predicted to be more stable than that with hexadentate DFO by DFT 
calculations.  Since DFO* contains an amine tail just like the standard DFO ligand, it was able to 
be modified with succinic anhydride to create a bifunctional chelator with a carboxylic acid end, 
which can be attached to the amine of a biomolecule.  This DFO*-CO2H (Figure 5.1) was then 
conjugated to the peptide bombesin (BBS) and radiolabeled with 
89
Zr at room temperature and 
neutral pH for 1.5-2 h.  The 
89
Zr-DFO*-BBS complex was evaluated in comparison with a 
89
Zr-
BBS complex made using p-SCN-Bn-DFO as a standard.  The stability of the two complexes 
was evaluated in a 300- and 3000-fold excess of DFO over 24 h as a transchelation challenge.  
The octadentate DFO* complex was shown to be significantly more stable than the hexadentate 
DFO complex in this challenge.  No additional stability experiments were reported for longer 
time points or conditions.  While the development of a bifunctional derivative of this ligand puts 
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it a step ahead synthetically of two of the previous ligands discussed, its stability has not yet been 
tested in vivo nor in serum, or in any experiments for longer than 24 h. 
Another set of non-hydroxamate-based ligands were investigated by Pandya et. al
6
 that 
contain four terephthalamide (TAM) binding groups for octadentate chelation. These two ligands 
abbreviated only as BFC 1 and 2 (Figure 5.1) are large di-macrocyclic structures with a built in 
amine pendant arm as well as two short PEG units. While the presence of the pendant amine 
makes these ligands by definition bifunctional, additional chemistry would be necessary to attach 
it to most biological molecules and in the current report, no conjugation was explored. Both 
ligands were shown to bind Zr in a 1:1 metal:ligand ratio both experimentally and theoretically. 
The 
89
Zr-ligand complexes performed well in in vitro stability studies, even showing improved 
stability over 
89
Zr-DFO in a DTPA competition experiment. In vivo biodistribution studies were 
also carried out on the 
89
Zr-ligand complexes and no prominent bone uptake was noted within 
the fast circulation time of the complex. BFC 1 was chosen as the preferred ligand based on the 
fact that the 
89
Zr complex cleared more quickly and showed less activity in the liver than BFC 2.  
Most recently, Zhai et. al
7
 have reported a competitive hexadentate ligand based on a derivatized 
fusarinine C (FSC) molecule (Figure 5.1). This is a cyclic ligand with a hydroxamate structure 
very similar to DFO. The prepared 
89
Zr-FSC-RGD complexes demonstrated improved stability 
over 
89
Zr-DFO-RGD in in vitro transchelation studies (93.9% stability vs 42.2% respectively). 
The cyclic nature of the ligand likely provides greater kinetic stability as it is more difficult for 
competing materials to access the metal. However, providing only six donor groups for the 
binding of Zr
4+
 allows for the possibility of additional molecules being needed to satisfy the 
coordination sphere. Currently, the 
89
Zr-FSC-RGD complex has only been evaluated with short 
term in vivo experiments (4 h biodistribution, 24 h PET image) which do not give a full picture 
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of its long term in vivo stability. Further experiments with longer circulating targeting molecules 
such as antibodies are necessary to reveal the practicality of this chelator.  
Additionally, our lab has investigated a catechol-based version of the HOPO ligand: 
3,4,3-LICAM (LICAM) (Figure 5.1, see Chapter 3 for additional information), which was also 
taken from the actinide literature.
13
 This variant was evaluated since catechols are known 
functionalities in siderophores, but was ultimately found to be unsuitable for 
89
Zr
4+
 due to the 
incompatibility between the pKa of the catechol group and the solubility of the Zr
4+
 cation. 
Despite being octadentate and oxygen-rich, the maximum radiolabeling yield reached for the 
LICAM ligand was <30%, despite varying temperature, pH, and reaction time. We believe the 
issue to lie in the fact that the pKa for full deprotonation of the catechol group is 13.0, which 
requires a higher pH for proper labeling; however, the Zr
4+
 cation is only soluble at lower pH, 
and antibody radiolabeling is typically performed at ~ pH 7. This leads to a precarious balance 
between keeping the 
89
Zr
4+
 in solution and trying to get the coordinating oxygen atoms of the 
catechol moiety deprotonated.  Unfortunately, an appropriate compromise could not be found 
that achieved >30% radiolabeling, so the ligand and catechol groups in general were dropped 
from further development.  
Thus far, there has been no reporting of a new ligand for 
89
Zr
4+
 that has been 
demonstrated to be viable in vivo for a sufficient length of time for antibody imaging. Several 
potential ligands require additional development while others simply require further evaluation. 
Herein, we present the first successful demonstration of an alternative chelator for 
89
Zr that 
includes PET imaging and biodistribution data that shows improved stability over DFO across a 
period of several days in vivo. 
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Figure 5.2. Chemical structures of the current standard bifunctional chelator, p-SCN-Bn-DFO, 
and our proposed alternative chelator, p-SCN-Bn-HOPO, based on the previously described 
3,4,3-(LI-1,2-HOPO) ligand. The binding oxygen donor groups are highlighted in red.
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5.1.2: p-SCN-Bn-HOPO 
The 3,4,3-(LI-1,2-HOPO) ligand showed tremendous promise in our preliminary 
evaluation, therefore we endeavored to develop a bifunctional variant of the HOPO ligand for 
further evaluation and application in antibody-based PET imaging. The result of this venture is 
the bifunctional chelator: p-SCN-Bn-HOPO (Figure 5.2). This molecule is the HOPO ligand 
with a para-benzyl-isothiocyanate pendant arm added to one of the secondary amines in order to 
be directly comparable with the current most used bifunctional chelator: p-SCN-Bn-DFO 
(Figure 5.2).  
5.2:  Results and discussion 
 5.2.1:  Synthesis and characterization  
  Initial attempts were made to attach a linker arm directly to one on the secondary amines 
of the original 3,4,3-(LI-1,2-HOPO) ligand in order to make it bifunctional, however our efforts 
were unsuccessful. Coupling to a single secondary amine that already had an amide bond proved 
to be impractical and so we developed a novel synthesis to rebuild the ligand from scratch 
(Figure 5.3). The new method built the pendant arm into the backbone itself before coupling the 
hydroxypyridinone groups onto it. The synthesis of the bifunctional chelator proved to be 
challenging, with a particular difficulty in the deprotection and purification steps, but it was 
ultimately achieved. The final product, p-SCN-BN-HOPO, was purified by HPLC and 
characterized by NMR, IR, and HRMS. 
 5.2.2:  Ligand-antibody conjugation 
  p-SCN-BN-DFO was conjugated to antibodies through the formation of a thiourea bond 
with the amine sidechain of a lysine residue. The p-SCN-BN-HOPO ligand was designed to be 
attached in the very same way. Both ligands were conjugated to trastuzumab at a ratio of 5:1
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Figure 5.3. Synthetic scheme for p-SCN-BN-HOPO. i) Ethyl trifluoroacetate, MeOH, -78 
o
C, 
1 h; ii) (BOC)2O, MeOH, r.t, 18 h; iii) con. NH4OH, r.t, 15 h (28% over 3 steps); iv) 4-Nitro 
phenylethyl bromide, K2CO3, DMF, 60 
o
C, 12 h, 38%;  v) 4 M HCl in Dioxane, r.t, 2 h; vi) 1-
(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carboxylic acid chloride, NEt3, DCM, 0-25 
o
C, 12 h, 
56% (over 2 steps); vii) Raney Ni, H2, MeOH, 3 h; viii) 1:1 (AcOH: HCl), 50 
o
C; ix) Di-2-
pyridyl thiocarbonate, NEt3, CH3CN, H2O, r.t, 1 h 
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ligand:antibody in the reaction mixture. The number of chelates per antibody was initially 
investigated by MALDI-TOF mass spectrometry, however the error was found to be too large to 
provide conclusive values. Subsequently, the average number of chelates per antibody was 
determined to be 2.0 ± 0.5 for p-SCN-BN-DFO and 2.8 ± 0.2 for p-SCN-BN-HOPO through a 
simplified isotopic dilution assay.  
 5.2.3:  Radiolabeling 
All compounds were radiolabeled under mild conditions using a 
89
Zr-oxalate solution 
at pH 7 and room temperature. Reaction progress was monitored using radioITLC. First, the 
bifunctional chelators p-SCN-Bn-HOPO and p-SCN-BN-DFO were radiolabeled on their 
own without being attached to any targeting vectors to compare their Zr binding ability. Both 
ligands labeled quantitatively within 1 h without issues. This confirmed that the benzyl 
isothiocyanate linker arm did not interfere with the metal binding. Next, the chelator -
modified trastuzumab complexes were radiolabeled under the same conditions. Both 
complexes labeled within 1-3 h at room temperature and achieved specific activities of 
approximately 2 mCi/mg. Radiolabeled antibody conjugates were purified via size exclusion 
chromatography and spin filtration. 
 5.2.4:  Serum stability 
The 
89
Zr-ligand complexes alone as well as the 
89
Zr-ligand-antibody complexes were 
evaluated for stability in human serum at 37 
o
C. Both 
89
Zr-ligand complexes showed great 
stability with 97.7 ± 0.2% of the p-SCN-Bn-DFO complex and 97.5 ± 0.5% of the p-SCN-Bn-
HOPO complex intact after 7 d. When the ligands were conjugated to trastuzumab and then 
labeled, both complexes demonstrated slight decreases in stability, with the 89Zr-DFO-
tratuzumab complex showing 94.7 ± 0.7% stability and the 89Zr-HOPO-tratuzumab complex 
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showing 89.2 ± 0.9% stability. While 89.2% for the HOPO complex is still reasonably stable, it 
is notably less than the 94.7% stability of the DFO conjugate. The reason for the change in 
stability between the 89Zr-ligand complexes and the 89Zr-ligand-antibody complexes is currently 
unknown, but may be due to the influence of the antibody sidechains altering the chelation 
environment of the metal either during radiolabeling or during the serum incubation.  
 5.2.5:  Immunoreactivity 
The viability of the 
89
Zr-labeled trastuzumab complexes was assayed against BT474 cells 
to ensure that the conjugation of the chelators did not disrupt the biologically activity of the 
antibody. The 
89
Zr-DFO-trastuzumab and 
89
Zr-HOPO-trastuzumab conjugates were found to 
have immunoreactive fractions of 88.6 ± 2.1  % and 92.4 ± 6.8 % respectively.  
 5.2.6:  In vivo studies 
 5.2.5.1: Imaging 
PET imaging was carried out in order to directly compare the in vivo behavior and 
pharmacokinetics of the DFO- and HOPO-based 
89
Zr-trastuzumab radioimmunoconjugates. 
Female, athymic nude mice with subcutaneous BT474 xenografts in their right shoulders were 
injected with either 
89
Zr-DFO-trastuzumab or 
89
Zr-HOPO-trastuzumab (n=4 for each compound) 
and imaged over 9 d. The resulting images showed good tumor uptake for both compounds, 
but with a marked decrease in the appearance of bone uptake for the 
89
Zr-HOPO-trastuzumab 
images (Figure 5.4). The reduced bone uptake seen with 
89
Zr-HOPO-trastuzumab suggests 
superior stability of the 
89
Zr-HOPO complex. The difference in in vivo performance in contrast 
to the in vitro stability study highlights the inadequacy of the serum stability assay alone.  
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Figure 5.4. PET images of 
89
Zr-HOPO-trastuzumab (top) and 
89
Zr-DFO-trastuzumab (bottom) in 
female, athymic nude mice with BT474 xenografts on their right shoulders (9.25-9.99 MBq 
[250-270 μCi] in 200 μL 0.9% sterile saline). Representative images are shown for each 
compound following a single mouse over 9 d with coronal slice images above corresponding 
maximum intensity projection images. Both compounds show good tumor to background 
contrast, but the 
89
Zr-DFO-trastuzumab shows evidence of bone uptake suggesting in vivo 
release of 
89
Zr
4+
. 
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This demonstrates the successful use of 
89
Zr-HOPO-trastuzumab to image BT474 breast cancer 
with low background, good tumor to organ contrast, and, importantly, very low bone uptake.  
 5.2.5.2: Biodistribution 
Acute biodistribution experiments were performed to further probe the localization and 
uptake of 
89
Zr-DFO-trastuzumab and 
89
Zr-HOPO-trastuzumab. These results corroborate the 
observations from the PET images with the activity associated with all collected tissues, except 
the tumors and the bone, decreasing over time (Figure 5.5). Both compounds showed good 
uptake in the tumor with the DFO complex achieving even higher uptake than the HOPO 
compound (138.2 ± 35.3 vs. 61.9 ± 26.4 %ID/g, Table 5.1). Biodistribution data confirmed the 
lower bone activity of the HOPO conjugate, measuring 17.0 ± 4.1 %ID/g in the bone for the 
89
Zr-DFO-trastuzumab while the 
89
Zr-HOPO-trastuzumab only had 2.4 ± 0.3 %ID/g. 
The amount of activity seen in the bone with 
89
Zr-HOPO-trastuzumab is consistently less than 
the residual bone activity which means it is possible that there is no specific bone accumulation 
since the %ID/g values do not increase over time (Figure 5.6). This is particularly striking when 
compared with the constantly increasing bone uptake seen with 
89
Zr-DFO-trastuzumab which is 
indicative of accumulation of 
89
Zr
4+
 in the skeleton. 
While 
89
Zr-DFO-trastuzumab has a better tumor:blood ratio than 
89
Zr-HOPO-
trastuzumab (31.4 vs. 14.4, respectively), the 
89
Zr-HOPO-trastuzumab complex has a drastically 
improved tumor:bone ratio of  25.8 compared to that of 
89
Zr-DFO-trastuzumab (8.1). Both 
compounds show a high contrast between the tumor and the general background as represented 
by the blood activity, but 
89
Zr-HOPO-trastuzumab provides a much better contrast between the 
tumor and the bone specifically. This benefit of the improved stability of the p-SCN-Bn-HOPO 
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Figure 5.5. Select biodistribution data of 
89
Zr-HOPO-trastuzumab (red) and 
89
Zr-DFO-
trastuzumab (blue) in female, athymic nude mice with BT474 xenografts (0.59-0.74 MBq [16-
20 μCi] in 200 μL 0.9% sterile saline). Both compounds successfully target and accumulate in 
the BT474 tumors with good tumor to background contrast, but 
89
Zr-DFO-trastuzumab has ~2.5 
times the absolute uptake in the tumor. The distribution pattern is very similar for all non-target 
organs except for the bone. The 
89
Zr-DFO-trastuzumab mice show an increasing level of activity 
in the bone suggesting in vivo release of 
89
Zr
4+
 and accumulation in the bone, whereas the 
89
Zr-
HOPO-trastuzumab mice show only a low level of activity in the bone which is below the level 
of the blood and does not increase over time. 
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Figure 5.6. Comparison of the levels of radioactivity in the blood and bone of BT474 tumor-
bearing female, athymic nude mice after injection of either 
89
Zr-HOPO-trastuzumab (red) or 
89
Zr-DFO-trastuzumab (blue) (0.59-0.74 MBq [16-20 μCi] in 200 μL 0.9% sterile saline). While 
the activity in the blood starts high and decreases over time, the activity in the bone is very 
different for the two compounds. The 
89
Zr-HOPO-trastuzumab mice show a near constant level 
(≤2.0 %ID/g) of activity in the bone which never exceeds the level of activity remaining in the 
blood. The 
89
Zr-DFO-trastuzumab mice show an increasing amount of radioactivity in the bone 
over time which far surpasses the level in the blood and suggests release of the 
89
Zr
4+
 cation in 
vivo which is known to preferentially accumulate in the bone. 
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ligand could make a meaningful difference in clinical imaging by enabling easier distinction of 
bone metathesis as well as reducing the radiation dose to healthy bone and bone marrow. 
5.3:  Conclusions 
The 3,4,3-(LI-1,2-HOPO) ligand was found to exhibit excellent stability for 
89
Zr 
complexes in a previous study.
4
 The development of a bifunctional derivative of the HOPO 
ligand was the next logical step and led to the design and synthesis of p-SCN-Bn-HOPO. This 
bifunctional ligand was shown to bind 
89
Zr as expected and was evaluated for conjugation to an 
antibody, radiolabeling of the ligand-antibody complex, and application of the 
radioimmunoconjugate in vivo. The p-SCN-Bn-HOPO prepared comparably to the standard of p-
SCN-Bn-DFO chelator, achieving specific activities ~2 mCi/mg and remaining ~90% stable 
through a 7 d incubation in human serum. The greatest distinction between the two compounds 
was the amount of bone uptake seen in the imaging and biodistribution experiments; the activity 
measured in the bone for 
89
Zr-HOPO-trastuzumab was more than 7 times lower than for 
89
Zr-
DFO-trastuzumab. While the absolute uptake in BT474 breast cancer tumors was just over 2 
times higher for 
89
Zr-DFO-trastuzumab, the tumor:bone ratio was more than 3 times higher for 
89
Zr-HOPO-trastuzumab. This improved contrast between tumor and bone could be 
advantageous for the detection of bone metathesis and for the general clarity of the images. 
Furthermore, the lower bone uptake is the ultimate proof that the p-SCN-Bn-HOPO ligand forms 
a more stable complex with 
89
Zr
4+
 than p-SCN-Bn-DFO and reduces the release of free 
89
Zr
4+
 in 
vivo.  
The bifunctional chelator p-SCN-Bn-HOPO was shown to be an effective alternative for 
the chelation of 
89
Zr
4+
 for immunoPET applications. It successfully reduces the levels of 
radioactivity in the bones of mice compared with the use of p-SCN-Bn-DFO. This study not only 
136 
 
led to a superior ligand for 
89
Zr, but also demonstrates the power of inorganic chemical 
principles to suggest the best chelation system for a metal which can actually be seen to make a 
difference in biological applications.  
5.4:  Experimental section 
 5.4.1:  Materials and methods 
  All chemicals, unless otherwise noted, were acquired from Sigma-Aldrich (St. Louis, 
MO) and used as received without further purification. All instruments were calibrated and 
maintained in accordance with standard quality-control procedures. High-resolution mass 
spectrometry was carried out through electrospray ionization using an Agilent 6520 QTOF 
instrument.
 1
H and 
13
C NMR spectra were recorded at varying temperatures on a Bruker Avance 
III spectrometer equipped with a triple resonance inverse cryoprobe, with 
1
H and 
13
C resonance 
frequencies of 600.13 MHz and 150 mHz or a Bruker DRX spectrometer equipped with a 
1
H, 
13
C 
cryoprobe, with respective resonance frequencies of 500.13 MHz and 125.76 MHz with Topsin 
software. The NMR spectra are expressed on the δ scale and were referenced to residual solvent 
peaks and/or internal tetramethylsilane. The HPLC system used for analysis and purification 
compounds consisted of a Rainin HPXL system with a Varian ProStar 325 UV-Vis Detector 
monitored at 254 nm.  Analytical chromatography was carried out using a Waters Symmetry C18 
Column, 100Å, 5 µm, 4.6 mm X 100 mm at a flow rate of 1.0 mL/min and purification was done 
with a preparatory Waters Symmetry C18 Prep Column, 100Å, 5 µm, 19 mm X 100 mm at a 
flow rate of 17.059 mL/min. IR spectroscopy was performed on a solid sample using an 
attenuated total reflectance attachment on a PerkinElmer Spectrum 2 FT-IR spectrometer with a 
UATR Two attachment.  
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89
Zr was produced at Memorial Sloan Kettering Cancer Center on a TR19/9 cyclotron 
(Ebco Industries Inc.) via the 
89
Y(p,n)
89
Zr reaction and purified to yield 
89
Zr with a specific 
activity of 196–496 MBq/mg. Activity measurements were made using a CRC-15R Dose 
Calibrator (Capintec). For the quantification of activities, experimental samples were counted on 
an Automatic Wizard (2) g-Counter (Perkin Elmer). The radiolabeling of ligands was monitored 
using salicylic acid impregnated instant thin-layer chromatography paper (ITLC-SA) (Agilent 
Technologies) and analyzed on a Bioscan AR-2000 radio-TLC plate reader using Winscan 
Radio-TLC software (Bioscan Inc., Washington, DC).  All in vivo experiments were performed 
according to protocols approved by the Memorial Sloan Kettering Institutional Animal Care and 
Use Committee (protocol 08−07−013). Purity of greater than 95% was confirmed using 
quantitative HPLC analysis for non-radioactive compounds (HOPO and Zr-HOPO) and radio-
TLC for radioactive compounds (
89
Zr-HOPO). 
 5.4.2:  Synthesis 
  Detailed analytical and spectral data are included in the Appendix. 
  5.4.2.1:  (N1, N4, N9 – Tri-tert-butoxycarbonyl)-1,12-di-amino-4,9-
diazadodecane (4): 
  The tri-BOC-protected spermine was prepared according to Geall et al.
14
 To a flask 
containing spermine (1) (2.02 g, 10 mmol) in 150 ml methanol at -78 
o
C under argon was added 
dropwise ethyl trifluoroacetate (1.42 g, 10 mmol ) in 100 mL of methanol over 30 min while 
stirring. Stirring was continued for another 30 min and the reaction mixture was allowed to come 
to 0 
o
C. An excess of di-tert-butyl dicarbonate (60 mmol) in 100 mL methanol was added over a 
period of 1 h. The reaction mixture was stirred at room temperature for 18 h. Concentrated 
ammonium hydroxide solution was added to the reaction mixture until the pH reached 11 and the 
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reaction was stirred for another 15 h at room temperature. The methanol was evaporated under 
reduced pressure and the resulting liquid was dissolved in methylene chloride, washed with 
water, dried over anhydrous sodium sulfate, and evaporated to dryness. The crude compound 
was purified by column chromatography silica using CH2Cl2: MeOH: conc NH3 70:10:1 to 
50:10:1 (v/v/v) yielding the desired product 4 (yield 28%). Products 2 and 3 were used directly 
and not isolated. 
   
1
H-NMR (CDCl3, 400 MHz): δ 3.07-3.21 (m, 10H), 2.68 (t, 2H), 2.08 (bs, 2H), 1.59-1.70 
(m, 4H), 1.41-1.46 (m, 31H). 
13
C-NMR (CDCl3, 100 MHz): δ 156.04, 155.55, 79.48, 78.88, 
46.80, 43.79, 38.76, 37.35, 32.46, 30.9, 28.42. HRMS calculated for C25H50N4O6 ([M+H]
+
), 
503.38, found 503.3817. 
  5.4.2.2:  tert-butyl(4-((tert-butoxycarbonyl)(3-((4-nitrophenethyl)amino) 
propyl)amino)butyl)(3-((tert-butoxycarbonyl)amino)propyl)carbamate (5): 
  A solution of 4-nitrophenylethyl bromide (0.126 g, 0.55 mmol) in DMF (2 mL) was 
added to a suspension of 4 (0.201 g, 0.5 mmol) and K2CO3 (0.138 g, 1 mmol) in DMF (5 mL) 
under N2. The resulting reaction mixture was stirred at 60 
o
C for 12 h. Solvent was removed 
under vacuum and the resulting residue was dissolved in methylene chloride, washed with water, 
dried over anhydrous sodium sulfate, and evaporated to dryness. The crude compound was 
purified by column chromatography silica using 1% methanol in methylene chloride to give 
compound 5 as a gummy solid. (Yield = 30%). 
1
H NMR (500 MHz, CDCl3): (mixture of rotamers)  8.10-8.09 (d, 2H), 7.36 (d, 2H), 
3.28-2.58 (m, 20H), 1.80 (bs, 2H), 1.58 (bs, 2H),  1.38-1.36 (m, 27H).  
13
C NMR (500 MHz, 
CDCl3): (mixture of rotamers)   156.1, 155.9, 129.8, 123.9, 79.3, 78.7, 78.3, 49.85, 49.83, 
49.80, 49.76, 49.72, 47.1, 47.0, 46.94, 46.91, 46.89, 46.86, 46.77, 46.72, 46.67, 46.60, 46.52, 
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46.46, 46.41, 46.38, 46.33, 46.27, 46.26, 46.23, 46.20, 45.69, 45.66, 44.28, 44.20, 43.88, 43.83, 
43.78, 43.52, 43.47, 43.40, 43.38, 43.32, 37.76, 37.68, 37.64, 37.60, 37.56, 37.51, 37.48, 37.38, 
34.45, 34.40, 34.15, 28.45; HRMS calculated for C33H57N5O8 ([M+H]
+
), 651.4207, found 
652.4387.  
  5.4.2.3:  N1-(3-aminopropyl)-N4-(3-((4-nitrophenethyl)amino)propyl)butane-
1,4-diamine (6): 
  A solution of 4M HCl in dioxane (5 mL) was added to a stirring solution of 5 (0.17g, .5 
mmol) in CH2Cl2 (10 mL), under nitrogen, at 25 °C. After 2 h, the solution was concentrated in 
vacuo and co-distilled with toluene (3×5 mL) (poly-HCl salt). This compound was not isolated, 
but rather used directly in the next step. 
  5.4.2.4:  1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-
carboxamido)propyl)-N-(4-(1-(benzyloxy)-N-(3-(1-(benzyloxy)-N-(4-nitrophenethyl)-2-oxo-
1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine-3-
carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (7): 
  A solution of 1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-carbonyl chloride (0.789g, 3 
mmol) in methylene chloride (15 mL) was added drop wise to a stirred solution of triethylamine 
(0.835 mL, 6 mmol), 6 (0.351g, 1 mmol) and DMAP (0.006g, 0.05 mmol) in dry methylene 
chloride (10 mL) at 0
o
C . The reaction mixture was warmed to room temperature and stirred for 
24 h. The reaction mixture was washed with 10% NaHCO3 solution, followed by water. The 
organic phase was dried over anhydrous Na2SO4 and was then removed with a rotary evaporator. 
The crude product was purified through column chromatography over silica gel using 2-4% 
methanol in dichloromethane eluent producing in 5 as brown foam (yield 56%). 
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1
H NMR (600 MHz, CDCl3): (mixture of rotamers)  8.16-7.25 (m, 20H), 7.19-4.86 (m, 
16H), 3.82-2.06 (m, 25H), 1.84-0.63 (m, 8H); 
13
C NMR (600 MHz, CDCl3): (mixture of 
rotamers)   1420.16, 142.14, 139.12, 139.05, 139.0, 138.97, 138.87, 138.82, 138.78, 138.70, 
138.66, 138.59, 138.55, 138.50, 133.16, 133.13, 133.06, 130.86, 130.80, 130.72, 130.66, 130.45, 
135.41, 135.37, 130.34, 130.32, 130.29, 130.26, 130.23, 129.79, 129.76, 129.73, 129.70, 129.65, 
129.62, 129.56, 123.97, 123.92, 123.83, 123.76, 123.74, 123.36, 122.79, 122.65, 122.57, 122.53, 
122.52, 122.48, 104.07, 103.62, 103.54, 103.49, 103.40, 103.34, 79.66, 46.97, 46.08, 46.02, 
41.99, 40.64, 36.95, 36.93, 36.89, 36.81, 34.61, 33.39, 33.23, 33.11, 26.09, 26.88, 25.52, 25.49, 
25.32, 25.18, 25.11, 24.84, 24.80, 24.53, 24.17, 24.13, 23.98; HRMS calculated for C70H69N9O14 
([M+H]
+
), 1260.5042, found 1260.5038. 
  5.4.2.5:  N-(4-(N-(3-(N-(4-aminophenethyl)-1-(benzyloxy)-2-oxo-1,2-
dihydropyridine-3-carboxamido)propyl)-1-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-
carboxamido)butyl)-1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-
carboxamido)propyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (8):  
  To a suspension of Raney nickel in (1:1) MeOH : THF (10 mL), 7 (0.2g, 0.157 mmol)  
was added and hydrogenated at balloon H2 pressure at room temperature for 3 h. The catalyst 
was filtered through a celite pad under inert atmosphere. The filtrate was evaporated under 
reduced pressure to obtain the crude amine. This crude product was used directly in the next step 
without further workup. For characterization purposes, some of this product was HPLC purified 
as a cream colored solid. 
  
1
H NMR (600 MHz, DMSO-d6): (mixture of rotamers)   8.70-8.64 (m, 1H), 7.44-7.33 
(m, 27H), 6.93-6.89 (m, 1H), 6.89-6.80 (m, 3H),  6.64-6.62 (m, 4H) , 6.31-6.10 (m, 4H), 5.38-
5.26 (m, 5H), 5.04-4.99 (m, 3H), 3.60-3.55 (m, 18H), 3.16-3.13 (m, 14H), 1.76-1.21 (m, 10H); 
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13
C NMR (600 MHz, DMSO-d6): (mixture of rotamers)   158.77, 158.70, 158.28, 158.25, 
158.18, 158.14, 155.63, 155.30, 155.27, 155.09, 155.06, 155.03, 141.89, 141.63, 141.60, 140.70, 
140.59, 140.51, 136.82, 136.77, 136.64, 131.65, 161.41, 131.38, 131.35, 127.49, 127.44, 127.38, 
127.29, 126.97, 126.87, 126.27, 126.23, 126.20, 120.31, 120.35, 119.75, 117.81, 115.46, 113.1, 
101.62, 100.26, 100.1, 76.16, 76.10, 59.81, 52.71, 45.56, 45.49, 43.71, 43.47, 43.31, 41.3, 39.83, 
39.65, 34.51, 34.45, 34.18, 34.11, 31.09, 29.71, 25.62, 24.36, 23.29, 22.73, 22.54, 22.43, 21.75, 
21.38, 21.29; HRMS calculated for C70H72N9O12 ([M+H]
+
), 1230.5300, found 1230.5299.  
  5.4.2.6:  4-(11,15-bis(1-hydroxy-2-oxo-1,2-dihydropyridine-3-carbonyl)-1-(1-
hydroxy-6-oxo-1,6-dihydropyridin-2-yl)-6-(1-hydroxy-6-oxo-1,6-dihydropyridine-2-
carbonyl)-1-oxo-2,6,11,15-tetraazaheptadecan-17-yl)benzenaminium chloride (9): 
  Crude 8 was dissolved in a 1:1 mixture of acetic acid and concentrated HCl (6 mL) at 
room temperature and heated to 45-50 
o
C for 18 h. The reaction progress was monitored by LC-
MS. The crude product was dried and redissolved in water/acetonitrile and purified by HPLC on 
a preparative C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 19 mm X 100 
mm) at 17.059 mL/min using a gradient of 10-23% MeCN in water (both containing 0.1% TFA) 
with an initial hold at 10% MeCN for 1.33 mins and then a ramp to 23% MeCN over 20 minutes. 
The product peak was collected from 6.45-8.26 min and the eluted solution was lyophilized to 
recover the product as an off white solid. The purified ligand was collected in multiple small 
batches with an approximate combined yield of 70%. 
  The purified sample was confirmed by HPLC on a analytical C18 column (Waters 
Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm X 100 mm) at 1 mL/min using a gradient of 
10-30% MeCN in water (both containing 0.1% TFA) with an initial hold at 10% MeCN for 1.33 
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mins and then a ramp to 30% MeCN over 30 minutes followed by a ramp to 95% MeCN over 1 
minute and an isocratic hold at 95% MeCN for 5.66 minutes.  
  
1
H NMR (500 MHz, CDCl3): (mixture of rotamers)   7.44-7.28 (m, 5H), 7.20-7.16 (dd, 
J1, J2=6 Hz, 1H), 7.08-7.01 (m, 2H), 6.54-6.53 (m, 4H),  6.33-6.32 (m, 3H) , 6.18-6.21 (m, 
0.5H), 5.74-5.67 (m, 0.5H), 3.65-3.51 (m, 4H), 3.51-3.16 (m, 8H), 3.12-2.70 (m, 11H), 1.91-1.38 
(m, 10H) ; 
13
C NMR (500 MHz, CDCl3): (mixture of rotamers)   158.8, 158.6, 158.4, 158.1, 
157.9, 157.8, 157.77, 157.73, 142.5, 142.49, 142.45, 142.41, 142.32, 142.24, 142.04, 138.10, 
138.0, 137.59, 137.51, 130.36, 130.31, 130.18, 130.08, 119.76, 119.45, 117.5, 115.6, 104.3, 
102.5, 102.47, 102.41, 50.01, 48.12, 47.9, 46.0, 46.0, 43.7, 42.3, 37.2, 37.0, 36.97, 33.80, 32.65, 
32.49, 28.16, 26.90, 26.23, 25.4, 25.4, 25.2, 25.1, 24.4, 24.3, 24.3, 24.2; HRMS calculated for 
C42H47N9O12 ([M+H]
+
), 870.3422, found 870.3420.  
  5.4.2.7:  1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6-dihydropyridine-2-
carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4-isothiocyanatophenethyl)-2-
oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine-3-
carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-Bn-HOPO, 10): 
  NEt3 (0.0012 g, 0.012 mmol) was added to a solution of 8 (0.01 g, 0.011 mmol) in (8:2) 
acetonitrile and water (1 mL). Next, Di-2-Pyridyl thionocarbonate (0.011 g, 0.05 mmol) was 
added at room temperature and stirred vigorously for 1 h. The crude reaction solution was 
directly purified by HPLC on a preparative C18 column (Waters Symmetry C18 Prep Column, 
100Å, 5 µm, 19 mm X 100 mm) using a gradient of 5-75% MeCN in water (both containing 
0.1% TFA) with an initial hold at 5% MeCN for 1.33 mins and then a ramp to 75% MeCN over 
30 minutes. The product peak was collected from 15.01-15.5 min and the eluted solution was 
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lyophilized to recover the product as a white solid. The purified ligand was collected in multiple 
small batches with an approximate combined yield of 32%. 
  The purified sample was confirmed by HPLC on a analytical C18 column (Waters 
Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm X 100 mm) at 1 mL/min using a gradient of 
5-75% MeCN in water (both containing 0.1% TFA) with an initial hold at 5% MeCN for 1.33 
mins and then a ramp to 75% MeCN over 30 minutes followed by a ramp to 95% MeCN over 1 
minute and an isocratic hold at 95% MeCN for 5.66 minutes.  
  
1
H NMR (500 MHz, CDCl3): (mixture of rotamers)   7.37-7.31 (m, 7H), 7.12-7.08 (m, 
1H), 6.58-6.52 (m, 4H), 6.34-5.81 (m, 4H),  3.62-3.54 (m, 12H) , 3.13-2.83 (m, 11H), 2.01-1.24 
(m, 11H) ; 
13
C NMR (500 MHz, CDCl3): (mixture of rotamers)   161.78, 161.71, 161.54, 161.4, 
160.65, 160.61, 157.89, 157.83, 157.78, 157.73, 142.59, 142.48, 142.41, 142.33, 142.31, 142.21, 
139.58, 138.49, 138.90, 138.81, 138.17, 138.0, 137.57, 137.50, 134.07, 130.76, 130.74, 130.59, 
130.52, 128.89, 128.66, 126.41, 126.32, 119.74, 119.53, 119.43,104.33, 102.50, 102.39, 49.62, 
48.11, 47.96, 46.49, 46.01, 45.70, 37.24, 37.01, 36.96, 34.04, 32.83, 32.71, 28.15, 27.12, 26.85, 
26.22, 25.46, 25.26, 25.17, 24.36, 24.18 ; HRMS calculated for C43H45N9O12S ([M+H]
+
), 
912.2987, found  912.2987. 
 5.4.3:  Ligand-antibody conjugation 
  Trastuzumab (purchased commercially as Herceptin, Genentech, San Francisco, CA) was 
purified using pre-packed size exclusion chromatography (SEC) columns (Sephadex G-25 M, 
PD-10 Desalting Columns, 50 kDa, GE Healthcare) and centrifugal filter units with a 50,000 
molecular weight cutoff (Amicon Ultra 4 Centrifugal Filtration Units, Millipore Corp., Billerica, 
MA) and phosphate buffered saline (PBS, pH 7.4) to remove α_α-trehalose dihydrate, L-
histidine, and polysorbate 20 additives. After purification, the antibody was taken up in PBS at 
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pH 7.4. Subsequently, ~60 μL of antibody solution (~13 nmol) were diluted to 1 mL with PBS at 
pH 7.4.  The pH antibody solution was raised to 8.8-9.0 with 0.1 M Na2CO3 before the slow 
addition of  5 equivalents of p-SCN-Bn-HOPO or p-SCN-Bn-HOPO in ~12 μL of DMSO. The 
reaction was incubated at 37 
o
C for 1 h and shaken at 300 rpm, followed by SEC and centrifugal 
filtration to purify the ligand-antibody conjugate. The final bioconjugates were stored in PBS pH 
7.4 at 4 
o
C.  
  Chelate number was investigated via MALDI-TOF mass spectrometry analysis 
conducted at the University of Alberta. Samples of 
89
Zr-DFO-trastuzumab, 
89
Zr-HOPO-
trastuzumab, and unmodified trastuzumab were submitted for analysis and the chelate number 
was calculated as the difference between the modified and unmodified antibody divided by the 
mass of the chelator. Samples were analyzed in triplicate and values were calculated from 
averages. When the triplicate MALD-TOF results were examined, the error was determined to be 
too large to provide meaningful results (Figure A.5.2). Identical samples gave values that 
differed by the masses of entire chelates. This method was determined insufficient for the current 
study.  
  Chelate number was then determined using an isotopic dilution assay. A stock solution of 
1 mM ZrCl4 was made up in 1 M oxalic acid. Approximately ~200 µCi of 
89
Zr oxalate solution 
in 1 M oxalic acid was added to 100 µL of the stock solution. This mixture was then neutralized 
to pH 7 with 1 M Na2CO3 to create a ~200 µL Zr working solution of ~500 µM Zr
4+
. Triplicate 
solutions of DFO-Trastuzumab and HOPO-Trastuzumab were prepared containing 300-400 
pmol of antibody in 30 µL of PBS. Aliquots of 20, 25, and 30 µL of the Zr working solution 
were added to the three ligand-antibody samples for each ligand. The solutions were incubated at 
room temperature with gentle mixing overnight. The next day a volume of 50 mM EDTA equal 
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to 1/9 of the volume of the reaction mixture was added to each sample and left to incubate for 15 
minutes in order to scavenge any nonspecifically bound Zr
4+
. Samples were then analyzed using 
radioITLC to determine the extent of radiolabeling. The average number of chelates per antibody 
was calculated as the ratio of bound vs. unbound radioactive 
89
Zr × the moles of Zr
4+
 ÷ the moles 
of antibody. The experiment was run in duplicate using the same batch of ligand-Trastuzumab 
conjugate as the in vivo studies.  
 5.4.4:  Radiolabeling studies 
  
89
Zr was received after target processing as 
89
Zr-oxalate in 1.0 M oxalic acid. This 
solution is then neutralized with 1.0 M sodium carbonate to reach pH 6.8-7.2. Both the DFO and 
HOPO ligands were labeled at various concentrations in water or saline with the neutralized 
89
Zr 
solution at room temperature for varying lengths of time, typically 10-60 min. Reactions were 
monitored via radio-TLC with different stationary phases depending on the nature of the 
reaction. 
89
Zr-ligand complexes required Varian ITLC-SA strips (Agilent Technologies) whereas 
89
Zr-ligand-trastuzumab complexes employed Varian ITLC-SG strips (Agilent Technologies), 
but both analysis methods used 50 mM EDTA at pH 5 as the mobile phase. 
89
Zr complexes 
remained at the origin, while free 
89
Zr was taken up by EDTA in the mobile phase and migrated 
along the ITLC strip. 
 5.4.5:  Serum stability studies 
  
89
Zr-ligand and 
89
Zr-ligand-antibody complexes were prepared according to the 
radiolabeling protocol as described above. For each 
89
Zr complex, samples were made consisting 
of 900 μL human serum and 100 μL of the 89Zr species and were placed in a heat block at 37 oC 
with agitation. Samples were monitored using radio-TLC before being added to the serum and 
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then after 1 week of incubation. The stability of the complexes was measured as the percentage 
of 
89
Zr that was retained at the origin of the ITLC strip and therefore still intact. 
 5.4.6:  Immunoreactivity assay 
  The immunoreactivity of the 
89
Zr-DFO-trastuzumab and 
89
Zr-HOPO-trastuzumab 
bioconjugates was determined using specific radioactive cellular-binding assays following 
procedures derived from Lindmo et al.
15, 16
 To this end, BT474 cells were suspended in 
microcentrifuge tubes at concentrations of 2.5, 2.0, 1.5, 1.25, 1.0, 0.75, and 0.25 ×10
6
 cells/mL 
in 500 μL PBS (pH 7.4). Aliquots of either 89Zr-DFO-trastuzumab or 89Zr-HOPO-trastuzumab 
(50 μL of a stock solution of ~10 μCi in 10 mL of 1% bovine serum albumin in PBS pH 7.4) 
were added to each tube (n = 3; final volume: 550 μL), and the samples were incubated on a 
mixer for 60 min at room temperature. The treated cells were then pelleted via centrifugation 
(600 G for 2 min), aspirated, and washed twice with cold PBS before removing the supernatant 
and counting the activity associated with the cell pellet. The activity data were background-
corrected and compared with the total number of counts in appropriate control samples. 
Immunoreactive fractions were determined by linear regression analysis of a plot of (total/bound) 
activity against (1/[normalized cell concentration]). No weighting was applied to the data, and 
data were obtained as n = 3. 
 5.4.7:  PET imaging 
  PET imaging experiments were conducted on a microPET Focus 120. Female, athymic 
nude mice with BT474 xenografts on their right shoulders were administered 
89
Zr-HOPO-
trastuzumab (9.25-9.99 MBq [250-270 μCi] in 200 μL 0.9% sterile saline) or 89Zr-DFO-
trastuzumab (9.25-9.99 MBq [250-270 μCi] in 200 μL 0.9% sterile saline) via intravenous tail 
vein injection (t = 0). Approximately 5 min prior to the acquisition of PET images, mice were 
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anesthetized by inhalation of 2% isoflurane (Baxter Healthcare, Deerfield, IL)/oxygen gas 
mixture and placed on the scanner bed; anesthesia was maintained using 1% isoflurane/gas 
mixture. PET data for each mouse were recorded via static scans at various time points (n=4) 
between 6 h and 9 d. An energy window of 350-700 keV and a coincidence timing window of 
6 ns were used. Data were sorted into 2D histograms by Fourier rebinning, and transverse images 
were reconstructed by filtered back-projection (FBP) into a 128 × 128 × 63 (0.72 × 0.72 × 
1.3 mm
3
) matrix. The image data were normalized to correct for non-uniformity of response of 
the PET, dead-time count losses, positron branching ratio, and physical decay to the time of 
injection, but no attenuation, scatter, or partial-volume averaging correction was applied. The 
counting rates in the reconstructed images were converted to activity concentrations (percentage 
injected dose per gram of tissue, %ID/g) by use of a system calibration factor derived from the 
imaging of a mouse-sized water-equivalent phantom containing 
89
Zr. Images were analyzed 
using ASIPro VM software (Concorde Microsystems). 
 5.4.8:  Biodistribution 
 Acute in vivo biodistribution studies were performed in order to compare the uptake of 
89
Zr-HOPO-trastuzumab and 
89
Zr-DFO-trastuzumab in BT474 tumor-bearing female, athymic 
nude mice. Mice were warmed gently with a heat lamp for 5 min before administration of 
89
Zr-
HOPO-trastuzumab (0.59-0.67 MBq [16-18 μCi] in 200 μL 0.9% sterile saline) or 89Zr-DFO-
trastuzumab (0.67-0.74 MBq [18-20 μCi] in 200 μL 0.9% sterile saline) via intravenous tail vein 
injection (t = 0). Animals (n = 4 per group) were euthanized by CO2(g) asphyxiation at 1, 3, 5, 7, 
9, and 14 d. After asphyxiation, 14 organs were removed, rinsed in water, dried in air for 5 min, 
weighed, and assayed for radioactivity on a gamma counter calibrated for 
89
Zr. Counts were 
converted into activity using a calibration curve generated from known standards. Count data 
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were background- and decay-corrected to the time of injection, and the percent injected dose per 
gram (%ID/g) for each tissue sample was calculated by normalization to the total activity 
injected. The full data set of organs is also included in the appendix with values represented in 
%ID without normalization (Table A.5.2). 
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CHAPTER 6: CONCLUSIONS AND FUTURE DIRECTIONS  
 
 
 
6.1: The HOPO journey  
This thesis follows an idea from its very inception to its fruition as a successful project 
which shows real and significant improvement over the current technology. The project started 
from the persistent observation of bone uptake with 
89
Zr-based immunoPET imaging agents and 
the recognition of the chelator, DFO, as the weak link in the modality. The idea of improving the 
performance of such agents by developing a better chelator was then paired with a firm 
foundation in a basic chemistry to approach the challenge. By taking an in depth look at the 
chemistry of Zr and DFO to begin with, we were able to begin forming our hypotheses for 
chelator optimization and building our knowledge of the techniques necessary to evaluate these 
chelators. Next we looked to existing literature
1
 to find suitable binding groups and ligand 
geometries. Our initial work with catechols and hydroxypyridinones led us rather directly to the 
3,4,3-(LI-1,2-HOPO) ligand. The robust stability demonstrated by this HOPO ligand when 
radiolabeled with 
89
Zr
4+
 was more than convincing enough to lead us to develop a bifunctional 
derivative to allow use with antibodies. Finally, p-SCN-Bn-HOPO proved to be an optimal 
bifunctional chelator compared to the “gold standard” DFO. When evaluated as an immunoPET 
imaging agent, the 
89
Zr-HOPO-trastuzumab complex showed dramatically decreased levels of 
89
Zr in the bones of mice, down to background blood levels, compared to 
89
Zr-DFO-trastuzumab. 
This feat is both something to be excited about and something to be proud of.  
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6.2:  Future directions 
 6.2.1:  Translation possibilities  
The most rewarding possible outcome of this work would be to see p-SCN-Bn-HOPO be 
moved forward into a clinical trial with 
89
Zr. Of particular interest is the 
89
Zr-J591 clinical trial 
currently taking place at Memorial Sloan Kettering Cancer Center.
2
 The 
89
Zr-DFO-huJ591 
radioconjugate is being lauded as an excellent imaging agent for the detection of bone metastases 
in advanced prostate cancer patients. This could be an ideal application of p-SCN-Bn-HOPO as 
it could lower the background signal in the bone by eliminating the release of the 
89
Zr
4+
 cation in 
vivo. Reduced background signal in the bone tissue could enable improved distinction of osseous 
lesions and possibly even allow for the detection of smaller lesions.  
 6.2.2: Other metals 
  Another possible avenue for investigation is the application of p-SCN-Bn-HOPO toward 
the chelation of other metals, whether radioactive or otherwise for imaging or therapeutic 
purposes. As the 3,4,3-(LI-1,2-HOPO) ligand was originally made for the purpose of chelating 
actinides
1
, it follows that the bifunctional ligand p-SCN-Bn-HOPO might also be useful actinides 
and lanthanides that have medical applications. Two specific examples of possible nuclides of 
interest are actium-225 and thorium-227 which both emit alpha particles suitable for 
radioimmunotherapy (RIT). The thermodynamic stability constant of Th-HOPO has been 
determined and is comparable to that of Zr-HOPO suggesting that 
227
Th might be a good 
candidate for evaluation with a p-SCN-Bn-HOPO-antibody system.
3
 Furthermore, 
225
Ac is at the 
forefront of radioimmunotherapy due to its decay chain containing many other radioactive 
daughter nuclides which increase the therapeutic payload of the RIT agent.
4
 Despite this, the 
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chelation of 
225
Ac has not been optimized and would be a ripe area for the further evaluation of 
p-SCN-Bn-HOPO.  
6.3:  Conclusions 
This project demonstrates the power of chemistry to predict and solve problems within 
biological applications. From looking at a library of existing ligands, we were able to select a 
chelator based on its chemical properties in relation to the metal of interest. We remade the 
ligand and proved its potential for Zr
4+
 before taking that framework and developing it into a 
bifunctional chelator for use in our intended area of study. This new molecule was then shown to 
outperform the existing chelator quite stunningly in fixing the exact issue we set out to address, 
namely reducing accumulation of radioactivity in bone tissue.  
These results show that innovation doesn’t have to start from scratch. There is an 
enormous volume of existing ligands in the literature that are just waiting to be harnessed for 
new applications. With increased collaboration and exchange between different branches of 
chemistry and other disciplines, it makes sense to take advantage of established molecules to 
solve different problems. Hopefully, this work can serve as an example and encourage others to 
pull from different branches of chemical research to help solve a myriad of new and exciting 
challenges.
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Zr-DFO MS report (Figure A.2.1)   
NMR comparison of DFO and the Zr-DFO complex (Figure A.2.2) 
Radio-ITLC method comparison (Figure A.2.3) 
HPLC radiotrace of 
89
Zr-DFO post-serum study (Figure A.2.4) 
Cell binding assay results (Figure A.2.5) 
Full biodistribution data (Table A.2.1) 
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Figure A.2.1. Non-radioactive Zr-DFO mass spectrometry analysis indicating the different states 
a) DFO, b) Zr-DFO, and c) an octa-coordinate Zr(OH)2-DFO similar to that suggested by DFT 
calculations. The low resolution mass spectrum was recorded using a Waters Acquity UPLC 
with electro-spray ionization (ESI) SQ detector.  
a) DFO: [M+H]
+
 (m/z expected: 561.36, measured: 561.4); [M-H]
-
 (m/z expected: 559.35, 
measured: 559.4); [M+Cl]
-
 (m/z expected: 595.32, measured: 595.5); b) Zr-DFO: [M]
+
 (m/z 
expected: 647.23, measured: 647.3); [M+H]
2+
 (m/z expected: 324.12, measured: 324.4); c) 
Zr(OH)2-DFO: [M+H+Cl]
-
 (m/z expected: 717.22, measured: 717.3) 
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Figure A.2.2. NMR measurement of DFO (upper panel) and Zr-DFO (lower panel) 
demonstrating the structural change of DFO before and after Zr chelation. Significant chemical 
shifts changes are observed for protons located the closest to hydroxamate binding groups (Ha, 
Hf, Hd, & Hb respectively 2.152.19, 2.52.65, 3.213.27, and 3.673.71).  
DFO:
 1
H-NMR (D2O, 500 MHz) δ: 1.28-1.8 (m, 18H, Hc); 2.15 (s, 3H, Ha); 2.55 (t, 4H, Hf); 2.83 
(m, 4H, He; s, 3H, Hh); 3.04 (t, 2H, Hg); 3.21 (t, 4H, Hd); 3.67 (mc, 6H, Hb).  
Zr-DFO: 
1
H-NMR (D2O, 500 MHz) δ: 1.26-1.82 (m, 18H, Hc), 2.19 (s, 3H, Ha); 2.65 (t, 4H, Hf); 
2.82 (m, 4H, He), 2.84 (s, 3H, Hh), 3.04 (t, 2H, Hg); 3.27 (t, 4H, Hd); 3.71 (m, 6H, Hb).  
In the time since this work was conducted, Ma et. al
1
 published a similar NMR analysis 
comparing DFO and Zr-DFO. Our results are similar to theirs, with a discrepancy in the 
assignments of He and Hf with theirs being the opposite of ours. Their study was more in depth 
than ours in that they used variable temperature NMR and 2D methods to make individual 
assignments, so their results are more likely to be accurate.
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Figure A.2.3. Comparison of radio-ITLC conditions for 
89
Zr-DFO radiolabeling reaction 
monitoring. Conditions evaluated included ITLC-SG, ITLC-SA, and cellulose strips with 50 mM 
EDTA at pH 5, 0.5 M citric acid, and Millipore water. 
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Figure A.2.3. The radioactive fraction from the SEC analysis was HPLC analyzed and the 
retention time of 
89
Zr-DFO remained unchanged confirming the stability of the 
89
Zr-DFO 
complex even after incubation with serum protein. 
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Figure A.2.4. Comparison of 
89
Zr-DFO-A33 and 
89
Zr-DFO through a 1 h incubation with 
SW1222 human colorectal cancer tumor cells shows the significantly lower affinity of 
89
Zr-DFO 
for the cells as compared to the 
89
Zr-labeled A33 antibody which actively binds an antigen found 
on the SW1222 tumor cells. 
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 SW1222 Healthy 
Blood 1.42 ± 0.35 3.99 ± 1.44 
Heart 0.53 ± 0.13 1.41 ± 0.56 
Lung 0.79 ± 0.25 1.47 ± 0.46 
Bone 0.95 ± 1.05 1.31 ± 0.49 
Kidney 8.72 ± 1.12 18.78 ± 13.17 
Bladder 4.61 ± 2.22 20.68 ± 10.36 
Tumor 1.14 ± 0.42 n/a 
Muscle 0.69 ± 0.50 2.4 ± 0.93 
 
Table A.2.1. Full biodistribution data for 
89
Zr-DFO in healthy and SW1222 tumor-bearing mice. 
Data presented as %ID/g. While the values are somewhat higher in heathy mice, the ratios are 
quite similar which suggests the same relative distribution. 
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HOPO MS report (Figure A.3.1)         
HOPO HPLC chromatogram (Figure A.3.2)   
LICAM MS report (Figure A.3.3)  
LICAM HPLC chromatogram (Figure A.3.4)      
Zr-CMM UV/Vis (Figure A.3.5)  
HOPO/Zr-HOPO HPLC chromatogram (Figure A.3.6) 
LICAM/Zr-LICAM HPLC chromatograms (Figure A.3.7) 
Zr-HOPO MS report (Figure A.3.8)  
Zr-LICAM MS report (Figure A.3.9) 
LICAM Radiolabeling Trends (Figure A.3.10-11)    
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Figure A.3.1. Mass spectrometry analysis of the HOPO ligand showing the expected mass 
signals. 
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Figures A.3.2. HPLC chromatogram of the HOPO ligand.  
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Figures A.3.3. Mass spectrometry analysis of the LICAM ligand showing the expected mass 
signals. 
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Figures A.3.4. HPLC chromatogram of the LICAM ligand.  
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Figure A.3.5. UV/Vis spectra of the catechol methyl monomer (CMM) mixed with different 
amounts of ZrCl4. No significant differences can be seen between samples; therefore no 
meaningful information can be extrapolated about binding. 
165 
 
Figure A.3.6. HPLC chromatogram of the HOPO ligand and the non-radioactive Zr-HOPO 
complex. 
  
166 
 
 
 
Figure A.3.7. HPLC chromatograms of the LICAM ligand alone and a mixture of ZrCl4 and 
LICAM. The top trace is over a gradient from 5-95% and the bottom is 50-95% MeCN in water 
both spiked with 0.1% TFA. The fact that one method shows the Zr-LICAM coming out slightly 
before the LICAM alone while the other shows it eluting slightly after suggests that the small 
change might be due to slight changes in the column over time rather than a consistent, 
meaningful change in retention time indicative of a change in speciation. This is insufficient to 
claim a new Zr-LICAM complex has been formed.  
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Figures A.3.8. Mass spectrometry analysis of the Zr-HOPO complex showing the expected mass 
signals indicating a 1:1 complex with full deprotonation of the hydroxypyridinone groups. 
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Figures A.3.9. Mass spectrometry analysis of the Zr-LICAM complex with notable signals 
highlighted. Masses suggest the LICAM ligand is not fully deprotonated, losing only 4 protons 
from the catechols instead of 8. 
 
865  [M+Cl]- 
832  [M-H]- 
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Figures A.3.10. Effects of temperature and pH on the 89Zr radiolabeling of LICAM. The two 
graphs show data from two different experiments. The effects are mostly inconsistent. The best 
results seem to be from pH 7, but they are still very low. Temperature and time don’t seem to 
improve the yields.  
 
1 2 6 24 
0 1 2 24 
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Figures A.3.11.  Effects of time and temperature on the 
89
Zr radiolabeling of LICAM. There is 
no significant effect comparing room temperature and 37 
o
C. There is also no meaningful 
improvement in labeling over time.  
 
 
0 1 5 24 
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Zr-HOPO HRMS report (Figure A.4.1)        
NMR comparison of the HOPO ligand the Zr-HOPO complex (Figure A.4.2)   
Experimental Zr-HOPO IR spectra (Figure A.4.3)                 
Computed Zr-HOPO IR spectra (Figure A.4.4)                 
Zr-HOPO UV-Vis spectroscopy (Figures A.4.5-6)              
Complete Gaussian 09 reference (Ref. 48)               
DFT basis set evaluation (Table A.4.1)               
DFT structure of Zr(1,2-HOPO)4 (Figure A.4.7)              
DFT structure of DFOH2 (Figure A.4.8)                
Cartesian coordinates of all optimized structures (gas phase)                                             
Cartesian coordinates of all optimized structures (CPCM,water)                                       
Maximum intensity projection PET images (Figure A.4.9)      
Full biodistribution data (Tables A.4.2-3)               
Calculated P values (Table A.4.4)         
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Figure A.4.1. High resolution mass spectrometry (HRMS) analysis of the Zr-HOPO complex 
showing the expected mass signal. 
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Figure A.4.2. 
1
H NMR comparison of the HOPO ligand (top) and the Zr-HOPO complex 
(bottom). Spectra were collected on a 500 MHz machine in D2O.  
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Figure A.4.3. Experimental Zr-HOPO IR spectra. The purple line is powdered ZrCl4. The red 
line is solid HOPO. The blue line is a mixture of solid HOPO and ZrCl4 powder while the green 
line is the lyophilized product of the complexation of HOPO and ZrCl4. The three peaks pointed 
out in the figure correspond to changes in the spectra as a result of the complexation (from 1630 
to 1610, 1564  to 1537, and 1375 to 1360 cm
-1
). This red-shift is characteristic of a hydroxamate, 
or in this case a hydroxypyridinone, binding a metal. Furthermore, similar signals are seen in the 
DFT calculated IR spectra associated with a number of highly coupled asymmetric carbonyl 
stretches (see Figure A.4.4). 
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Figure A.4.4. Computed Zr-HOPO IR spectrum. The spectrum is scaled by 0.992 and with a 
resolution of 15 cm
-1
. The prominent peaks resembling those in the experimental (between 1600 
and 1300 cm
-1
) correspond to various highly coupled asymmetric carbonyl stretches. 
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Figure A.4.5. Zr-HOPO UV-Vis spectroscopy. Solutions of HOPO were prepared with 0.1 
equivalent increments of ZrCl4 from 0.0 to 2.0 equivalents in PBS at a pH of 7.4 and allowed to 
equilibrate at room temperature for 24 h. The figure above shows a) the full spectrum and b) a 
zoomed in section highlighting the peak which undergoes the greatest change. While the peak 
does shift slightly lower in absorbance and to slightly lower wavelengths, neither of these 
changes shows a consistent stopping point corresponding to a specific ratio of Zr:HOPO.  
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Figure A.4.6. Zr-HOPO UV-Vis spectroscopy. The figure above shows a) a profile of the 
absorbance at 326 nm, b) a profile of the maximum peak absorbance, and c) a profile of the peak 
wavelength all according to the amount of ZrCl4. None of these graphs demonstrate a distinct 
end point to the spectral changes. All of the shifts are small and continual over the entire range 
from 0.0 to 2.0 equivalents of ZrCl4. There is no notable plateau at the 1:1 stoichiometry 
suggested by other experiments. These results are neither negative nor positive; they simply do 
not confer any information. 
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Complete reference for GAUSSIAN 09 (Ref. 48) 
Gaussian 09, Revision A.02, 
M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. 
Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. 
Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, 
R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. 
Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. 
Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. Iyengar, J. 
Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, 
J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. 
Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J . 
Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, and 
D. J. Fox, Gaussian, Inc., Wallingford CT, 2009. 
 
Gaussian 09, Revision C.01, 
M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R.  Cheeseman, G. 
Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. 
Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, 
R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, J. A. 
Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. Bearpark, J. J. Heyd, E. Brothers, K. N. Kudin, V. N. 
Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J. C. Burant, S. S. 
Iyengar, J. Tomasi, M. Cossi, N. Rega, J. M. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, 
C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. 
Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth,  P. Salvador, J. 
J. Dannenberg, S. Dapprich, A. D. Daniels, O. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski, 
and D. J. Fox, Gaussian, Inc., Wallingford CT, 2010. 
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Basis set MeOH to MeO- EtOH to EtO- 
cep-121g 381.5 377.5 
cep-31g 387.6 384.7 
LANL2DZ 389.9 385.5 
QZVP 380.0 376.7 
cc-pVTZ 385.6 381.6 
aug-cc-pVTZ 377.6 374.7 
cc-pVQZ 382.1 378.2 
aug-cc-pVQZ 377.7 374.9 
expt. 381.6 ± 0.7 378.6 ± 0.8 
Table A.4.1. Deprotonation enthalpies obtained with B3LYP using different basis sets. 
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Figure A.4.7. Optimized DFT structure of Zr bond by four free 1,2-HOPO groups. The 
geometry is a very close match to a previously reported crystal structure of Zr bound by four 
hydroxamate groups.
35 
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Figure A.4.8. Optimized DFT structure of DFOH2 (CPCM). The zwitterionic form was found to 
be more stable with the protonated amine tail forming hydrogen bonds with oxygens including a 
deprotonated hydroxylamine group.
182 
 
Cartesian coordinates of optimized structures (gas phase) 
Zr[3,4,3-(LI-1,2-HOPO)], I 
 C                0   -1.23222400    1.60141000   -2.98443100 M  
 C                0   -0.77771400    1.91113600   -4.27624200 M 
 C                0    0.19081800    1.08409800   -4.90943400 M 
 C                0    0.67740500   -0.06858800   -4.27771900 M  
 C                0    0.20918400   -0.40120300   -2.97100800 H 
 N                0   -0.70732800    0.47741000   -2.37676900 H 
 H                0    0.54247800    1.34155300   -5.90519700 M 
 H                0   -1.21969800    2.76002600   -4.78322500 M 
 H                0    1.39696600   -0.73290900   -4.74243600 M 
 O                0   -1.12462800    0.07982700   -1.10260700 H 
 O                0    0.53746700   -1.43737000   -2.23719100 H 
 C                0   -2.43003700    2.37135800   -2.42180900 M 
 O                0   -3.37992500    2.58309800   -3.24876000 M 
 N                0   -2.47721800    2.86782100   -1.13646400 M 
 C                0   -1.40004800    2.81003500   -0.11008700 M 
 H                0   -1.89769600    2.59825600    0.84485300 M 
 H                0   -0.75881800    1.95292000   -0.29558700 M 
 C                0    4.28088800   -1.35477400   -1.13329500 M  
 C                0    5.13414200   -2.33810900   -1.65603700 M 
 C                0    4.70397400   -3.69036000   -1.73127600 M 
 C                0    3.42047800   -4.05712100   -1.30613300 M  
 C                0    2.53963400   -3.06097900   -0.78813400 H 
 N                0    3.02770900   -1.75196500   -0.69651800 H 
 H                0    5.37572000   -4.44446900   -2.13371100 M 
 H                0    6.10912000   -2.01115200   -1.99617000 M 
 H                0    3.04744300   -5.07328500   -1.36387400 M 
 O                0    2.12534800   -0.85524800   -0.09288000 H 
 O                0    1.30694700   -3.24771500   -0.37396200 H 
 C                0    4.76962900    0.09246400   -1.10173300 M 
 O                0    5.92902800    0.34459800   -1.57047600 M 
 N                0    3.94257400    1.05656100   -0.59343100 M 
 H                0    3.06081000    0.74650000   -0.18471800 M 
 C                0    4.40629700    2.46063100   -0.50249600 M 
 H                0    5.10286300    2.55840200    0.34021700 M 
 H                0    4.97238600    2.66732100   -1.41809300 M 
 C                0    1.87019800    0.77539800    3.16906400 M  
 C                0    2.30090200    0.41829100    4.45568600 M 
 C                0    1.88456600   -0.81223100    5.03263200 M 
 C                0    1.13124200   -1.72335500    4.28270700 M  
 C                0    0.74005700   -1.38588700    2.95217800 H 
 N                0    1.00881500   -0.08137800    2.50394700 H 
 H                0    2.20223200   -1.06962100    6.03971700 M 
 H                0    3.01282900    1.06344900    4.95688300 M 
 H                0    0.86267600   -2.70786900    4.64867200 M 
 O                0    0.39396700    0.26281200    1.28425800 H 
 O                0    0.17330900   -2.18178100    2.07790300 H 
 C                0    2.60942900    1.88918500    2.43149800 M 
 O                0    3.87999900    1.79601000    2.43254000 M 
 N                0    1.94895100    2.93266500    1.81730200 M 
 C                0    2.81960900    3.90616900    1.08314900 M 
 H                0    2.27236600    4.84904100    1.01882000 M 
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 H                0    3.72249800    4.07902700    1.68375100 M 
 C                0   -4.47294000   -1.81500700    0.82513400 M  
 C                0   -5.37183400   -2.87717100    0.63626500 M 
 C                0   -4.91088600   -4.12311200    0.13713400 M 
 C                0   -3.56225600   -4.29189900   -0.21158300 M  
 C                0   -2.65186000   -3.21385100   -0.02513800 H 
 N                0   -3.13163900   -2.03700600    0.55578200 H 
 H                0   -5.61283000   -4.94131700    0.00000400 M 
 H                0   -6.41451900   -2.68243500    0.85618700 M 
 H                0   -3.17199700   -5.21010200   -0.63542000 M 
 O                0   -2.14650600   -1.09057300    0.84800500 H 
 O                0   -1.37373100   -3.19969200   -0.35714400 H 
 C                0   -5.02956000   -0.44035500    1.17421300 M 
 O                0   -6.25674300   -0.35026900    1.50393700 M 
 N                0   -4.20324300    0.64416200    1.00550700 M 
 H                0   -3.21870100    0.44982100    0.81134500 M 
 C                0   -4.73459100    2.02065700    1.10307100 M 
 H                0   -4.08548000    2.60806700    1.76952600 M 
 H                0   -5.71224000    1.93518600    1.58594100 M 
 C                0    3.23975500    3.48132700   -0.35931200 M 
 H                0    2.36213400    3.12262000   -0.91540800 M 
 H                0    3.56401200    4.40894700   -0.85605900 M 
 C                0    0.54840000    3.26490900    2.26327500 M 
 H                0   -0.03541400    2.34322400    2.18440200 M 
 H                0    0.58615600    3.55392900    3.32581500 M 
 C                0   -0.17926100    4.40307300    1.50229000 M 
 H                0    0.38635900    5.34260400    1.57040600 M 
 H                0   -1.10400700    4.57786000    2.07632400 M 
 C                0   -0.57932100    4.12753600    0.02532400 M 
 H                0    0.30569700    4.08239300   -0.62267700 M 
 H                0   -1.17784100    4.97971900   -0.32745900 M 
 C                0   -3.71785900    3.61911900   -0.75985300 M 
 H                0   -4.04482100    4.18477700   -1.63841100 M 
 H                0   -3.43556600    4.33306700    0.02539400 M 
 C                0   -4.90642900    2.74291600   -0.27304600 M 
 H                0   -5.16190400    2.00740900   -1.04476900 M 
 H                0   -5.76930100    3.42226600   -0.18892700 M 
 Zr               0   -0.03898100   -1.53592300   -0.02999300 H 
 
  
184 
 
Zr[3,3,3-(LI-1,2-HOPO)], II 
 C                0   -0.80378600    1.81417600   -2.88042100 M  
 C                0   -0.22144600    2.14064800   -4.11534000 M 
 C                0    0.66673500    1.22707700   -4.74739700 M 
 C                0    0.95253000   -0.01759800   -4.16897100 M  
 C                0    0.35905400   -0.36258500   -2.91735800 H 
 N                0   -0.49140300    0.58558100   -2.33105000 H 
 H                0    1.11889200    1.49493300   -5.69888100 M 
 H                0   -0.50156500    3.07832800   -4.57945700 M 
 H                0    1.61462700   -0.74051600   -4.63180000 M 
 O                0   -1.06311900    0.16218100   -1.12756000 H 
 O                0    0.51925800   -1.46578700   -2.22576400 H 
 C                0   -1.90911200    2.71095000   -2.31850200 M 
 O                0   -2.76043000    3.13205500   -3.17133800 M 
 N                0   -1.96933000    3.09215900   -0.99019500 M 
 C                0   -0.98434000    2.68901100    0.05881900 M 
 C                0    4.21006100   -1.36716000   -0.99402900 M  
 C                0    5.07821200   -2.35472600   -1.48272700 M 
 C                0    4.64871300   -3.70742800   -1.55959800 M 
 C                0    3.35304500   -4.07099100   -1.16994200 M  
 C                0    2.45615900   -3.07079000   -0.68794700 H 
 N                0    2.94412500   -1.76121700   -0.59344800 H 
 H                0    5.33168800   -4.46516000   -1.93542000 M 
 H                0    6.06317700   -2.03189100   -1.79702900 M 
 H                0    2.98221300   -5.08777000   -1.23088000 M 
 O                0    2.02711700   -0.85602800   -0.02553200 H 
 O                0    1.21105100   -3.25266400   -0.30958600 H 
 C                0    4.69596200    0.08131600   -0.95667600 M 
 O                0    5.86168100    0.33375700   -1.40875900 M 
 N                0    3.86242700    1.04602400   -0.45693000 M 
 H                0    2.97512600    0.73548400   -0.06075200 M 
 C                0    4.32595500    2.44965000   -0.35953500 M 
 H                0    4.99075200    2.55216900    0.50872700 M 
 H                0    4.92799400    2.64640700   -1.25373000 M 
 C                0    1.59852300    0.80088900    3.26491600 M  
 C                0    1.95022000    0.46090200    4.57972400 M 
 C                0    1.51145900   -0.77143900    5.13710200 M 
 C                0    0.81693000   -1.69856600    4.34931900 M  
 C                0    0.50427500   -1.37593600    2.99426300 H 
 N                0    0.79250900   -0.07281800    2.55668500 H 
 H                0    1.76764100   -1.01793800    6.16423600 M 
 H                0    2.62117500    1.11736700    5.12125000 M 
 H                0    0.53674600   -2.68232100    4.70861700 M 
 O                0    0.25960000    0.26224900    1.30278500 H 
 O                0   -0.00693800   -2.17616900    2.08927200 H 
 C                0    2.37898200    1.89836000    2.54413700 M 
 O                0    3.64675100    1.80325500    2.62012800 M 
 N                0    1.76976700    2.91986800    1.84115700 M 
 C                0    2.69194300    3.88862400    1.16405700 M 
 H                0    2.15745200    4.84333900    1.10257700 M 
 H                0    3.56987500    4.03165800    1.80668800 M 
 C                0   -4.59923200   -1.56767300    0.52412900 M  
 C                0   -5.55262200   -2.55566500    0.23236100 M 
 C                0   -5.14039600   -3.81988500   -0.26552900 M 
185 
 
 C                0   -3.78332000   -4.08135100   -0.50980100 M  
 C                0   -2.81547800   -3.07766800   -0.22191100 H 
 N                0   -3.26102000   -1.88305000    0.35046300 H 
 H                0   -5.88531800   -4.58073900   -0.48288800 M 
 H                0   -6.59366100   -2.29263900    0.37620000 M 
 H                0   -3.42846900   -5.01657600   -0.92746800 M 
 O                0   -2.23753600   -1.01552000    0.74064000 H 
 O                0   -1.51607800   -3.14241500   -0.45025000 H 
 C                0   -5.07443900   -0.16477900    0.88749400 M 
 O                0   -6.31166000    0.01304800    1.13139500 M 
 N                0   -4.14892900    0.84777800    0.83092600 M 
 H                0   -3.17529100    0.57007900    0.69256400 M 
 C                0   -4.54324700    2.26379400    0.97882200 M 
 H                0   -3.91142200    2.72915200    1.75111500 M 
 H                0   -5.57118000    2.25669400    1.35264600 M 
 C                0    3.16336600    3.48156900   -0.26491300 M 
 H                0    2.30673700    3.14016400   -0.86314500 M 
 H                0    3.52167100    4.40946700   -0.73673800 M 
 C                0    0.37873600    3.37277300    2.14307000 M 
 H                0   -0.14182500    2.55019000    2.64308600 M 
 H                0    0.45101900    4.20552400    2.86322600 M 
 C                0   -0.46426800    3.85829000    0.93164100 M 
 C                0   -3.17664800    3.89713100   -0.61175700 M 
 H                0   -3.36825600    4.58935300   -1.43761600 M 
 H                0   -2.92525900    4.48834100    0.27421200 M 
 C                0   -4.48064900    3.08992900   -0.34706900 M 
 H                0   -4.69489400    2.43654700   -1.20086500 M 
 H                0   -5.29147900    3.83437600   -0.31381200 M 
 Zr               0   -0.13388400   -1.52716300   -0.03042700 H 
 H                0    0.09691000    4.57530000    0.31675200 M 
 H                0   -1.30089700    4.41885200    1.36962000 M 
 H                0   -0.13917900    2.20489000   -0.42609700 M 
 H                0   -1.42550900    1.92436300    0.70284300 M 
  
186 
 
[ZrDFO(H2O)2]
2+
 with non hydrogen bonded amine group, III 
 Zr                 0.51294000   -0.56367600    1.31312000 
 N                 -8.36488900   -4.47147000   -2.52212900 
 C                 -7.40649400   -3.24073600   -2.58617200 
 C                 -6.41532600   -3.23871700   -1.40213900 
 C                 -5.47950400   -1.99378200   -1.47141700 
 C                 -4.46685500   -1.94006200   -0.29190300 
 C                 -3.59193900   -0.66363500   -0.39101600 
 N                 -2.55856400   -0.57508900    0.67107200 
 C                 -2.48120400    0.27028000    1.71587000 
 C                 -3.69248100    1.00100600    2.28535300 
 C                 -3.57444600    2.54780600    2.24813900 
 C                 -3.78174000    3.09453000    0.82001400 
 O                 -4.31054200    2.37463100   -0.08849800 
 N                 -3.36066700    4.38154100    0.59771100 
 C                 -3.36756400    5.02339400   -0.74385900 
 C                 -1.94301100    5.07915300   -1.36485600 
 C                 -1.30279900    3.67618700   -1.52974500 
 C                  0.16049900    3.72034500   -2.03768600 
 C                  0.84878300    2.33199900   -2.03720200 
 N                  1.02154800    1.74791200   -0.67417100 
 C                  2.05775600    1.84597300    0.16414300 
 C                  3.18312900    2.85532700    0.00683700 
 C                  4.58411500    2.18673100   -0.01275100 
 C                  4.75797600    1.29918800   -1.26064300 
 O                  3.77603800    1.06811200   -2.03699400 
 N                  6.00511700    0.75846200   -1.47091200 
 C                  6.29117200   -0.17789200   -2.58920500 
 C                  6.61179000   -1.61945200   -2.10359900 
 C                  5.54197700   -2.26450900   -1.17794700 
 C                  4.15711900   -2.50302600   -1.84128200 
 C                  3.18164500   -3.32691900   -0.95632600 
 N                  2.61354300   -2.55440800    0.18632400 
 C                  3.01311000   -2.43684800    1.46303900 
 C                  4.18486200   -3.19323300    2.05627100 
 O                 -1.39225800   -1.35897700    0.42185600 
 O                 -1.31295000    0.37412700    2.31508100 
 O                  0.04313100    0.78606300   -0.28472600 
 O                  2.04412800    1.02725200    1.20749200 
 O                  1.49365600   -1.75338300   -0.17507100 
 O                  2.31089500   -1.62241300    2.22473100 
 H                 -9.02445800   -4.46740400   -3.31171500 
 H                 -7.82803800   -5.34804900   -2.55365600 
 H                 -8.90701900   -4.46010500   -1.64826700 
 H                 -8.05540500   -2.35900500   -2.58480500 
 H                 -6.89843300   -3.30989300   -3.55343200 
 H                 -6.96830100   -3.22541800   -0.45006300 
 H                 -5.80604400   -4.15560700   -1.41879300 
 H                 -6.09000000   -1.07809500   -1.46797600 
 H                 -4.92769100   -2.00446600   -2.42372400 
 H                 -3.81879800   -2.82745700   -0.30813500 
 H                 -5.01016100   -1.94541400    0.66537900 
 H                 -4.18597400    0.25487600   -0.36070900 
 H                 -3.02450100   -0.66383400   -1.32875700 
187 
 
 H                 -4.60712300    0.69353800    1.77400700 
 H                 -3.76352700    0.68131900    3.33409700 
 H                 -2.59967400    2.86252300    2.64217800 
 H                 -4.34483200    2.97580000    2.90515300 
 H                 -2.94987200    4.89710000    1.36875000 
 H                 -4.04231500    4.43408600   -1.37187100 
 H                 -3.78452200    6.03360300   -0.64620800 
 H                 -2.01624300    5.58548000   -2.33945300 
 H                 -1.29607200    5.71168000   -0.73422700 
 H                 -1.91263100    3.07341800   -2.21994600 
 H                 -1.32418500    3.14951300   -0.56687700 
 H                  0.19428000    4.10393400   -3.06892600 
 H                  0.74871800    4.42333200   -1.42665200 
 H                  1.83832300    2.35365700   -2.50272900 
 H                  0.24338200    1.59507800   -2.57361500 
 H                  3.03820900    3.45121800   -0.89731000 
 H                  3.13362600    3.53344600    0.87014200 
 H                  4.71264900    1.57421500    0.88978800 
 H                  5.35692900    2.96696500    0.00796500 
 H                  6.76058400    1.00693900   -0.84114300 
 H                  5.40925800   -0.16214600   -3.23486000 
 H                  7.13797800    0.21085400   -3.16968800 
 H                  6.75832300   -2.24496800   -2.99755800 
 H                  7.57596200   -1.61524300   -1.57143800 
 H                  5.42157400   -1.63452500   -0.28312800 
 H                  5.94419300   -3.23011400   -0.83090100 
 H                  3.67457800   -1.55456600   -2.10678500 
 H                  4.29393200   -3.07072000   -2.77490200 
 H                  3.67046200   -4.22535600   -0.55988700 
 H                  2.30889000   -3.63890800   -1.53813600 
 H                  4.96526900   -2.47999900    2.34670700 
 H                  3.85207000   -3.70051700    2.96874400 
 H                  4.61732500   -3.92627700    1.37348100 
 O                 -0.26060200   -2.64698400    2.20488600 
 H                 -1.03059300   -2.81089700    1.61288900 
 H                  0.08949800   -3.41120900    2.69538200 
 O                  0.86709300   -0.06962200    3.51260300 
 H                  1.72608600   -0.31741400    3.90156600 
 H                  0.24194700    0.40434100    4.08759100 
 
  
188 
 
[ZrDFO(H2O)2]
2+
 with hydrogen bonded amine group, IIIa 
 Zr                 0.07347200   -0.92732700   -1.26674700 
 N                 -0.89282600    0.00719600    2.23131500 
 C                 -0.89247200   -0.24855200    3.73860200 
 C                 -0.54621200   -1.70477500    4.15699500 
 C                  0.95958300   -2.12057200    4.30389100 
 C                  1.62984200   -2.84551300    3.08656300 
 C                  2.56330600   -1.94448400    2.22154000 
 N                  2.17431300   -1.94804000    0.77890200 
 C                  2.92510600   -1.83318100   -0.32477800 
 C                  4.40013100   -2.20275300   -0.39282600 
 C                  5.30075900   -1.05884900   -0.92759800 
 C                  5.28552900    0.14530400    0.03571800 
 O                  4.70224700    0.06139600    1.16358900 
 N                  5.90128500    1.28991000   -0.40841900 
 C                  5.92834400    2.55341800    0.37791100 
 C                  4.73927300    3.49923900    0.04573600 
 C                  3.36471100    2.83268400    0.31563700 
 C                  2.15711700    3.79298200    0.18318500 
 C                  0.82028400    3.13250700    0.61103400 
 N                  0.32439600    2.07036500   -0.31356900 
 C                 -0.67750200    2.10890700   -1.20112400 
 C                 -1.49507900    3.35645100   -1.48581700 
 C                 -3.00853400    3.09803400   -1.24473100 
 C                 -3.35827700    2.59722600    0.17340500 
 O                 -2.48862800    2.04124100    0.93195300 
 N                 -4.67253100    2.72462600    0.52619100 
 C                 -5.29222400    2.08956800    1.71981900 
 C                 -6.27861800    0.95417400    1.31760900 
 C                 -5.66849400   -0.16756400    0.42955100 
 C                 -4.61898600   -1.05478000    1.15090000 
 C                 -3.99950200   -2.15523700    0.25053400 
 N                 -2.93056100   -1.66455300   -0.67095800 
 C                 -2.85991900   -1.74872600   -2.01385100 
 C                 -4.05510300   -2.09124900   -2.88367100 
 O                  0.77532900   -1.76363400    0.57589800 
 O                  2.28036600   -1.47937100   -1.43223800 
 O                  0.81032300    0.74735200   -0.06639100 
 O                 -0.97021600    0.97501300   -1.81152500 
 O                 -1.68349300   -1.38671400   -0.02879600 
 O                 -1.67819000   -1.54763900   -2.55659500 
 H                  0.04913100    0.07560600    1.81563300 
 H                 -1.34344100   -0.75693700    1.68959000 
 H                 -1.41580900    0.86549600    1.97362100 
 H                 -1.90550300   -0.00468500    4.07743800 
 H                 -0.20531400    0.47441600    4.19302300 
 H                 -1.01359000   -1.82573200    5.14451000 
 H                 -1.06863900   -2.41147100    3.49348800 
 H                  1.00539600   -2.80539700    5.16008000 
 H                  1.55790400   -1.24467600    4.60215000 
 H                  0.85505000   -3.27615600    2.44324400 
 H                  2.22379600   -3.68478700    3.46871300 
 H                  3.60936600   -2.24919600    2.28484300 
 H                  2.53553900   -0.89369600    2.53787000 
189 
 
 H                  4.75695200   -2.52703900    0.58590400 
 H                  4.47661800   -3.05826000   -1.07981100 
 H                  4.96968600   -0.74548200   -1.92661500 
 H                  6.32609600   -1.43908100   -1.03150600 
 H                  6.37157300    1.27396900   -1.30695300 
 H                  5.90460600    2.27797300    1.43761100 
 H                  6.88304000    3.05362300    0.17735000 
 H                  4.85084700    4.40107100    0.66774000 
 H                  4.80669100    3.82934300   -1.00317700 
 H                  3.37358400    2.40610100    1.32865900 
 H                  3.22326500    1.98329300   -0.36442700 
 H                  2.30164900    4.66584900    0.83856500 
 H                  2.06861500    4.18227800   -0.84256000 
 H                  0.02712600    3.87862200    0.71504400 
 H                  0.94407000    2.64554300    1.58548400 
 H                 -1.14657900    4.20367300   -0.89089900 
 H                 -1.36275900    3.62343700   -2.54246300 
 H                 -3.35061200    2.33008000   -1.95197100 
 H                 -3.56463600    4.01693200   -1.47018500 
 H                 -5.29197100    3.21803800   -0.10953900 
 H                 -4.47488500    1.71988700    2.34393300 
 H                 -5.82481600    2.85853400    2.29242700 
 H                 -6.68856100    0.52233500    2.24283200 
 H                 -7.13345600    1.39875400    0.78607600 
 H                 -5.21992000    0.28326900   -0.46959100 
 H                 -6.49255400   -0.80766900    0.07938500 
 H                 -3.81091300   -0.43680100    1.56193300 
 H                 -5.09816300   -1.56386100    2.00017300 
 H                 -4.77168100   -2.64049800   -0.35660600 
 H                 -3.51930500   -2.92926800    0.86212000 
 H                 -3.90664900   -1.63057900   -3.86347700 
 H                 -4.12339700   -3.17800500   -3.02975200 
 H                 -4.99970000   -1.74010000   -2.46077600 
 O                  0.34993100   -3.00396900   -2.37585900 
 H                 -0.34544200   -3.21689800   -3.02867700 
 O                  1.01877500   -0.31861000   -3.27477500 
 H                  1.95412300   -0.59866200   -3.34092100 
 H                  1.17997000   -3.50120100   -2.49773900 
 H                  0.68624600    0.20849900   -4.02364900 
  
190 
 
ZrDFO(OH)2, IV 
 Zr                 0.38923500    0.30749800    1.25615500 
 N                 -1.28893100    0.80555000   -1.94847600 
 C                 -0.95999200    1.99042200   -2.84091000 
 C                 -1.19578600    3.35709900   -2.12724800 
 C                 -0.12330900    4.44556500   -2.45209700 
 C                  1.09586700    4.52315500   -1.47764000 
 C                  2.15447900    3.37934500   -1.57499200 
 N                  2.03229500    2.37997000   -0.48834700 
 C                  3.02139900    1.69574700    0.12344300 
 C                  4.49245500    2.08630600   -0.08361100 
 C                  5.44922600    1.19945000    0.75331000 
 C                  5.68536300   -0.15986600    0.07247300 
 O                  5.99186600   -0.22606100   -1.16272500 
 N                  5.57805400   -1.27941200    0.87466800 
 C                  5.74750600   -2.65847400    0.36204100 
 C                  4.40280200   -3.39640200    0.10796200 
 C                  3.45656500   -2.63784400   -0.86184900 
 C                  2.26787600   -3.51292000   -1.33971900 
 C                  1.16916400   -2.70501400   -2.09020200 
 N                  0.34259300   -1.87248000   -1.18689600 
 C                 -0.70510600   -2.24647300   -0.42092900 
 C                 -1.44404000   -3.55634900   -0.70940200 
 C                 -2.95377400   -3.40330300   -0.41496300 
 C                 -3.65790500   -2.33689500   -1.28026900 
 O                 -3.04133900   -1.56236100   -2.08237300 
 N                 -5.02029800   -2.25342200   -1.08524800 
 C                 -5.87544200   -1.17638300   -1.63648800 
 C                 -6.63886700   -0.41818700   -0.51369300 
 C                 -5.74339000    0.18649900    0.60344200 
 C                 -4.84382300    1.36928700    0.15579800 
 C                 -3.95631700    1.93274900    1.30245100 
 N                 -2.75537300    1.11571300    1.59251200 
 C                 -2.46489900    0.42013300    2.71791100 
 C                 -3.50944000    0.22349000    3.81494800 
 O                  0.70271600    1.98902500   -0.17321500 
 O                  2.69011600    0.71529500    0.91470600 
 O                  0.79582800   -0.52659100   -0.97521400 
 O                 -1.13627000   -1.44489800    0.50439900 
 O                 -1.66877800    1.33290400    0.69038600 
 O                 -1.27042900   -0.06161700    2.87364300 
 H                 -0.37684400    0.29869700   -1.66675600 
 H                 -1.66760000    1.09850700   -1.01020400 
 H                 -1.93178800    0.10960400   -2.34654400 
 H                 -1.56029500    1.91556200   -3.75638300 
 H                  0.09034600    1.88001200   -3.12626600 
 H                 -2.19069900    3.73551100   -2.40870400 
 H                 -1.19700100    3.18835300   -1.04642500 
 H                 -0.61548200    5.43013000   -2.42256200 
 H                  0.24127700    4.32696700   -3.48771700 
 H                  0.73276500    4.56929800   -0.44395300 
 H                  1.61501200    5.47229100   -1.68452600 
 H                  3.16436300    3.80154800   -1.51908000 
 H                  2.07258500    2.86071200   -2.54373100 
191 
 
 H                  4.77220000    1.98778700   -1.14071400 
 H                  4.62732100    3.14108300    0.19849500 
 H                  5.06054900    1.07734600    1.76942900 
 H                  6.42424100    1.70606400    0.81397100 
 H                  5.22962000   -1.15552700    1.81778700 
 H                  6.31091600   -2.57481500   -0.57335300 
 H                  6.36046200   -3.22966000    1.07938500 
 H                  4.65061600   -4.39536600   -0.29384400 
 H                  3.88086000   -3.56718900    1.06582100 
 H                  4.02842200   -2.28979200   -1.73523400 
 H                  3.06772200   -1.74287000   -0.36589300 
 H                  2.63516400   -4.30526600   -2.01411800 
 H                  1.80464300   -4.01747000   -0.47752700 
 H                  0.51272700   -3.38483100   -2.65032500 
 H                  1.62179600   -2.00737400   -2.80351800 
 H                 -1.29059400   -3.86549000   -1.74825800 
 H                 -1.04304400   -4.34984000   -0.06193800 
 H                 -3.07904000   -3.10567200    0.63417400 
 H                 -3.45839400   -4.37113500   -0.55113100 
 H                 -5.45483000   -2.92319300   -0.45675900 
 H                 -5.21627200   -0.51239600   -2.20231000 
 H                 -6.59956200   -1.60549700   -2.34694400 
 H                 -7.23925900    0.37596400   -0.98855900 
 H                 -7.36478500   -1.10900100   -0.05066200 
 H                 -5.11144400   -0.60669700    1.02890200 
 H                 -6.40378000    0.53290900    1.41702300 
 H                 -4.19092200    1.07000500   -0.67400900 
 H                 -5.47831200    2.19047200   -0.21465100 
 H                 -4.54905000    2.03561500    2.22072400 
 H                 -3.57907400    2.92704000    1.03135300 
 H                 -3.11871400   -0.53097800    4.50153900 
 H                 -3.67204700    1.15352200    4.37911600 
 H                 -4.47525400   -0.11251300    3.42349600 
 O                  0.88658700    1.51136900    2.82176700 
 H                  0.42339500    1.49627800    3.68413500 
 O                  1.32747100   -1.40627200    1.85676700 
 H                  2.30351700   -1.36323200    1.90980200 
  
192 
 
Zr(1,2-HOPO)4 
 C                0    2.24941700    2.76647900   -2.47700200 M  
 C                0    1.93531200    3.38461000   -3.69591300 M 
 C                0    0.70521100    3.10123300   -4.34706500 M 
 C                0   -0.20909300    2.20183500   -3.78364100 M  
 C                0    0.10008500    1.56785000   -2.54304300 H 
 N                0    1.32269100    1.88257200   -1.94069200 H 
 H                0    0.47417800    3.58678500   -5.29149800 M 
 H                0    2.66970700    4.07093900   -4.09947400 M 
 H                0   -1.15660700    1.95811900   -4.25032300 M 
 O                0    1.53776700    1.22363600   -0.71964500 H 
 O                0   -0.65240300    0.70931900   -1.89204600 H 
 C                0    3.58799100    3.09567200   -1.81784800 M 
 O                0    4.35293000    3.92955900   -2.40260700 M 
 N                0    3.89616200    2.47007500   -0.63933700 M 
 H                0    3.20014600    1.82903800   -0.25550000 M 
 C                0    5.16794800    2.72338600    0.06082600 M 
 H                0    5.00070300    3.30461800    0.97814400 M 
 H                0    5.64539800    1.77231600    0.32546200 M 
 H                0    5.82567800    3.29187700   -0.60018600 M 
 Zr               0    0.00024700   -0.25688200   -0.00029000 H 
 C                0   -3.76927600   -2.68057000   -0.33573300 M  
 C                0   -4.35757100   -3.61145600    0.53382200 M 
 C                0   -3.73352600   -3.93222100    1.76854700 M 
 C                0   -2.52289000   -3.32718500    2.13493700 M  
 C                0   -1.91903800   -2.38053400    1.25669100 H 
 N                0   -2.57530300   -2.09369000    0.05662900 H 
 H                0   -4.19991200   -4.65446700    2.43333900 M 
 H                0   -5.29031100   -4.05883700    0.21253900 M 
 H                0   -2.01273400   -3.54663400    3.06591600 M 
 O                0   -1.91753000   -1.15042300   -0.74256200 H 
 O                0   -0.78734200   -1.73139900    1.44902000 H 
 C                0   -4.46670400   -2.37001900   -1.65879000 M 
 O                0   -5.56922900   -2.95951200   -1.90591600 M 
 N                0   -3.86610100   -1.47884300   -2.50786500 M 
 H                0   -2.97609300   -1.07317900   -2.20774500 M 
 C                0   -4.45096700   -1.14598200   -3.81802700 M 
 H                0   -4.59600000   -0.06154900   -3.90645500 M 
 H                0   -3.79288200   -1.48200600   -4.63060600 M 
 H                0   -5.41621500   -1.64861300   -3.90976600 M 
 C                0   -2.24951800    2.76404200    2.47881300 M  
 C                0   -1.93520100    3.38189300    3.69780900 M 
 C                0   -0.70477700    3.09871100    4.34844100 M 
 C                0    0.20964600    2.19981600    3.78439900 M  
 C                0   -0.09973200    1.56615600    2.54368200 H 
 N                0   -1.32264600    1.88068500    1.94186400 H 
 H                0   -0.47357800    3.58402600    5.29295600 M 
 H                0   -2.66969700    4.06782900    4.10185900 M 
 H                0    1.15740700    1.95627700    4.25067300 M 
 O                0   -1.53794600    1.22209100    0.72067000 H 
 O                0    0.65282000    0.70809600    1.89213200 H 
 C                0   -3.58846200    3.09287400    1.82024300 M 
 O                0   -4.35352200    3.92638800    2.40536400 M 
 N                0   -3.89702500    2.46719500    0.64189800 M 
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 H                0   -3.20078900    1.82682500    0.25735400 M 
 C                0   -5.16933800    2.72023400   -0.05740100 M 
 H                0   -5.00499400    3.31324400   -0.96773500 M 
 H                0   -5.63946000    1.76888300   -0.33360400 M 
 H                0   -5.83208000    3.27677200    0.60880100 M 
 C                0    3.76933900   -2.68139600    0.33399100 M  
 C                0    4.35767200   -3.61167300   -0.53618700 M 
 C                0    3.73399500   -3.93113300   -1.77143700 M 
 C                0    2.52369300   -3.32538100   -2.13774000 M  
 C                0    1.91981100   -2.37932800   -1.25886900 H 
 N                0    2.57573300   -2.09373200   -0.05832500 H 
 H                0    4.20040300   -4.65293500   -2.43669600 M 
 H                0    5.29013000   -4.05966500   -0.21493700 M 
 H                0    2.01380300   -3.54384200   -3.06909800 M 
 O                0    1.91803700   -1.15085200    0.74138700 H 
 O                0    0.78836900   -1.72969500   -1.45103300 H 
 C                0    4.46630900   -2.37234700    1.65764300 M 
 O                0    5.56858200   -2.96239400    1.90459700 M 
 N                0    3.86540800   -1.48211800    2.50749400 M 
 H                0    2.97592600   -1.07548700    2.20711300 M 
 C                0    4.44972900   -1.15071100    3.81826800 M 
 H                0    4.60839000   -0.06782000    3.90308000 M 
 H                0    3.78417900   -1.47500600    4.62944100 M 
 H                0    5.40834500   -1.66484400    3.91550800 M 
  
194 
 
3,4,3-(LI-1,2-HOPO)H4 
 C                 -2.20811500    2.82795000    2.11987900 
 C                 -1.22503700    3.31664700    2.98040600 
 C                 -0.58246300    4.56188200    2.68518300 
 C                 -0.93253500    5.31722900    1.56809700 
 C                 -1.96329400    4.86100600    0.66874100 
 N                 -2.53951000    3.60492500    1.03134500 
 H                  0.20110000    4.92436100    3.34529300 
 H                 -0.97313000    2.74338400    3.86461000 
 H                 -0.43625400    6.25060200    1.33167900 
 O                 -3.56324600    3.15601200    0.13498700 
 O                 -2.43205600    5.40416500   -0.40169100 
 C                 -2.95586100    1.53242200    2.42931100 
 O                 -3.65749600    1.48638600    3.48869100 
 N                 -2.77181300    0.44123700    1.60654700 
 C                 -1.92854100    0.44143100    0.37596800 
 H                 -2.30765200   -0.36069000   -0.26923600 
 H                 -2.08473700    1.37569200   -0.17106900 
 C                  8.37401600   -3.08409600    0.79645900 
 C                  8.45381600   -3.62065400    2.08251200 
 C                  9.72641000   -3.79793000    2.71216900 
 C                 10.91171500   -3.44478200    2.07132700 
 C                 10.88193500   -2.88545000    0.74144000 
 N                  9.57253800   -2.74428700    0.18812900 
 H                  9.76362000   -4.21789500    3.71419300 
 H                  7.52123200   -3.88871600    2.56325700 
 H                 11.88541200   -3.57042400    2.53125700 
 O                  9.60573900   -2.18350100   -1.13144000 
 O                 11.84844300   -2.49763100   -0.01510800 
 C                  6.99909900   -2.91148600    0.15658200 
 O                  5.97266500   -3.25918200    0.82497100 
 N                  6.91774300   -2.40051200   -1.11278300 
 H                  7.77104000   -2.12452900   -1.58820500 
 C                  5.60386500   -2.22704200   -1.77147900 
 H                  5.77285300   -2.24128100   -2.85559000 
 H                  4.97869100   -3.08837500   -1.50632700 
 C                  2.20837300    2.82808700   -2.11979000 
 C                  1.22536300    3.31696000   -2.98029200 
 C                  0.58301200    4.56230400   -2.68503500 
 C                  0.93322100    5.31757200   -1.56793900 
 C                  1.96387900    4.86113800   -0.66857000 
 N                  2.53989100    3.60497900   -1.03123000 
 H                 -0.20048500    4.92493600   -3.34514100 
 H                  0.97333800    2.74376800   -3.86450700 
 H                  0.43712200    6.25104400   -1.33152700 
 O                  3.56354400    3.15584400   -0.13489100 
 O                  2.43273100    5.40418800    0.40187200 
 C                  2.95600900    1.53250000   -2.42927000 
 O                  3.65785500    1.48651300   -3.48850400 
 N                  2.77169500    0.44124300   -1.60665200 
 C                  3.47597500   -0.82113900   -1.97760500 
 H                  2.85276900   -1.66066600   -1.64183100 
 H                  3.54726600   -0.85536300   -3.06985100 
 C                 -8.37429900   -3.08372400   -0.79654800 
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 C                 -8.45407700   -3.62007300   -2.08269000 
 C                 -9.72666400   -3.79732400   -2.71236800 
 C                -10.91198600   -3.44436200   -2.07145700 
 C                -10.88223200   -2.88525500   -0.74147600 
 N                 -9.57283900   -2.74408800   -0.18815300 
 H                 -9.76385300   -4.21712400   -3.71446200 
 H                 -7.52148100   -3.88800000   -2.56348700 
 H                -11.88567900   -3.56999200   -2.53140000 
 O                 -9.60606900   -2.18353300    1.13151200 
 O                -11.84876400   -2.49765000    0.01515300 
 C                 -6.99938500   -2.91113000   -0.15665900 
 O                 -5.97294100   -3.25871100   -0.82509700 
 N                 -6.91802300   -2.40028800    1.11275400 
 H                 -7.77131700   -2.12443900    1.58825400 
 C                 -5.60413600   -2.22687100    1.77145000 
 H                 -4.97899800   -3.08824400    1.50633200 
 H                 -5.77313400   -2.24106800    2.85555900 
 C                  4.89192500   -0.91264400   -1.34894600 
 H                  5.48467600   -0.04675200   -1.66896200 
 H                  4.81862000   -0.88653800   -0.25428300 
 C                  1.92840800    0.44144700   -0.37608100 
 H                  2.30750600   -0.36067300    0.26913400 
 H                  2.08459800    1.37570900    0.17095400 
 C                  0.41527000    0.22615200   -0.65722100 
 H                  0.26750100   -0.71760300   -1.20292900 
 H                  0.06196800    1.03182200   -1.31675000 
 C                 -0.41539900    0.22614600    0.65709900 
 H                 -0.06210100    1.03181600    1.31663000 
 H                 -0.26761600   -0.71760900    1.20280500 
 C                 -3.47613800   -0.82112500    1.97748800 
 H                 -3.54736500   -0.85540000    3.06973600 
 H                 -2.85299900   -1.66067000    1.64163300 
 C                 -4.89212400   -0.91251800    1.34889600 
 H                 -4.81886600   -0.88640100    0.25423300 
 H                 -5.48480000   -0.04659000    1.66895600 
 H                -10.60632800   -2.06118500    1.24773000 
 H                 -3.60440700    3.93956500   -0.49926300 
 H                  3.60483100    3.93933900    0.49941200 
 H                 10.60598900   -2.06107200   -1.24763700 
 
  
196 
 
3,3,3-(LI-1,2-HOPO)H4 
 C                 -0.51872700    5.01900300    0.50295100 
 C                  0.20588700    5.91439900    1.28802900 
 C                  1.39704500    6.51138600    0.75973000 
 C                  1.84357600    6.23587100   -0.53120800 
 C                  1.11000400    5.32981900   -1.38405600 
 N                 -0.05292700    4.77034400   -0.77095400 
 H                  1.96004300    7.20175700    1.38323400 
 H                 -0.16088800    6.15846100    2.27780300 
 H                  2.73983700    6.68420500   -0.94488500 
 O                 -0.77635200    3.86873400   -1.61713000 
 O                  1.33874000    4.95883000   -2.59338100 
 C                 -1.85412300    4.43682900    0.95928800 
 O                 -2.80343100    5.24977300    1.18882900 
 N                 -1.96184000    3.07133400    1.14323300 
 C                 -0.84127800    2.11046800    0.93267900 
 H                 -1.07941200    1.46817600    0.07635000 
 H                  0.05195200    2.68100800    0.66551200 
 C                  7.26148800   -0.75510800   -1.00392000 
 C                  8.20989200    0.01608600   -0.32988600 
 C                  9.58384300   -0.38250100   -0.31394700 
 C                 10.01449500   -1.53857200   -0.96099200 
 C                  9.07251500   -2.36965900   -1.67073400 
 N                  7.72463900   -1.89793100   -1.63722800 
 H                 10.30452500    0.23432600    0.21705900 
 H                  7.85443100    0.91036000    0.16669000 
 H                 11.05054200   -1.85798100   -0.96027800 
 O                  6.83588800   -2.76328400   -2.35694500 
 O                  9.26133600   -3.46293600   -2.32385900 
 C                  5.80531800   -0.29739300   -0.99915100 
 O                  5.51038200    0.77385400   -0.37741900 
 N                  4.87203600   -1.04613900   -1.66753200 
 H                  5.16609000   -1.89888700   -2.13270900 
 C                  3.45240400   -0.62629400   -1.69651100 
 H                  3.42329600    0.45812400   -1.86136800 
 H                  2.98078800   -1.11936200   -2.55572000 
 C                 -0.79677000   -2.22321600    2.34523100 
 C                 -2.18041300   -2.30999800    2.49057000 
 C                 -2.72179900   -2.73641700    3.74826700 
 C                 -1.90666600   -3.08323200    4.82460900 
 C                 -0.46924200   -3.02001100    4.70455400 
 N                 -0.01571600   -2.57516400    3.42690100 
 H                 -3.80246000   -2.79516900    3.85426600 
 H                 -2.83054900   -2.05968100    1.66031700 
 H                 -2.30707900   -3.41425100    5.77646500 
 O                  1.41152400   -2.51450400    3.30781100 
 O                  0.44965500   -3.30407600    5.55985200 
 C                 -0.13294200   -1.88553600    1.01222500 
 O                 -0.25915000   -2.70731600    0.05163900 
 N                  0.53721200   -0.68410900    0.88595500 
 C                  1.24918600   -0.43154300   -0.40310900 
 H                  0.67402600   -0.91292600   -1.20065600 
 H                  1.25194500    0.65112700   -0.58071900 
 C                 -5.85367100   -1.97899200   -1.51177100 
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 C                 -5.26993400   -3.24078000   -1.63189000 
 C                 -5.71677200   -4.14696900   -2.64631700 
 C                 -6.73467500   -3.80369700   -3.53231400 
 C                 -7.36911100   -2.50957200   -3.44885300 
 N                 -6.86192100   -1.66863900   -2.41261000 
 H                 -5.24490600   -5.12311300   -2.72251800 
 H                 -4.47513000   -3.49108300   -0.94037000 
 H                 -7.08659100   -4.47568900   -4.30689900 
 O                 -7.52758700   -0.39850600   -2.37746500 
 O                 -8.31384400   -2.00323100   -4.16091500 
 C                 -5.35236200   -1.03239200   -0.42885600 
 O                 -4.47753800   -1.45800800    0.39137900 
 N                 -5.84202300    0.24487300   -0.37893300 
 H                 -6.55091300    0.52599000   -1.04932900 
 C                 -5.34110200    1.19876300    0.63809800 
 H                 -5.27027600    0.66625600    1.59488100 
 H                 -6.08650900    1.99595200    0.74238300 
 C                  2.70268400   -0.97559600   -0.38193900 
 H                  3.25180300   -0.53556900    0.45973800 
 H                  2.68101900   -2.06294200   -0.23841500 
 C                  0.69400500    0.31109400    1.98905600 
 H                  0.91282300   -0.21179500    2.92439100 
 H                  1.58585900    0.90471300    1.75283000 
 C                 -0.53356400    1.24694800    2.18448700 
 H                 -0.32412600    1.90762200    3.03903400 
 H                 -1.40248200    0.63483500    2.45440100 
 C                 -3.31196200    2.52436900    1.46699400 
 H                 -3.93056700    3.37291300    1.77140500 
 H                 -3.22287000    1.84328900    2.32279300 
 C                 -3.94988300    1.78188500    0.26277700 
 H                 -3.30775000    0.95009000   -0.05018800 
 H                 -4.04368000    2.46955800   -0.58767100 
 H                  1.68348800   -2.87274600    4.21111300 
 H                 -0.23719800    3.94727000   -2.46619400 
 H                 -8.17878800   -0.51851800   -3.14635100 
 H                  7.49244700   -3.46959300   -2.67192500 
 
  
198 
 
DFOH2 
 N                 -0.75175200    2.00718300   -1.81725700 
 C                  0.02321200    3.22952100   -2.25505600 
 C                  0.41235100    4.11088700   -1.03877900 
 C                  1.58064800    3.49536200   -0.20417600 
 C                  1.50597100    3.83320900    1.30841100 
 C                  2.56836300    3.09307000    2.16836200 
 N                  2.47273700    1.61862500    2.02121400 
 C                  3.47046100    0.70831100    1.75973400 
 C                  4.91149200    1.26779800    1.65211700 
 C                  6.00974500    0.16294200    1.63288800 
 C                  6.28800100   -0.45776900    0.24757700 
 O                  7.37457300   -0.21895200   -0.37484700 
 N                  5.31316200   -1.28240700   -0.25740100 
 C                  5.47288900   -1.97037800   -1.56027300 
 C                  4.31775300   -2.97558100   -1.78926200 
 C                  2.95073800   -2.29310000   -2.08197400 
 C                  1.74983300   -3.24289900   -1.83162900 
 C                  0.35918200   -2.59330400   -2.08411100 
 N                  0.24166600   -1.20210200   -1.54689300 
 C                  0.13921100   -0.87588800   -0.25113700 
 C                  0.09692500   -1.93765000    0.85176300 
 C                 -1.05522700   -1.67495900    1.87010600 
 C                 -2.43501200   -2.01913500    1.30379800 
 O                 -2.80622200   -1.65805000    0.13631500 
 N                 -3.27149800   -2.76024900    2.10708700 
 C                 -4.60929500   -3.24727900    1.67774200 
 C                 -5.78956500   -2.30466500    2.04926800 
 C                 -5.81694700   -0.94275100    1.29829600 
 C                 -6.04327000   -1.07754400   -0.23070600 
 C                 -6.00647300    0.27282100   -0.98940400 
 N                 -4.67311900    0.93609500   -0.91512700 
 C                 -4.44689000    2.29976900   -0.80641000 
 C                 -5.59057800    3.16408800   -0.25837700 
 O                  1.16401500    1.11640900    2.34130600 
 O                  3.22560300   -0.53966400    1.61776000 
 O                  0.37162900   -0.22709600   -2.56180300 
 O                  0.09807900    0.38795500    0.15196400 
 O                 -3.64840700    0.19821200   -1.62100300 
 O                 -3.33544000    2.83624600   -1.11200600 
 H                 -0.42711100    1.63761300   -0.89102500 
 H                 -1.76842500    2.19016400   -1.74567000 
 H                 -0.50678800    1.13142100   -2.38355300 
 H                 -0.59912600    3.78561800   -2.96554400 
 H                  0.91807700    2.87831000   -2.78234300 
 H                  0.68682900    5.11379200   -1.39746400 
 H                 -0.48103400    4.24005600   -0.40879200 
 H                  2.54306900    3.83525600   -0.62006500 
 H                  1.56822100    2.40368700   -0.31380400 
 H                  0.51141600    3.56800000    1.68948400 
 H                  1.63670300    4.91461200    1.47318600 
 H                  2.42599400    3.34888600    3.22907400 
 H                  3.57582800    3.40268800    1.87356200 
 H                  4.99937800    1.89960900    0.75612500 
199 
 
 H                  5.09691100    1.92095000    2.51571800 
 H                  5.74028300   -0.62535200    2.34680600 
 H                  6.95792600    0.60886800    1.94900900 
 H                  4.45271800   -1.37325300    0.28480700 
 H                  5.50692300   -1.22762300   -2.37214600 
 H                  6.44493200   -2.48145300   -1.56404300 
 H                  4.58962500   -3.63826200   -2.62477900 
 H                  4.23315400   -3.61860500   -0.89746500 
 H                  2.92887300   -1.92072700   -3.11592500 
 H                  2.83255200   -1.40709200   -1.44519500 
 H                  1.82378800   -4.13144100   -2.48009600 
 H                  1.80858000   -3.61175300   -0.79565600 
 H                 -0.44507400   -3.22211300   -1.67858800 
 H                  0.18287900   -2.46086100   -3.15351600 
 H                  0.01886500   -2.95181500    0.45063400 
 H                  1.04898000   -1.85540500    1.39558000 
 H                 -1.04565300   -0.61170400    2.13917700 
 H                 -0.86642900   -2.24713400    2.78805700 
 H                 -2.93722100   -3.02521200    3.02611800 
 H                 -4.56365600   -3.40410900    0.59541600 
 H                 -4.76363300   -4.22602100    2.15104400 
 H                 -6.72372300   -2.85407900    1.84563800 
 H                 -5.76632200   -2.12057600    3.13459900 
 H                 -4.87837000   -0.40237700    1.48047900 
 H                 -6.62231100   -0.32751000    1.73271900 
 H                 -5.28646400   -1.73695800   -0.66886300 
 H                 -7.02589500   -1.53645900   -0.42565100 
 H                 -6.75016600    0.96142600   -0.57579900 
 H                 -6.23970300    0.10899900   -2.05193100 
 H                 -6.39002400    3.27974200   -1.00233400 
 H                 -6.02712000    2.74734100    0.65617000 
 H                 -5.17239800    4.14891700   -0.04196900 
 H                  0.73540600    0.79107500    1.44886300 
 H                 -3.23137000   -0.42887800   -0.95549300 
 
  
200 
 
Cartesian coordinates of optimized structures (CPCM, water) 
Zr[3,4,3-(LI-1,2-HOPO)], I, CPCM 
 C                 -1.11977300    1.68752700   -2.92473200 
 C                 -0.54350100    2.10061100   -4.13392300 
 C                  0.46292500    1.30306000   -4.74769100 
 C                  0.86883700    0.08875700   -4.17484000 
 C                  0.28220700   -0.33139200   -2.94805000 
 N                 -0.67476900    0.50305800   -2.37379700 
 H                  0.91371800    1.63648500   -5.67753700 
 H                 -0.88782100    3.01873500   -4.59398600 
 H                  1.62152900   -0.54287500   -4.63198700 
 O                 -1.22269400    0.01694800   -1.17526300 
 O                  0.54884600   -1.43101900   -2.25910400 
 C                 -2.34416500    2.41534800   -2.36902000 
 O                 -3.31691400    2.57314100   -3.20204000 
 N                 -2.39029400    2.91150700   -1.10131800 
 C                 -1.28229900    2.84992900   -0.09819400 
 H                 -1.74809000    2.57264100    0.85281700 
 H                 -0.60697700    2.03927400   -0.35863500 
 C                  4.30599000   -1.40039000   -1.07411800 
 C                  5.16545100   -2.39192400   -1.56773400 
 C                  4.72732000   -3.74112500   -1.65895700 
 C                  3.42961300   -4.09517300   -1.26765500 
 C                  2.55093000   -3.09092400   -0.77146400 
 N                  3.03354300   -1.78808300   -0.67827000 
 H                  5.40253500   -4.49931800   -2.04321000 
 H                  6.15775400   -2.09483000   -1.88093300 
 H                  3.06062100   -5.11196500   -1.33612000 
 O                  2.12410300   -0.88143300   -0.10246200 
 O                  1.29816700   -3.27462300   -0.37806700 
 C                  4.78889500    0.04454200   -1.02468600 
 O                  6.00862200    0.28791800   -1.36479400 
 N                  3.92637700    1.02436300   -0.65698000 
 H                  2.99517800    0.73737400   -0.35193800 
 C                  4.34596400    2.44993100   -0.62420300 
 H                  5.13137200    2.57820100    0.13210700 
 H                  4.79635000    2.68252200   -1.59764100 
 C                  1.73472900    0.75944800    3.20579600 
 C                  2.07466000    0.45123000    4.52894000 
 C                  1.62424400   -0.76617000    5.11299300 
 C                  0.93392500   -1.70920000    4.34014000 
 C                  0.62140700   -1.40716600    2.98370700 
 N                  0.91808000   -0.12355900    2.51923700 
 H                  1.86774600   -0.98801400    6.14761500 
 H                  2.72780600    1.12330000    5.07297400 
 H                  0.65019900   -2.68070200    4.72843600 
 O                  0.34671200    0.20951200    1.27194500 
 O                  0.08514500   -2.22257800    2.09271100 
 C                  2.53428600    1.80759700    2.43333600 
 O                  3.79456700    1.56130000    2.35706000 
 N                  1.95923300    2.90745500    1.87306400 
 C                  2.86671500    3.83364800    1.11713900 
 H                  2.38824200    4.81323000    1.11469200 
201 
 
 H                  3.80651900    3.92412700    1.67466000 
 C                 -4.51496700   -1.80233700    0.60774500 
 C                 -5.41342900   -2.84881100    0.35331500 
 C                 -4.93765100   -4.12335300   -0.05300100 
 C                 -3.56526500   -4.33809800   -0.23879800 
 C                 -2.65442000   -3.27582100    0.01034600 
 N                 -3.15744700   -2.06461900    0.47697800 
 H                 -5.64349500   -4.92579000   -0.24261300 
 H                 -6.47112700   -2.64308700    0.45297600 
 H                 -3.16665000   -5.28614500   -0.58064200 
 O                 -2.17443000   -1.12413000    0.82671700 
 O                 -1.33834500   -3.32071200   -0.17386600 
 C                 -5.06652300   -0.41701700    0.91751100 
 O                 -6.33958900   -0.29432700    1.06514200 
 N                 -4.20596600    0.63502900    0.96388400 
 H                 -3.21088700    0.42367800    0.86983100 
 C                 -4.67769100    2.03303100    1.11617700 
 H                 -3.98131600    2.55312600    1.78354400 
 H                 -5.65026400    1.99242700    1.61317200 
 C                  3.16902300    3.42968100   -0.36085600 
 H                  2.25589100    3.05530400   -0.84140000 
 H                  3.42612400    4.36605500   -0.87439300 
 C                  0.58833800    3.34229500    2.34341900 
 H                 -0.04413800    2.45026700    2.35432000 
 H                  0.68976300    3.69012900    3.38082000 
 C                 -0.11177400    4.47044900    1.54368400 
 H                  0.47456200    5.39700000    1.59469100 
 H                 -1.03329300    4.66954800    2.11225900 
 C                 -0.51025300    4.19187300    0.06567600 
 H                  0.36849500    4.19188700   -0.58962100 
 H                 -1.14261600    5.02740200   -0.26311100 
 C                 -3.62057300    3.66720000   -0.68855200 
 H                 -3.93379100    4.28620000   -1.53564200 
 H                 -3.32221500    4.33483600    0.12597500 
 C                 -4.83051800    2.80264400   -0.23589500 
 H                 -5.11308300    2.09931700   -1.02864100 
 H                 -5.66817900    3.50636100   -0.12318100 
 Zr                -0.06953100   -1.52930400   -0.06471100 
 
  
202 
 
Zr[3,3,3-(LI-1,2-HOPO)], II, CPCM 
 C                 -0.79686800    1.79162900   -2.83027500 
 C                 -0.14014800    2.18645500   -4.00420400 
 C                  0.81158800    1.31922000   -4.61011400 
 C                  1.08829200    0.05785900   -4.06200900 
 C                  0.42378100   -0.34267300   -2.86906300 
 N                 -0.48664500    0.55189100   -2.30797600 
 H                  1.32387000    1.63778000   -5.51287100 
 H                 -0.38067200    3.14702700   -4.44281800 
 H                  1.80169700   -0.62339800   -4.51095200 
 O                 -1.12634900    0.07714400   -1.15151100 
 O                  0.58147300   -1.47335100   -2.19602500 
 C                 -1.96646800    2.61594000   -2.28951200 
 O                 -2.87077300    2.91851300   -3.15830200 
 N                 -2.03433700    3.04358400   -0.99361400 
 C                 -1.00829000    2.72146500    0.05132200 
 C                  4.28015500   -1.37388700   -0.87970800 
 C                  5.17773800   -2.36255700   -1.30567800 
 C                  4.76975500   -3.72346400   -1.36128100 
 C                  3.46375000   -4.09251100   -1.01165600 
 C                  2.54473900   -3.09146100   -0.58682200 
 N                  3.00554100   -1.77898200   -0.51169000 
 H                  5.47532700   -4.48028200   -1.68963500 
 H                  6.17337600   -2.05598300   -1.59865400 
 H                  3.11993600   -5.11912700   -1.06101800 
 O                  2.07059500   -0.87204200    0.01890300 
 O                  1.27586700   -3.28226700   -0.24591800 
 C                  4.71619000    0.08800900   -0.88733200 
 O                  5.93534300    0.35325100   -1.21134700 
 N                  3.81265300    1.05865100   -0.59872300 
 H                  2.88251600    0.75986600   -0.30233700 
 C                  4.17766700    2.49773900   -0.67576100 
 H                  4.97620300    2.70774100    0.04862300 
 H                  4.59841100    2.67809100   -1.67364900 
 C                  1.48890800    0.92885200    3.25044700 
 C                  1.76584000    0.68536900    4.60180600 
 C                  1.33263200   -0.52900100    5.20496300 
 C                  0.72037200   -1.52938000    4.43526600 
 C                  0.46788100   -1.29057900    3.05479100 
 N                  0.75018600   -0.01576100    2.55994100 
 H                  1.52859300   -0.70327700    6.25860400 
 H                  2.35882000    1.40349900    5.15586400 
 H                  0.45417500   -2.49509200    4.84945800 
 O                  0.24909700    0.25250900    1.27457600 
 O                  0.00110400   -2.15127700    2.16272000 
 C                  2.29895900    1.95703700    2.45762500 
 O                  3.56677600    1.73508900    2.45880800 
 N                  1.74134800    2.99888600    1.78044800 
 C                  2.66859700    3.89671000    1.01291200 
 H                  2.19422000    4.88166800    0.99116500 
 H                  3.60255200    3.98872600    1.57785500 
 C                 -4.57876800   -1.62021900    0.40339900 
 C                 -5.51419700   -2.59906200    0.03924000 
 C                 -5.08281700   -3.86403900   -0.44191800 
203 
 
 C                 -3.71612900   -4.13149100   -0.59670300 
 C                 -2.76759900   -3.13605800   -0.23606200 
 N                 -3.23049500   -1.94107100    0.30719700 
 H                 -5.81718600   -4.61548400   -0.71402600 
 H                 -6.56442400   -2.34786200    0.11133100 
 H                 -3.34853700   -5.07000300   -0.99504300 
 O                 -2.21962700   -1.08189400    0.77740900 
 O                 -1.44981200   -3.22837200   -0.38038800 
 C                 -5.06974000   -0.22652400    0.77127600 
 O                 -6.33779300   -0.04038700    0.88876100 
 N                 -4.15100500    0.76856300    0.88404900 
 H                 -3.16914400    0.49400500    0.81612700 
 C                 -4.52868700    2.19193700    1.05031800 
 H                 -3.83461800    2.64262500    1.76882400 
 H                 -5.52993800    2.21209400    1.48811700 
 C                  2.97668000    3.45758200   -0.45206900 
 H                  2.07214700    3.05075800   -0.92237800 
 H                  3.21919400    4.38100200   -0.99529100 
 C                  0.36513500    3.52018400    2.07413200 
 H                 -0.17216200    2.76082500    2.65083300 
 H                  0.49080600    4.39952500    2.72133700 
 C                 -0.47551700    3.94241300    0.83882800 
 C                 -3.25600200    3.82666900   -0.60421800 
 H                 -3.48111100    4.50655400   -1.43169800 
 H                 -2.99670000    4.43317300    0.26515700 
 C                 -4.53441300    2.99871200   -0.28931000 
 H                 -4.77164400    2.32582700   -1.12249200 
 H                 -5.35172500    3.73221100   -0.23251900 
 Zr                -0.09754700   -1.52700200   -0.01249400 
 H                  0.09390400    4.60905900    0.17968700 
 H                 -1.30190000    4.53469800    1.24892000 
 H                 -0.17716300    2.21574100   -0.43438600 
 H                 -1.44297200    2.00717800    0.75293800 
 
  
204 
 
[ZrDFO(H2O)2]
2+
 with non hydrogen bonded amine group, III, CPCM 
 Zr                 0.29537800   -0.31543800    1.16681300 
 N                 -8.15471000   -5.01405300   -1.65216500 
 C                 -7.38446300   -3.76034900   -2.08030900 
 C                 -6.32197900   -3.37389400   -1.03226200 
 C                 -5.55838200   -2.09129800   -1.45883600 
 C                 -4.48329500   -1.68000800   -0.41826700 
 C                 -3.74740700   -0.38893000   -0.85561600 
 N                 -2.63834700   -0.02408000    0.06624700 
 C                 -2.60973300    0.85526000    1.07405700 
 C                 -3.82720200    1.64161300    1.53519700 
 C                 -3.56264100    3.16056300    1.69805700 
 C                 -3.34975400    3.87892700    0.35503700 
 O                 -3.89548400    3.44932900   -0.72906300 
 N                 -2.57099500    4.99991100    0.39181700 
 C                 -2.19489200    5.80238700   -0.79983700 
 C                 -0.68719500    5.66224200   -1.14489200 
 C                 -0.25908900    4.20137500   -1.43869100 
 C                  1.24844600    4.07316600   -1.77308200 
 C                  1.72777200    2.61235300   -1.97520500 
 N                  1.65363100    1.78057300   -0.73604100 
 C                  2.53827200    1.66199900    0.25869500 
 C                  3.85751800    2.41520800    0.29847500 
 C                  5.09412200    1.47186400    0.24960400 
 C                  5.18681300    0.69607300   -1.07490600 
 O                  4.78711300    1.21290900   -2.18431700 
 N                  5.70441900   -0.56277500   -1.01173500 
 C                  5.80577300   -1.46962600   -2.18529300 
 C                  5.91042200   -2.94927600   -1.73489000 
 C                  4.74208600   -3.45664600   -0.84237900 
 C                  3.35880400   -3.49344900   -1.54356900 
 C                  2.21144700   -3.96268400   -0.60877100 
 N                  1.81843500   -2.92784100    0.38986900 
 C                  2.15011500   -2.77761400    1.68053900 
 C                  3.00813400   -3.75429400    2.45317500 
 O                 -1.44636900   -0.78813500   -0.12727100 
 O                 -1.45959700    0.97267100    1.72124300 
 O                  0.47362300    0.99178200   -0.58195100 
 O                  2.20836200    0.83461900    1.23962200 
 O                  0.98482200   -1.89759700   -0.14750300 
 O                  1.67012100   -1.70958700    2.29452100 
 H                 -8.88112500   -5.24501300   -2.33645900 
 H                 -7.52977400   -5.82230300   -1.57151400 
 H                 -8.61031000   -4.87376400   -0.74509400 
 H                 -8.13062900   -2.97152600   -2.20919500 
 H                 -6.93446500   -3.99063000   -3.04969700 
 H                 -6.80839800   -3.20643900   -0.06016700 
 H                 -5.61040300   -4.20295500   -0.90598500 
 H                 -6.27541300   -1.26648400   -1.59199400 
 H                 -5.07820000   -2.25894800   -2.43509600 
 H                 -3.75239600   -2.49170800   -0.29902500 
 H                 -4.95505500   -1.51349400    0.56071400 
 H                 -4.43835200    0.45573500   -0.91665500 
 H                 -3.28564100   -0.52062300   -1.83976600 
205 
 
 H                 -4.66996200    1.47630500    0.86334900 
 H                 -4.10558800    1.23561600    2.51728900 
 H                 -2.70843200    3.33616700    2.36024100 
 H                 -4.44304800    3.60531200    2.18204500 
 H                 -2.15708700    5.26621900    1.27935300 
 H                 -2.81399400    5.45912300   -1.63367800 
 H                 -2.43842400    6.85409800   -0.60240900 
 H                 -0.48282000    6.30028000   -2.01857000 
 H                 -0.08684700    6.06106500   -0.31177600 
 H                 -0.85319400    3.80460600   -2.27727600 
 H                 -0.48867900    3.57750400   -0.56453100 
 H                  1.47123000    4.61323400   -2.70602900 
 H                  1.84843600    4.54674300   -0.98186900 
 H                  2.76187500    2.57832600   -2.32836200 
 H                  1.10091400    2.09420800   -2.70726200 
 H                  3.91014700    3.13909300   -0.51549600 
 H                  3.88535300    2.97199400    1.24300100 
 H                  5.08456800    0.77811300    1.09689700 
 H                  5.99431000    2.09363500    0.34744300 
 H                  6.03881600   -0.90403000   -0.11724700 
 H                  4.92343900   -1.30317600   -2.81300900 
 H                  6.68690600   -1.20488400   -2.78710100 
 H                  5.98226400   -3.56637800   -2.64244500 
 H                  6.85506000   -3.08535000   -1.18613800 
 H                  4.68023000   -2.83360900    0.06141700 
 H                  4.98969900   -4.47270200   -0.49920600 
 H                  3.09779600   -2.50981200   -1.95587500 
 H                  3.39366200   -4.19500100   -2.39027700 
 H                  2.49133100   -4.87149900   -0.06863600 
 H                  1.30533900   -4.17426600   -1.18470900 
 H                  3.90341100   -3.23298900    2.81064700 
 H                  2.44508100   -4.09484900    3.32929000 
 H                  3.31412500   -4.61802800    1.86318500 
 O                 -1.04210300   -1.89677400    2.25505600 
 H                 -1.79404300   -2.30502300    1.78753600 
 H                 -0.75630000   -2.42380800    3.02378600 
 O                  0.40828600    0.33028200    3.33421000 
 H                  1.08472600    0.04595400    3.97408600 
 H                 -0.29463000    0.87558800    3.73122600 
 
  
206 
 
[ZrDFO(H2O)2]
2+
 with hydrogen bonded amine group, IIIa, CPCM 
 Zr                 0.09593700   -0.90110900   -1.06389700 
 N                 -1.23474300    0.18668800    2.32465400 
 C                 -1.05209400    0.02372800    3.82895800 
 C                 -0.39117200   -1.33147000    4.16965400 
 C                  1.07274400   -1.48431600    3.64369200 
 C                  1.40367100   -2.93651300    3.18761500 
 C                  2.51062700   -3.02668400    2.11129800 
 N                  2.14088800   -2.27480500    0.86456500 
 C                  2.94319600   -1.85243800   -0.12427500 
 C                  4.43563100   -2.15918900   -0.13330800 
 C                  5.29107600   -1.16062500   -0.94775300 
 C                  5.54115500    0.16232700   -0.20353300 
 O                  5.64298200    0.19610400    1.07932400 
 N                  5.68305300    1.27741700   -0.97993000 
 C                  5.91353300    2.64446000   -0.44456700 
 C                  4.62748600    3.51744700   -0.45993900 
 C                  3.45376800    2.87046300    0.31717300 
 C                  2.19046600    3.76378700    0.39723800 
 C                  0.97960300    3.03699400    1.03821700 
 N                  0.36472900    2.01353500    0.14449800 
 C                 -0.65286500    2.13705200   -0.71725600 
 C                 -1.36834900    3.45542500   -0.96233000 
 C                 -2.90634700    3.29020500   -1.01857600 
 C                 -3.51517700    2.69444700    0.26354000 
 O                 -2.78294200    2.32005400    1.25498100 
 N                 -4.86971400    2.56645500    0.26643100 
 C                 -5.65543500    1.84928400    1.30311300 
 C                 -6.51113400    0.71491100    0.67344100 
 C                 -5.70246900   -0.35562400   -0.11034000 
 C                 -4.80863500   -1.25661900    0.78257500 
 C                 -4.03089200   -2.34208200   -0.00664400 
 N                 -2.88184700   -1.81054300   -0.79347000 
 C                 -2.73986600   -1.68891800   -2.12193500 
 C                 -3.86073200   -1.99669600   -3.09336800 
 O                  0.74471800   -2.12284800    0.60540400 
 O                  2.35645600   -1.24031100   -1.13743800 
 O                  0.87187000    0.67988700    0.27861400 
 O                 -1.01425400    1.04848400   -1.37111100 
 O                 -1.70240800   -1.54342500   -0.03037900 
 O                 -1.55489100   -1.30782900   -2.56231500 
 H                 -0.33200500    0.29000900    1.83250200 
 H                 -1.68779800   -0.63109300    1.89286200 
 H                 -1.81141600    1.01440400    2.08203000 
 H                 -2.04658700    0.09598300    4.27835500 
 H                 -0.44947800    0.87242700    4.16750500 
 H                 -0.42222800   -1.44906600    5.26115400 
 H                 -1.02229100   -2.13153900    3.75427200 
 H                  1.78188400   -1.16350800    4.42017700 
 H                  1.23044900   -0.81293300    2.79134100 
 H                  0.49877200   -3.41436800    2.79581200 
 H                  1.74119800   -3.54392100    4.03925500 
 H                  2.68990800   -4.07582800    1.84313400 
 H                  3.44686700   -2.59722200    2.48271400 
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 H                  4.81387300   -2.22299800    0.88977200 
 H                  4.54565800   -3.16007000   -0.57562100 
 H                  4.84456600   -0.97162500   -1.92848400 
 H                  6.27141900   -1.62531000   -1.12215200 
 H                  5.56151700    1.18299700   -1.98273000 
 H                  6.28573500    2.53662300    0.57879700 
 H                  6.69811200    3.11777900   -1.04737800 
 H                  4.88318700    4.49493100   -0.02214900 
 H                  4.32346400    3.70310200   -1.50217100 
 H                  3.78095700    2.62876000    1.34062100 
 H                  3.19097200    1.91936500   -0.16240500 
 H                  2.40174100    4.65383000    1.00884100 
 H                  1.90621700    4.12330500   -0.60281500 
 H                  0.19960700    3.75056300    1.31714200 
 H                  1.28116400    2.49978900    1.94297200 
 H                 -1.09004700    4.19024700   -0.20493000 
 H                 -1.03074700    3.84663100   -1.93151800 
 H                 -3.18877800    2.64531200   -1.85937600 
 H                 -3.35865100    4.27167100   -1.20759700 
 H                 -5.37598100    2.90149700   -0.54754600 
 H                 -4.94641900    1.45876600    2.03749600 
 H                 -6.31287200    2.56327000    1.81642100 
 H                 -7.08084200    0.23694600    1.48503400 
 H                 -7.24987000    1.16960600   -0.00435100 
 H                 -5.08436100    0.14297500   -0.87115600 
 H                 -6.41315900   -0.99620300   -0.65478100 
 H                 -4.09590400   -0.65426800    1.36008600 
 H                 -5.43956500   -1.78641200    1.51201100 
 H                 -4.69289100   -2.86822200   -0.70149700 
 H                 -3.60191800   -3.08064600    0.67910400 
 H                 -3.56684900   -1.64017000   -4.08233000 
 H                 -4.03192400   -3.07936100   -3.14399000 
 H                 -4.79631500   -1.51562100   -2.79713100 
 O                  0.48348200   -2.87358900   -2.23591000 
 H                 -0.11465900   -3.13169500   -2.96146600 
 O                  0.94682300   -0.10890200   -3.00379200 
 H                  1.87673400   -0.27168400   -3.24683400 
 H                  1.32648900   -3.36155600   -2.26200800 
 H                  0.46760200    0.41052000   -3.67354700 
 
  
208 
 
ZrDFO(OH)2, IV, CPCM 
 Zr                -0.19003800   -0.46726400    1.46791600 
 N                  1.15924900   -0.65663700   -2.01812900 
 C                  1.28625000   -1.49762200   -3.28188000 
 C                  1.17770100   -3.03804200   -3.06642700 
 C                 -0.18405400   -3.74692800   -3.37789200 
 C                 -1.19014800   -3.94678500   -2.20241500 
 C                 -2.08922800   -2.71084300   -1.89069400 
 N                 -1.95581400   -2.23114500   -0.48876300 
 C                 -2.89358500   -1.79178400    0.37439300 
 C                 -4.35426400   -2.23342500    0.26642700 
 C                 -5.36571300   -1.26177800    0.92457400 
 C                 -5.68593200   -0.04272100    0.04524500 
 O                 -5.87599400   -0.17492600   -1.22205400 
 N                 -5.79307300    1.16223000    0.68003300 
 C                 -6.08387400    2.44538800   -0.01057100 
 C                 -4.81850300    3.32867800   -0.19833000 
 C                 -3.66928500    2.59064700   -0.93007600 
 C                 -2.45196800    3.49484600   -1.25240400 
 C                 -1.22151900    2.69175700   -1.75628300 
 N                 -0.52168800    1.95361700   -0.66988600 
 C                  0.54068900    2.33081200    0.05586600 
 C                  1.24393200    3.66499400   -0.16098100 
 C                  2.78433800    3.53207600   -0.11120500 
 C                  3.36396800    2.55110900   -1.14696100 
 O                  2.61648900    1.85783900   -1.93417000 
 N                  4.72241900    2.44783900   -1.15022500 
 C                  5.50210700    1.43143200   -1.90053200 
 C                  6.43668900    0.63389300   -0.94844400 
 C                  5.70950700   -0.10291400    0.21103800 
 C                  4.83429200   -1.29971000   -0.24616100 
 C                  4.10626400   -2.01688300    0.92131400 
 N                  2.93699400   -1.26450200    1.45387500 
 C                  2.77970300   -0.69394400    2.66238500 
 C                  3.92024700   -0.62282300    3.66382400 
 O                 -0.60865400   -1.95796100   -0.11767200 
 O                 -2.47987000   -1.06355800    1.38694200 
 O                 -0.99782600    0.63161700   -0.40299600 
 O                  0.97096800    1.49858600    0.98154500 
 O                  1.76495700   -1.32670100    0.63803900 
 O                  1.59485500   -0.21635500    2.96869700 
 H                  0.18606400   -0.51653900   -1.70303600 
 H                  1.62911900   -1.08557400   -1.19547300 
 H                  1.59356000    0.27316400   -2.14646600 
 H                  2.27334100   -1.25921400   -3.68907200 
 H                  0.53280600   -1.13518600   -3.98848400 
 H                  1.92285800   -3.47813900   -3.74367800 
 H                  1.50969700   -3.29440400   -2.04999200 
 H                  0.06390600   -4.74947200   -3.75682300 
 H                 -0.68589500   -3.22600400   -4.20941400 
 H                 -0.64034400   -4.23174300   -1.29716900 
 H                 -1.84421100   -4.79263900   -2.45456900 
 H                 -3.14242100   -2.93598500   -2.07124100 
 H                 -1.81445100   -1.86573200   -2.53655100 
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 H                 -4.63499900   -2.40512300   -0.77531500 
 H                 -4.42294800   -3.20422400    0.77801000 
 H                 -5.01589400   -0.94915500    1.91268300 
 H                 -6.30827100   -1.80800800    1.06803600 
 H                 -5.59856300    1.19876200    1.67477100 
 H                 -6.52107200    2.19926100   -0.98301800 
 H                 -6.83641100    2.98504500    0.57743700 
 H                 -5.12079300    4.22405300   -0.76400300 
 H                 -4.46462200    3.67658200    0.78496200 
 H                 -4.04880400    2.16104300   -1.87051900 
 H                 -3.33358800    1.74880100   -0.31261400 
 H                 -2.72431800    4.22036300   -2.03400300 
 H                 -2.15742600    4.07638100   -0.36590400 
 H                 -0.50149100    3.35619100   -2.24121900 
 H                 -1.52452900    1.93612000   -2.48930700 
 H                  0.93393200    4.11993300   -1.10375300 
 H                  0.93589200    4.34846900    0.64219900 
 H                  3.10307100    3.19680200    0.88324800 
 H                  3.23107200    4.52215600   -0.26864800 
 H                  5.23927000    3.04294400   -0.51021500 
 H                  4.78677800    0.77645700   -2.40424900 
 H                  6.10310700    1.92925800   -2.67325900 
 H                  7.00067100   -0.08755500   -1.55931400 
 H                  7.17533300    1.32991400   -0.52138700 
 H                  5.09115800    0.61734100    0.76674900 
 H                  6.46858700   -0.47317800    0.91736300 
 H                  4.09152800   -0.98130600   -0.98896500 
 H                  5.47242600   -2.04930600   -0.73830200 
 H                  4.79695600   -2.20371700    1.74961400 
 H                  3.71197800   -2.98309700    0.58508700 
 H                  3.63707300    0.07138100    4.45788100 
 H                  4.09938300   -1.61023100    4.10867300 
 H                  4.85075700   -0.28190600    3.20196000 
 O                 -0.33366200   -2.11374700    2.80329500 
 H                  0.29281000   -2.14752400    3.55369100 
 O                 -1.11186900    0.83771800    2.82302700 
 H                 -2.00801400    0.63861200    3.15853200 
 
 
  
210 
 
3,4,3-(LI-1,2-HOPO)H4, CPCM 
 C                 -1.63787300   -3.85791800   -0.60821300 
 C                 -0.36246600   -4.17890200   -1.06558700 
 C                  0.40445300   -5.16251800   -0.36156800 
 C                 -0.10086600   -5.80530400    0.76908400 
 C                 -1.41805600   -5.49385700    1.26250300 
 N                 -2.10981000   -4.51800900    0.50727600 
 H                  1.40029500   -5.40942700   -0.71834300 
 H                  0.02856700   -3.68341800   -1.94577200 
 H                  0.47201000   -6.55004100    1.31038600 
 O                 -3.41694100   -4.18068800    0.98284200 
 O                 -2.04376600   -5.98078500    2.29209200 
 C                 -2.59426400   -2.92198100   -1.34023300 
 O                 -3.35936000   -3.42833300   -2.24119000 
 N                 -2.57673900   -1.60024500   -1.01968500 
 C                 -1.68970000   -1.01009000    0.03197300 
 H                 -2.28791800   -0.27583800    0.58416700 
 H                 -1.40104600   -1.79334900    0.73868500 
 C                  8.98027700   -1.19216800   -0.32575500 
 C                  9.32743300   -2.06891200   -1.35543300 
 C                 10.65212200   -2.06939300   -1.89165100 
 C                 11.62653400   -1.20053500   -1.40432500 
 C                 11.31150900   -0.28045600   -0.34394300 
 N                  9.97901700   -0.34168100    0.13229600 
 H                 10.89792600   -2.76058200   -2.69220100 
 H                  8.56552200   -2.74040100   -1.72789200 
 H                 12.63681000   -1.18519100   -1.79728400 
 O                  9.71345000    0.59386200    1.18299700 
 O                 12.08209700    0.59553000    0.23037900 
 C                  7.55677200   -1.22122100    0.22244400 
 O                  6.72881700   -2.05631000   -0.29719400 
 N                  7.21316600   -0.38230800    1.23533000 
 H                  7.91074900    0.26302500    1.59307200 
 C                  5.84932500   -0.34965100    1.81481400 
 H                  5.43364000   -1.36218300    1.78299400 
 H                  5.95226700   -0.05033300    2.86370200 
 C                  1.63804700    3.85807300    0.60895900 
 C                  0.36275300    4.17906000    1.06665600 
 C                 -0.40426600    5.16281400    0.36294000 
 C                  0.10084900    5.80574400   -0.76772300 
 C                  1.41791800    5.49430100   -1.26146300 
 N                  2.10977300    4.51829200   -0.50653700 
 H                 -1.40002000    5.40972000    0.71996300 
 H                 -0.02811100    3.68347400    1.94685800 
 H                 -0.47210100    6.55059200   -1.30879300 
 O                  3.41678100    4.18097200   -0.98244100 
 O                  2.04343700    5.98134400   -2.29111500 
 C                  2.59452200    2.92200000    1.34070000 
 O                  3.35974700    3.42820700    2.24162800 
 N                  2.57691100    1.60030700    1.01998600 
 C                  3.51289500    0.67569300    1.73186000 
 H                  3.59854900    1.00570000    2.77205500 
 H                  3.05973200   -0.32059300    1.72411100 
 C                 -8.98046200    1.19204200    0.32487500 
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 C                 -9.32785900    2.06911000    1.35419500 
 C                -10.65262500    2.06963100    1.89022500 
 C                -11.62686900    1.20049200    1.40306600 
 C                -11.31159000    0.28005100    0.34307000 
 N                 -9.97903000    0.34125500   -0.13299300 
 H                -10.89862300    2.76107900    2.69049100 
 H                 -8.56608100    2.74082600    1.72651600 
 H                -12.63720500    1.18518600    1.79587400 
 O                 -9.71314200   -0.59467000   -1.18326700 
 O                -12.08201900   -0.59620100   -0.23105100 
 C                 -7.55689000    1.22109300   -0.22315400 
 O                 -6.72905600    2.05632400    0.29644700 
 N                 -7.21309800    0.38203400   -1.23585400 
 H                 -7.91058200   -0.26342600   -1.59355700 
 C                 -5.84918700    0.34938400   -1.81517000 
 H                 -5.43357900    1.36195100   -1.78346600 
 H                 -5.95198200    0.04988800   -2.86402200 
 C                  4.91343400    0.63772000    1.06485500 
 H                  4.81693800    0.32733200    0.01643100 
 H                  5.35724100    1.64104800    1.07929300 
 C                  1.68973000    1.01031200   -0.03163900 
 H                  1.40104800    1.79366000   -0.73824200 
 H                  2.28786200    0.27609200   -0.58396800 
 C                  0.42466400    0.33364100    0.55761600 
 H                 -0.17451000    1.08947700    1.08428500 
 H                  0.72067400   -0.42275400    1.29820900 
 C                 -0.42461000   -0.33343300   -0.55724600 
 H                  0.17457000   -1.08928500   -1.08388500 
 H                 -0.72059300    0.42295000   -1.29786200 
 C                 -3.51268600   -0.67575500   -1.73176900 
 H                 -3.59819100   -1.00588000   -2.77193800 
 H                 -3.05958400    0.32055900   -1.72407100 
 C                 -4.91331300   -0.63780200   -1.06494700 
 H                 -4.81698200   -0.32726400   -0.01655300 
 H                 -5.35703500   -1.64117000   -1.07930500 
 H                 -3.50561700   -4.76919900    1.78868500 
 H                -10.60355100   -1.05408300   -1.27769000 
 H                  3.50530900    4.76961600   -1.78820500 
 H                 10.60397200    1.05308500    1.27741800 
 
 
  
212 
 
3,3,3-(LI-1,2-HOPO)H4, CPCM 
 C                 -0.96116800   -3.59363300   -1.48149300 
 C                  0.19362600   -3.80111100   -2.23137200 
 C                  1.16164800   -4.75251600   -1.77336500 
 C                  0.96877000   -5.47578000   -0.59589200 
 C                 -0.21745500   -5.28177000    0.19831300 
 N                 -1.12149300   -4.32811100   -0.32482200 
 H                  2.06307700   -4.91139900   -2.35825900 
 H                  0.34113600   -3.24588300   -3.14945900 
 H                  1.69504600   -6.19830900   -0.24054200 
 O                 -2.30129400   -4.10445800    0.45372600 
 O                 -0.56015300   -5.85559000    1.31268600 
 C                 -2.12518300   -2.71426700   -1.92638600 
 O                 -3.06190900   -3.26259800   -2.61518000 
 N                 -2.11072900   -1.39629200   -1.58810200 
 C                 -1.02768400   -0.75441800   -0.78040000 
 H                 -1.51149400   -0.05976700   -0.08376700 
 H                 -0.52397700   -1.51820300   -0.18118400 
 C                  8.06955500   -0.85444400    1.51869600 
 C                  8.13559200   -1.61203600    2.68971400 
 C                  9.25064000   -1.48503600    3.57438900 
 C                 10.29478200   -0.60586800    3.29452400 
 C                 10.26805800    0.19279600    2.09778700 
 N                  9.13068900    0.00810700    1.27330300 
 H                  9.27851600   -2.08511500    4.47891800 
 H                  7.31982700   -2.29013600    2.90142900 
 H                 11.14909400   -0.49355300    3.95250000 
 O                  9.15189500    0.81752400    0.09310800 
 O                 11.14486000    1.05480500    1.67523900 
 C                  6.85984900   -1.01481500    0.60341000 
 O                  5.97108600   -1.88512900    0.92849600 
 N                  6.75638200   -0.24367100   -0.51144500 
 H                  7.48823000    0.43207700   -0.70909900 
 C                  5.59731600   -0.32613000   -1.43215700 
 H                  5.95718400   -0.04131900   -2.42704200 
 H                  5.25661300   -1.36595200   -1.47242400 
 C                  0.96157000    3.59393100   -1.48196200 
 C                 -0.19334300    3.80136900   -2.23167500 
 C                 -1.16123900    4.75287800   -1.77362600 
 C                 -0.96811200    5.47631400   -0.59629300 
 C                  0.21829900    5.28244600    0.19765300 
 N                  1.12216400    4.32861400   -0.32546900 
 H                 -2.06279600    4.91167400   -2.35834400 
 H                 -0.34104700    3.24599100   -3.14964100 
 H                 -1.69432200    6.19887900   -0.24088400 
 O                  2.30216300    4.10516400    0.45282800 
 O                  0.56118600    5.85629800    1.31195900 
 C                  2.12545300    2.71444100   -1.92694800 
 O                  3.06211200    3.26262200   -2.61595200 
 N                  2.11098500    1.39654400   -1.58837300 
 C                  3.25995900    0.53511700   -2.00839400 
 H                  2.88830800   -0.49093600   -2.09361000 
 H                  3.59312300    0.86292500   -2.99802200 
 C                 -8.07017200    0.85394000    1.51797700 
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 C                 -8.13654900    1.61146400    2.68901600 
 C                 -9.25182300    1.48435900    3.57339600 
 C                -10.29585700    0.60516800    3.29319800 
 C                -10.26879800   -0.19341700    2.09640800 
 N                 -9.13120200   -0.00865500    1.27225800 
 H                 -9.27995800    2.08438000    4.47795500 
 H                 -7.32088000    2.28960200    2.90097900 
 H                -11.15033300    0.49276300    3.95094500 
 O                 -9.15203600   -0.81798100    0.09199400 
 O                -11.14542000   -1.05549200    1.67364000 
 C                 -6.86027300    1.01448700    0.60298600 
 O                 -5.97162300    1.88479800    0.92838300 
 N                 -6.75649200    0.24344500   -0.51191200 
 H                 -7.48820200   -0.43240600   -0.70973200 
 C                 -5.59723700    0.32610500   -1.43236600 
 H                 -5.25666300    1.36597300   -1.47248100 
 H                 -5.95685100    0.04132700   -2.42735200 
 C                  4.43295100    0.60430800   -0.99434600 
 H                  4.80021100    1.63578800   -0.92451000 
 H                  4.07923300    0.30518300    0.00079600 
 C                  1.02790400    0.75491400   -0.78052700 
 H                  1.51161900    0.06030700   -0.08378500 
 H                  0.52430800    1.51887000   -0.18143700 
 C                  0.00003900    0.00026800   -1.66463700 
 H                  0.51704400   -0.71891900   -2.31139600 
 H                 -0.51706000    0.71950700   -2.31126400 
 C                 -3.25974900   -0.53501400   -2.00829600 
 H                 -3.59278500   -0.86293700   -2.99793100 
 H                 -2.88817900    0.49106300   -2.09356300 
 C                 -4.43284600   -0.60421500   -0.99437100 
 H                 -4.07924800   -0.30498900    0.00078300 
 H                 -4.80004500   -1.63571500   -0.92450500 
 H                -10.01636300   -1.32102800    0.20226300 
 H                 -2.17056100   -4.73735900    1.21894200 
 H                  2.17175900    4.73849400    1.21775400 
 H                 10.01622300    1.32051800    0.20372300 
 
 
  
214 
 
DFOH2, CPCM 
 N                 -2.21171500    1.03373600    1.95342200 
 C                 -2.32889200    2.54685100    1.85768100 
 C                 -0.95665800    3.24086700    1.66407600 
 C                 -1.07442800    4.55132200    0.82508200 
 C                 -0.89500300    4.39421900   -0.71563500 
 C                 -2.00182200    3.67462900   -1.53369800 
 N                 -1.97851300    2.18104800   -1.44946300 
 C                 -3.05025200    1.32872600   -1.63267800 
 C                 -4.46600700    1.89064400   -1.41253700 
 C                 -5.52624200    0.76923400   -1.31415900 
 C                 -5.29597200   -0.21255200   -0.15128000 
 O                 -4.76358500    0.16833200    0.96028800 
 N                 -5.73330100   -1.48766100   -0.35233700 
 C                 -5.72239500   -2.59117100    0.64703500 
 C                 -4.56871000   -3.61015400    0.41810400 
 C                 -3.20274000   -3.10285700    0.95056300 
 C                 -1.99366400   -3.95202800    0.47648200 
 C                 -0.63746300   -3.52346300    1.10963600 
 N                 -0.45251900   -2.03591200    1.13880100 
 C                 -0.15539600   -1.26454600    0.08238300 
 C                  0.24806000   -1.86656000   -1.26472400 
 C                  1.60581200   -1.31338300   -1.80482900 
 C                  2.81716200   -1.80799600   -1.01227900 
 O                  2.89392400   -1.61978200    0.26699100 
 N                  3.79741100   -2.44911000   -1.69852700 
 C                  5.06199700   -2.95686400   -1.10160200 
 C                  6.28366800   -2.04636600   -1.41475100 
 C                  6.19538500   -0.61196700   -0.82295200 
 C                  6.31736900   -0.56146300    0.72386500 
 C                  5.95704100    0.81994400    1.32916100 
 N                  4.52330800    1.17067700    1.12755900 
 C                  3.98162000    2.28895200    0.53696600 
 C                  4.94963600    3.26339700   -0.13953600 
 O                 -0.68007900    1.63111300   -1.78272500 
 O                 -2.87492800    0.08980100   -1.92028200 
 O                 -0.78274900   -1.44345400    2.38425800 
 O                 -0.22235800    0.06229100    0.18564000 
 O                  3.62279800    0.32022500    1.87080300 
 O                  2.71571800    2.50843000    0.53422700 
 H                 -1.48075700    0.65255600    1.30306600 
 H                 -1.93632900    0.71658500    2.88497900 
 H                 -3.12044300    0.60128300    1.70638000 
 H                 -2.83524200    2.89812000    2.76185000 
 H                 -2.98341600    2.74593100    1.01121600 
 H                 -0.52491000    3.46849400    2.64805200 
 H                 -0.25890200    2.55545600    1.16623200 
 H                 -0.29201500    5.24765900    1.16042100 
 H                 -2.03604000    5.04601800    1.03838800 
 H                  0.06856500    3.91074100   -0.92173800 
 H                 -0.83310700    5.40597300   -1.14435200 
 H                 -1.88051600    3.94305400   -2.59395400 
 H                 -2.99388400    4.00905000   -1.21676500 
 H                 -4.49540400    2.51381600   -0.51344200 
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 H                 -4.72503100    2.54452500   -2.25657500 
 H                 -5.58560900    0.21525900   -2.25651700 
 H                 -6.50630400    1.24168400   -1.15496500 
 H                 -6.12125400   -1.71209700   -1.26273100 
 H                 -5.65003400   -2.14498800    1.64425800 
 H                 -6.69109700   -3.09932600    0.56940800 
 H                 -4.83701300   -4.55134000    0.92169300 
 H                 -4.50333000   -3.83381800   -0.65818800 
 H                 -3.23634500   -3.08051100    2.05029600 
 H                 -3.05189200   -2.06657700    0.62215100 
 H                 -2.15046900   -5.01325200    0.72527800 
 H                 -1.92379700   -3.89086700   -0.61990900 
 H                  0.19995500   -4.00160500    0.58915400 
 H                 -0.59311100   -3.81727300    2.16143400 
 H                  0.28339600   -2.95752500   -1.23028600 
 H                 -0.52612000   -1.58854500   -1.99148000 
 H                  1.60167000   -0.21793100   -1.75118700 
 H                  1.70432800   -1.59370900   -2.85872700 
 H                  3.67469500   -2.57384000   -2.69806800 
 H                  4.90264900   -3.05249300   -0.02457200 
 H                  5.23854100   -3.95901300   -1.50963000 
 H                  7.18118100   -2.55562000   -1.03036400 
 H                  6.39939400   -1.98245200   -2.50717800 
 H                  5.24669400   -0.15037200   -1.13393100 
 H                  6.99595400    0.00155500   -1.26391000 
 H                  5.67780200   -1.32258000    1.18885500 
 H                  7.35031000   -0.79236700    1.02415500 
 H                  6.56250800    1.60979500    0.87799800 
 H                  6.14665100    0.82141200    2.41080400 
 H                  5.62529500    3.72184800    0.59221000 
 H                  5.55821200    2.76579000   -0.90212500 
 H                  4.35499000    4.04759800   -0.61266500 
 H                 -0.44614300    0.97108300   -1.01107800 
 H                  3.31045700   -0.40675900    1.23404200 
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Figure A.4.9. Maximum intensity projection PET images  
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 10 min 1 h 4 h 12 h 24 h 
 Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO 
Blood  3.24 ± 0.66 5.11 ± 0.90 0.17 ± 0.10 0.10 ± 0.04 0.05 ± 0.04 0.03 ± 0.01 0.02 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.02 
Heart  1.57 ± 0.22 2.17 ± 0.62 0.12 ± 0.06 0.06 ± 0.02 0.06 ± 0.01 0.03 ± 0.01 0.06 ± 0.01 0.02 ± 0.00 0.07 ± 0.01 0.02 ± 0.01 
Lung  1.07 ± 0.17 2.16 ± 1.08 0.17 ± 0.09 0.14 ± 0.04 0.08 ± 0.01 0.04 ± 0.02 0.06 ± 0.01 0.02 ± 0.01 0.09 ± 0.05 0.04 ± 0.01 
Gall 
Bladder  
6.61 ± 2.87 1.57 ± 0.25 6.94 ± 3.38 0.47 ± 0.14 1.00 ± 0.41 0.26 ± 0.15 2.45 ± 1.02 0.16 ± 0.14 1.15 ± 0.59 0.23 ± 0.21 
Liver  3.29 ± 0.75 0.88 ± 0.49 0.22 ± 0.09 0.24 ± 0.07 0.13 ± 0.01 0.12 ± 0.03 0.09 ± 0.02 0.06 ± 0.02 0.06 ± 0.03 0.11 ± 0.02 
Spleen  0.31 ± 0.04 0.37 ± 0.22 0.09 ± 0.03 0.06 ± 0.02 0.06 ± 0.01 0.03 ± 0.01 0.05 ± 0.01 0.02 ± 0.01 0.06 ± 0.01 0.02 ± 0.01 
Stomach  1.22 ± 0.39 0.62 ± 0.28 0.30 ± 0.15 1.10 ± 0.51 0.50 ± 0.74 0.06 ± 0.02 0.01 ± 0.00 0.01 ± 0.00 0.02 ± 0.00 0.01 ± 0.01 
Large 
Intestine  
0.26 ± 0.15 0.43 ± 0.13 0.09 ± 0.06 0.02 ± 0.01 7.17 ± 2.15 0.62 ± 0.55 0.10 ± 0.03 0.07 ± 0.05 0.03 ± 0.02 0.02 ± 0.01 
Small 
Intestine  
5.99 ± 1.18 0.94 ± 0.16 1.11 ± 0.35 0.35 ± 0.17 0.12 ± 0.13 0.04 ± 0.02 0.02 ± 0.01 0.01 ± 0.01 0.02 ± 0.00 0.02 ± 0.01 
Kidney  9.46 ± 2.71 14.44 ± 5.88 1.05 ± 0.51 1.39 ± 0.55 0.40 ± 0.14 1.10 ± 0.44 0.53 ± 0.23 0.36 ± 0.13 0.51 ± 0.29 1.12 ± 0.33 
Bladder  2.04 ± 1.06 2.50 ± 0.48 0.73 ± 0.36 2.47 ± 1.30 0.58 ± 0.27 1.22 ± 0.77 0.54 ± 0.26 0.69 ± 0.31 0.28 ± 0.14 0.56 ± 0.41 
Muscle  0.36 ± 0.06 0.73 ± 0.56 0.10 ± 0.03 0.02 ± 0.01 0.09 ± 0.06 0.01 ± 0.01 0.06 ± 0.01 0.01 ± 0.00 0.06 ± 0.01 0.01 ± 0.00 
Bone  1.04 ± 0.44 0.43 ± 0.10 0.29 ± 0.09 0.07 ± 0.04 0.23 ± 0.12 0.04 ± 0.02 0.25 ± 0.07 0.03 ± 0.01 0.17 ± 0.03 0.06 ± 0.01 
Tail  4.25 ± 1.46 5.13 ± 2.92 0.81 ± 0.34 0.26 ± 0.05 0.29 ± 0.18 0.14 ± 0.08 0.11 ± 0.04 0.13 ± 0.05 0.05 ± 0.01 0.08 ± 0.02 
 
Table A.4.2. Full biodistribution data including all tissues collected. All values expressed as 
%ID/g. 
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 10 min 1 h 4 h 12 h 24 h 
 Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO Zr-HOPO Zr-DFO 
Blood 1.28 ± 0.39 2.71 ± 0.94 0.08 ± 0.03 0.04 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.01 
Heart 0.27 ± 0.02 0.33 ± 0.10 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 
Lung 0.13 ± 0.04 0.30 ± 0.21 0.03 ± 0.01 0.02 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
Gall 
Bladder 
0.34 ± 0.29 0.13 ± 0.09 0.10 ± 0.16 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 
Liver 1.20 ± 0.09 0.31 ± 0.10 0.10 ± 0.01 0.12 ± 0.02 0.04 ± 0.01 0.05 ± 0.02 0.04 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.05 ± 0.02 
Spleen 0.04 ± 0.01 0.07 ± 0.02 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 
Stomach 0.67 ± 0.68 0.22 ± 0.10 0.16 ± 0.08 0.66 ± 0.26 0.45 ± 0.50 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
Large 
Intestine 
0.23 ± 0.11 0.41 ± 0.13 1.05 ± 1.93 0.02 ± 0.00 6.53 ± 1.86 1.37 ± 1.58 0.11 ± 0.02 0.07 ± 0.04 0.04 ± 0.01 0.02 ± 0.01 
Small 
Intestine 
2.18 ± 1.25 0.43 ± 0.13 0.77 ± 0.33 0.19 ± 0.13 0.35 ± 0.62 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 0.01 ± 0.00 
Kidney 2.78 ± 1.57 6.11 ± 2.87 0.40 ± 0.20 0.57 ± 0.18 0.16 ± 0.07 0.44 ± 0.17 0.21 ± 0.10 0.14 ± 0.05 0.21 ± 0.12 0.46 ± 0.16 
Bladder 0.08 ± 0.09 0.07 ± 0.04 0.01 ± 0.01 0.05 ± 0.03 0.01 ± 0.00 0.02 ± 0.01 0.01 ± 0.00 0.01 ± 0.01 0.01 ± 0.00 0.01 ± 0.01 
Muscle 0.04 ± 0.01 0.10 ± 0.10 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 
Bone 0.05 ± 0.04 0.02 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 0.01 ± 0.00 0.00 ± 0.00 
Tail 2.55 ± 0.95 1.74 ± 0.72 0.27 ± 0.05 0.12 ± 0.03 0.14 ± 0.07 0.07 ± 0.03 0.05 ± 0.01 0.07 ± 0.03 0.03 ± 0.01 0.04 ± 0.01 
 
Table A.4.3. Biodistribution data without normalization. All values expressed as %ID. 
  
219 
 
 
 10 min 1 h 4 h 12 h 24 h 
Blood 0.01529 0.25713 0.27915 n/a 0.35592 
Heart 0.11823 0.16419 0.00164 0.00013 0.00011 
Lung 0.09260 0.63237 0.00928 0.00042 0.14603 
Gall Bladder 0.01283 0.01075 0.01512 0.00447 0.02669 
Liver 0.00169 0.70805 0.63334 0.08529 0.02658 
Spleen 0.57396 0.19204 0.00677 0.00144 0.00015 
Stomach 0.14010 0.02319 0.18904 0.13398 0.20703 
Large Intestine 0.12945 0.04036 0.00384 0.37090 0.34642 
Small Intestine 0.03807 0.00781 0.30326 0.11353 1.00000 
Kidney 0.11012 0.39845 0.02181 0.24716 0.03458 
Bladder 0.46929 0.04248 0.17054 0.49863 0.24675 
Muscle 0.24602 0.00310 0.03876 0.00003 0.00036 
Bone 0.03801 0.00481 0.01486 0.00090 0.00088 
Tail 0.60666 0.02000 0.15382 0.47791 0.03349 
 
Table A.4.4. Calculated P values for the comparison of 
89
Zr-HOPO and 
89
Zr-DFO 
biodistribution data. Multiple unpaired t tests were carried out using GraphPad Prism. Significant 
values are shown in bold (P < 0.05). 
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CHAPTER 5: APPENDIX  
       
                                                
p-SCN-BN-HOPO synthetic scheme (Figure 5.3)        
Compound 4 
1
H NMR (Figure A.5.1)   
Compound 4 
13
C NMR (Figure A.5.2)   
Compound 5 
1
H NMR (Figure A.5.3)   
Compound 5 
13
C NMR (Figure A.5.4) 
Compound 7 
1
H NMR (Figure A.5.5)   
Compound 7 
13
C NMR (Figure A.5.6) 
Compound 8 
1
H NMR (Figure A.5.7)   
Compound 8 
13
C NMR (Figure A.5.8) 
Compound 9 
1
H NMR (Figure A.5.9)   
Compound 9 
13
C NMR (Figure A.5.10) 
Compound 9 crude prep HPLC (Figure A.5.11)  
Compound 9 pure analytical HPLC (Figure A.5.12)  
Compound 10 
1
H NMR (Figure A.5.13)   
Compound 10 
13
C NMR (Figure A.5.14) 
Compound 10 HRMS (Figure A.5.15)  
Compound 10 crude prep HPLC (Figure A.5.16)  
Compound 10 pure analytical HPLC (Figure A.5.17)   
Compounds 9 and 10 IR comparison (Figure A.5.18) 
MALDI-TOF data (Table A.5.1)  
Biodistribution data as %ID (Table A.5.2)   
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Figure 5.3. Synthetic scheme for p-SCN-BN-HOPO. Reproduced here for reference for the 
following characterization data.  
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Figure A.5.1. Proton NMR of compound 4: (N1, N4, N9 – Tri-tert-butoxycarbonyl)-1,12-di-
amino-4,9-diazadodecane. 
 
1
H-NMR (CDCl3, 400 MHz): δ 3.07-3.21 (m, 10H), 2.68 (t, 2H), 2.08 (bs, 2H), 1.59-1.70 (m, 
4H), 1.41-1.46 (m, 31H).  
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Figure A.5.2. Carbon NMR of compound 4: (N1, N4, N9 – Tri-tert-butoxycarbonyl)-1,12-di-
amino-4,9-diazadodecane. 
 
13
C-NMR (CDCl3, 100 MHz): δ 156.04, 155.55, 79.48, 78.88, 46.80, 43.79, 38.76, 37.35, 32.46, 
30.9, 28.42.  
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Figure A.5.3. Proton NMR of compound 5: tert-butyl(4-((tert-butoxycarbonyl)(3-((4-
nitrophenethyl)amino)propyl)amino)butyl)(3-((tert butoxycarbonyl)amino)propyl)carbamate. 
 
1
H NMR (500 MHz, CDCl3): (mixture of rotamers)  8.10-8.09 (d, 2H), 7.36 (d, 2H), 3.28-2.58 
(m, 20H), 1.80 (bs, 2H), 1.58 (bs, 2H),  1.38-1.36 (m, 27H).   
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Figure A.5.4. Carbon NMR of compound 5: tert-butyl(4-((tert-butoxycarbonyl)(3-((4-
nitrophenethyl)amino)propyl)amino)butyl)(3-((tert butoxycarbonyl)amino)propyl)carbamate. 
 
13
C NMR (500 MHz, CDCl3): (mixture of rotamers)   156.1, 155.9, 129.8, 123.9, 79.3, 78.7, 
78.3, 49.85, 49.83, 49.80, 49.76, 49.72, 47.1, 47.0, 46.94, 46.91, 46.89, 46.86, 46.77, 46.72, 
46.67, 46.60, 46.52, 46.46, 46.41, 46.38, 46.33, 46.27, 46.26, 46.23, 46.20, 45.69, 45.66, 44.28, 
44.20, 43.88, 43.83, 43.78, 43.52, 43.47, 43.40, 43.38, 43.32, 37.76, 37.68, 37.64, 37.60, 37.56, 
37.51, 37.48, 37.38, 34.45, 34.40, 34.15, 28.45 
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Figure A.5.5. Proton NMR of compound 7: 1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-
dihydropyridine-2-carboxamido)propyl)-N-(4-(1-(benzyloxy)-N-(3-(1-(benzyloxy)-N-(4-
nitrophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine-
3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide. 
 
1
H NMR (600 MHz, CDCl3): (mixture of rotamers)  8.16-7.25 (m, 20H), 7.19-4.86 (m, 16H), 
3.82-2.06 (m, 25H), 1.84-0.63 (m, 8H) 
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Figure A.5.6. Carbon NMR of compound 7: 1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-
dihydropyridine-2-carboxamido)propyl)-N-(4-(1-(benzyloxy)-N-(3-(1-(benzyloxy)-N-(4-
nitrophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-dihydropyridine-
3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide. 
 
13
C NMR (600 MHz, CDCl3): (mixture of rotamers)  longer scan in progress to improve 
resolution 
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Figure A.5.7. Proton NMR of compound 8: N-(4-(N-(3-(N-(4-aminophenethyl)-1-(benzyloxy)-
2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-1-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-
carboxamido)butyl)-1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-
carboxamido)propyl)-6-oxo-1,6-dihydropyridine-2-carboxamide. 
 
1
H NMR (600 MHz, DMSO-d6): (mixture of rotamers)   8.70-8.64 (m, 1H), 7.44-7.33 (m, 27H), 
6.93-6.89 (m, 1H), 6.89-6.80 (m, 3H),  6.64-6.62 (m, 4H) , 6.31-6.10 (m, 4H), 5.38-5.26 (m, 5H), 
5.04-4.99 (m, 3H), 3.60-3.55 (m, 18H), 3.16-3.13 (m, 14H), 1.76-1.21 (m, 10H) 
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Figure A.5.8. Carbon NMR of compound 8: N-(4-(N-(3-(N-(4-aminophenethyl)-1-(benzyloxy)-
2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-1-(benzyloxy)-2-oxo-1,2-dihydropyridine-3-
carboxamido)butyl)-1-(benzyloxy)-N-(3-(1-(benzyloxy)-6-oxo-1,6-dihydropyridine-2-
carboxamido)propyl)-6-oxo-1,6-dihydropyridine-2-carboxamide. 
 
13
C NMR (600 MHz, DMSO-d6): (mixture of rotamers)   158.77, 158.70, 158.28, 158.25, 
158.18, 158.14, 155.63, 155.30, 155.27, 155.09, 155.06, 155.03, 141.89, 141.63, 141.60, 140.70, 
140.59, 140.51, 136.82, 136.77, 136.64, 131.65, 161.41, 131.38, 131.35, 127.49, 127.44, 127.38, 
127.29, 126.97, 126.87, 126.27, 126.23, 126.20, 120.31, 120.35, 119.75, 117.81, 115.46, 113.1, 
101.62, 100.26, 100.1, 76.16, 76.10, 59.81, 52.71, 45.56, 45.49, 43.71, 43.47, 43.31, 41.3, 39.83, 
39.65, 34.51, 34.45, 34.18, 34.11, 31.09, 29.71, 25.62, 24.36, 23.29, 22.73, 22.54, 22.43, 21.75, 
21.38, 21.29 
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Figure A.5.9. Proton NMR of compound 9: 4-(11,15-bis(1-hydroxy-2-oxo-1,2-dihydropyridine-
3-carbonyl)-1-(1-hydroxy-6-oxo-1,6-dihydropyridin-2-yl)-6-(1-hydroxy-6-oxo-1,6-
dihydropyridine-2-carbonyl)-1-oxo-2,6,11,15-tetraazaheptadecan-17-yl)benzenaminium 
chloride. 
 
1
H NMR (500 MHz, CDCl3): (mixture of rotamers)   7.44-7.28 (m, 5H), 7.20-7.16 (dd, J1, J2=6 
Hz, 1H), 7.08-7.01 (m, 2H), 6.54-6.53 (m, 4H),  6.33-6.32 (m, 3H) , 6.18-6.21 (m, 0.5H), 5.74-
5.67 (m, 0.5H), 3.65-3.51 (m, 4H), 3.51-3.16 (m, 8H), 3.12-2.70 (m, 11H), 1.91-1.38 (m, 10H) 
231 
 
 
Figure A.5.10. Carbon NMR of compound 9: 4-(11,15-bis(1-hydroxy-2-oxo-1,2-
dihydropyridine-3-carbonyl)-1-(1-hydroxy-6-oxo-1,6-dihydropyridin-2-yl)-6-(1-hydroxy-6-oxo-
1,6-dihydropyridine-2-carbonyl)-1-oxo-2,6,11,15-tetraazaheptadecan-17-yl)benzenaminium 
chloride. 
 
13
C NMR (500 MHz, CDCl3): (mixture of rotamers)   158.8, 158.6, 158.4, 158.1, 157.9, 157.8, 
157.77, 157.73, 142.5, 142.49, 142.45, 142.41, 142.32, 142.24, 142.04, 138.10, 138.0, 137.59, 
137.51, 130.36, 130.31, 130.18, 130.08, 119.76, 119.45, 117.5, 115.6, 104.3, 102.5, 102.47, 
102.41, 50.01, 48.12, 47.9, 46.0, 46.0, 43.7, 42.3, 37.2, 37.0, 36.97, 33.80, 32.65, 32.49, 28.16, 
26.90, 26.23, 25.4, 25.4, 25.2, 25.1, 24.4, 24.3, 24.3, 24.2 
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Figure A.5.11. Crude compound 9 HPLC chromatogram. The crude product was purified by 
HPLC on a preparative C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 19 mm X 
100 mm) at 17.059 mL/min using a gradient of 10-23% MeCN in water (both containing 0.1% 
TFA) with an initial hold at 10% MeCN for 1.33 mins and then a ramp to 23% MeCN over 20 
minutes. The product peak was collected from 6.45-8.26 min and the eluted solution was lyophilized 
to recover the product as an off white solid. 
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Figure A.5.12. Purified compound 9 HPLC chromatogram. The purified sample was confirmed 
by HPLC on a analytical C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm 
X 100 mm) at 1 mL/min using a gradient of 10-30% MeCN in water (both containing 0.1% TFA) 
with an initial hold at 10% MeCN for 1.33 mins and then a ramp to 30% MeCN over 30 minutes 
followed by a ramp to 95% MeCN over 1 minute and an isocratic hold at 95% MeCN for 5.66 
minutes. 
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Figure A.5.13. Proton NMR of compound 10: 1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6-
dihydropyridine-2-carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4-
isothiocyanatophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-
dihydropyridine-3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-Bn-
HOPO). 
 
1
H NMR (500 MHz, CDCl3): (mixture of rotamers)   7.37-7.31 (m, 7H), 7.12-7.08 (m, 1H), 
6.58-6.52 (m, 4H), 6.34-5.81 (m, 4H),  3.62-3.54 (m, 12H) , 3.13-2.83 (m, 11H), 2.01-1.24 (m, 
11H) 
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Figure A.5.14. Carbon NMR of compound 10: 1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6-
dihydropyridine-2-carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4-
isothiocyanatophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-
dihydropyridine-3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-Bn-
HOPO). 
 
13
C NMR (500 MHz, CDCl3): (mixture of rotamers)   161.78, 161.71, 161.54, 161.4, 160.65, 
160.61, 157.89, 157.83, 157.78, 157.73, 142.59, 142.48, 142.41, 142.33, 142.31, 142.21, 139.58, 
138.49, 138.90, 138.81, 138.17, 138.0, 137.57, 137.50, 134.07, 130.76, 130.74, 130.59, 130.52, 
128.89, 128.66, 126.41, 126.32, 119.74, 119.53, 119.43,104.33, 102.50, 102.39, 49.62, 48.11, 
47.96, 46.49, 46.01, 45.70, 37.24, 37.01, 36.96, 34.04, 32.83, 32.71, 28.15, 27.12, 26.85, 26.22, 
25.46, 25.26, 25.17, 24.36, 24.18 
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Figure A.5.15. HRMS spectra of compound 10: 1-hydroxy-N-(3-(1-hydroxy-6-oxo-1,6-
dihydropyridine-2-carboxamido)propyl)-N-(4-(1-hydroxy-N-(3-(1-hydroxy-N-(4-
isothiocyanatophenethyl)-2-oxo-1,2-dihydropyridine-3-carboxamido)propyl)-2-oxo-1,2-
dihydropyridine-3-carboxamido)butyl)-6-oxo-1,6-dihydropyridine-2-carboxamide (p-SCN-Bn-
HOPO). 
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Figure A.5.16. Crude compound 10 HPLC chromatogram. The crude reaction solution was 
directly purified by HPLC on a preparative C18 column (Waters Symmetry C18 Prep Column, 
100Å, 5 µm, 19 mm X 100 mm) using a gradient of 5-75% MeCN in water (both containing 0.1% 
TFA) with an initial hold at 5% MeCN for 1.33 mins and then a ramp to 75% MeCN over 30 
minutes. The product peak was collected from 15.01-15.5 min and the eluted solution was 
lyophilized to recover the product as a white solid.  
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Figure A.5.17. Purified compound 10 HPLC chromatogram. The purified sample was confirmed 
by HPLC on a analytical C18 column (Waters Symmetry C18 Prep Column, 100Å, 5 µm, 4.6 mm 
X 100 mm) at 1 mL/min using a gradient of 5-75% MeCN in water (both containing 0.1% TFA) 
with an initial hold at 5% MeCN for 1.33 mins and then a ramp to 75% MeCN over 30 minutes 
followed by a ramp to 95% MeCN over 1 minute and an isocratic hold at 95% MeCN for 5.66 
minutes.  
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Figure A.5.18. Comparison of infrared spectra for compounds 9 and 10. The blue spectrum is 
from compound 9 and the red spectrum is from compound 10. The major difference between the 
compounds is the formation of the isothiocyanate group from the amine and this change can be 
seen in the appearance of the corresponding band at ~2,100-2,200 cm
-1
. 
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Trastuzumab DFO-Trastuzumab HOPO-Trastuzumab 
1 147995.6 147912.7 150494.7 
2 147637.3 147933.3 149203.8 
3 147740.2 147949.1 149101.9 
Average 147791.0333 147931.7 149600.1333 
Std Dev 184.4796556 18.25267104 776.3910376 
 
Differences 140.6666667 1809.1 
Chelator Mass 750 911 
Chelate Number 0.187555556 1.985839737 
 
Table A.5.1. MALDI-TOF data for determination of chelate number. Mass values shown in 
amu. These data were found unusable due to the large inconsistencies in the measured mass 
values for the antibody constructs with respect to the masses of the individual chelators. 
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